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Abstract 
Anna Glaser. The role of neutrophils in autoimmune disease 
Background: Juvenile-onset systemic lupus erythematosus (JSLE) is a 
multisystem autoimmune disease with manifestations being very diverse 
between individuals. Neutrophils (PMN), the main innate phagocytic cells have 
been implied to contribute to disease development and show an Interferon-
induced gene signatures (IGS) in patients. Contribution of PMN to disease 
development and patient stratification have mainly been investigated with 
genomic, transcriptomic, proteomic approaches. 
Aims: (1) To explore the ability to stratify patients with autoimmune diseases 
based on their IGS, including a metabolomics approach using urine and serum. 
(2) To investigate the phagocytosis-related gene (PRG) signature (PGS) and IGS 
in PMN of JSLE and healthy paediatric controls. (3) To determine if the PGS is 
translated onto protein and functional level in PMN of JSLE patients. (4) To 
determine the influence of factors present in the neutrophil environment 
including Tumour Necrosis Factor (TNF) , Interferon (IFN) , nucleosomes and 
signal released from apoptosing cells, on the PRG signature.  
Methods: Metabolite profiles of serum and urine were obtained from JSLE 
patients, Juvenile Idiopathic Arthritis (JIA) and paediatric controls using 1H 
NMR spectroscopy, bucket tables for serum samples were created with 
TopSpin® and Chenomx Profiler® whereas urine sample metabolites were 
annotated and quantified in Chenomx Profiler® for each sample individually. 
JSLE and paediatric controls were tested for differences in IGS and PGS using 
real-time PCR, flow cytometry and ELISA. Effects of stimulation with apoptotic 
supernatant, nucleosomes, IFN and TNF on IGS and PGS were also 
investigated. Phagocytosis was measured using pHrodo coated bioparticles 
(S.aureus, E.coli, zymosan) with flow cytometry and confocal microscopy.  
Results: JSLE, JIA and paediatric control patients and the JSLE IFN subgroups 
were distinguishable from each other in a model with partial-least squares 
discriminant analysis. Urine metabolites built better models than metabolites of 
serum. Pathway analysis suggested increased inflammation in patients despite 
low disease activity and differences for metabolites involved in phagocytosis. 
The PGS genes TLR2 and S100A9 had increased mRNA and protein expression 
in neutrophils of JSLE patients compared to paediatric control patients. The 
main difference between JSLE IFN high and IFN low patients was in FcRIIIb, 
which was only high in IFN high patients. Increased PRG expression was 
reflected in increased phagocytosis of E.coli and zymosan particles. All 
stimulants tested contributed to the PGS and IGS, in particular the nucleosomes 
which increased IFNα, IGS expression and triggered S100A8/A9 release. 
Conclusions: Factors in the neutrophil cell environment of JSLE patients can 
contribute to increased expression of the PGS and IGS. Differences between 
JSLE, JSLE IFN high, JSLE IFN low and paediatric control patients can be 
measured at the mRNA, protein and metabolite level. Strong differences suggest 
that IFN high and IFN low patient subgroups may have different 
aetiopathogenesis and different cytokine profiles.  
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 Introduction 
1.1 Autoimmune diseases 
The role of the immune system is to defend against external pathogens such as 
bacteria, fungi and viruses. To achieve this there are a number of key defensive 
and killing mechanisms in place that include processes such as inflammation 
and antibody production. Environmental factors and genetic predisposition can 
disturb the homeostasis of the immune system which may lead to autoimmune 
diseases [1]. In the autoimmune state, the tolerance against self is lost as B-cells 
develop autoantibodies that target healthy cells. The constant attack and the 
formation of antibody complexes directed against autoantigens, so called 
immune complexes, leads to pathology [2]. While in some autoimmune diseases 
the damage is localized only in one organ, in other autoimmune diseases it 
involves the whole body, and these are called systemic autoimmune disorders. 
 
1.2 Juvenile idiopathic arthritis (JIA) – An autoinflammatory and 
autoimmune disease 
1.1.1 Clinical manifestations of JIA 
JIA is a term used to describe not one disease, but a spectrum of disorders which 
comprise different subgroups of childhood-onset inflammatory arthritis with 
unknown aetiology characterised by autoinflammation and/or autoimmunity. 
Due to these dual characteristics of JIA, it has been used frequently when a 
comparison is needed to explore an autoimmune disease mechanism 
characterized by inflammation [3], [4]. Diagnosis of JIA is based on a set of 
inclusion and exclusion criteria, based predominantly on clinical features in 
which symptoms of arthritis need to be present for longer than six weeks and 
diagnosis needs to be before the 16th birthday [5]. 
The classification of JIA is divided into seven subtypes. This comprises: 
oligoarthritis (sub-divided then into persistent and extended oligoarthritis), 
polyarthritis rheumatoid factor negative, polyarthritis rheumatoid factor 
positive, psoriatic-associated, enthesitis-related, undifferentiated and systemic 
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arthritis [5]. The different subtypes are listed in Table 1.1 together with their 
inclusion and exclusion criteria.  
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Type of 
arthritis 
Inclusion criteria Exclusion 
criteria 
Oligoarthritis 
 
- Persistent  
 
- Extended 
 
Arthritis in 1-4 joints (during the first six 
months from disease onset) 
Affected joints remain less than four thereafter 
 
≥ 4 joints after the first six months 
1), 2), 3), 
4), 5) 
Polyarthritis  
RF-negative 
≥ 5 joints during first six months  
RF test negative 
1), 2), 3), 
4), 5) 
Polyarthritis  
RF-positive 
≥ 5 joints during first six months  
RF test positive ≥ twice at least three months 
apart during first six months of disease 
1), 2), 3), 
5) 
Systemic 
arthritis 
Arthritis in ≥ 1 joints 
Fever > 2 weeks duration 
+ One of the following: 
A) Evanescent rash 
B) Lymph node enlargement 
C) Hepatomegaly and/or splenomegaly 
D) Serositis 
1), 2), 3), 
4) 
 
Psoriatic 
arthritis 
Arthritis and psoriasis  
Or 
Arthritis + two of the following: 
A) Dactylitis 
B) Nail pitting or onycholysis 
C) Psoriasis in first-degree relative 
2), 3), 4), 
5) 
Enthesitis-
related arthritis 
Arthritis and enthesitis  
Or 
Arthritis or enthesitis + ≥ two of the following: 
A) Past of sacroiliac joint tenderness and/or 
inflammatory lumbosacral 
B) HLA-B27 positive 
C) If male, arthritis ≥ 6 years of age 
D) Acute (symptomatic) anterior uveitis 
E) Ankylosing spondylitis, enthesitis related 
arthritis, sacroiliitis with inflammatory 
bowel disease, Reiter’s syndrome or acute 
anterior uveitis (or family history in first 
degree relative) 
1), 4), 5) 
Undifferentiated 
arthritis 
If no other category or several can be assigned  
Table 1.1: Overview of subtypes of juvenile arthritis.  The seven subtypes of 
JIA are summarised in this table including their diagnosis criteria. Exclusion 
criteria are abbreviated in the table as numbers 1-5: 1) Diagnosis of psoriasis 
(or family history in first degree relative) 2) Arthritis if HLA-B27 positive male ( 
> 6 years) 3) Ankylosing spondylitis, enthesitis related arthritis, sacroiliitis with 
inflammatory bowel disease, Reiter’s syndrome or acute anterior uveitis (or 
family history in first degree relative) 4) IgM rheumatoid factor (RF) ≥ twice at 
least three months apart 5) Presence of systemic JIA (sJIA) in the patient. 
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Heterogeneity of symptoms and disease development may hinder clear 
classification of the disease subtype, as well as prediction of active or inactive 
disease state. Being able to accurately predict disease state and treatment 
response remains a significant problem and challenge, despite extensive 
prediction models having been developed including a range of clinical 
parameters, imaging modalities and biological data including genetic, molecular, 
proteomic, as well as microbiota samples. The current clinical classification 
criteria of JIA into specific subtypes allows development of moderately effective 
prediction models [6], but there is still a considerable paucity of understanding 
in this area. Despite these differences, most patients are managed with the same 
or similar standard treatments and treatment protocols, such as intra-articular 
corticosteroid injections with or without non-steroidal anti-inflammatory drugs 
(NSAID), and/or methotrexate with or without the addition of systemic 
corticosteroids or the newer biological agents. 
Within the different JIA subtypes, systemic-onset JIA (sJIA) is considered to be 
one of the most severe types. Even with new biologic therapies the burden on 
patients and their caregivers is extremely high. sJIA patients have reduced 
physical function, their social lives are affected, and they often need at a young 
age an assistive mobility device which may be only a walking stick but can be a 
wheelchair [7].  
A relatively common and very severe complication associated with sJIA is 
macrophage activation syndrome (MAS). Symptoms are severe and include 
fever, hepatosplenomegaly, lymphadenopathy, cytopenia, coagulopathy and 
inflammation of the central nervous system. MAS is difficult to diagnose and can 
be detected more easily in bone marrow aspirates which can be obtained only 
invasively [6]. Nevertheless, diagnosis is essential as a complication with MAS 
can need critical care intervention in an intensive care unit in case of severe 
deterioration. Biologics are a new generation of treatment which are derived 
from humans, animals or microorganisms and an example are antibodies 
targeting specific cytokines. This treatment has benefitted JIA patients, but 
despite intensive care intervention and disease management with biologic 
drugs about 8% of sJIA patients die of MAS [8].  
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1.1.2 Pathogenesis of JIA 
Already the name idiopathic arthritis implies that there is no known cause for 
the onset of the disease. This shows how poorly understood this disease is and 
that there is not much known about its triggers. A starting point to explore 
diseases is to investigate the genomic background.  
One common risk allele for JIA is coding for the human leukocyte antigen (HLA) 
which represents the human form of the major histocompatibility complex 
(MHC). This protein is important for the presentation of peptides to T-cells and 
activation of the immune system. It was suggested that the different subtypes of 
JIA have specific variants of HLA markers. In one study, HLA-DRB1 was linked to 
oligoarthritis and RF-negative and -positive polyarthritis, while HLA-DRB1*11 
was connected to sJIA and HLA-B*27 for enthesitis-related arthritis [9].  
Further, non-HLA genes have been linked to oligoarthritis and RF-negative 
polyarthritis. These include genes encoding for protein tyrosine phosphatase, 
non-receptor type 22 (PTPN22), IL-2 receptor subunit alpha (IL2RA) or beta 
(IL2RB), all important for T-cell stimulation and therefore indicating 
importance of these cells [10]. Other studies additionally found capillary 
morphogenesis gene 2 (CMG-2) and C-X-C chemokine receptor type 4 (CXCR4) 
to be linked to JIA [11]. CMG-2 regulates extracellular matrix collagen type IV 
[12] which may explain the decreased synovial lining with type IV collagen 
found in rheumatoid arthritis (RA) patients [13] and may apply for the juvenile 
form of the disease. CXCR4 is expressed on cells of the innate and adaptive 
immune system and is involved in cell growth and migration [14] and may 
explain abnormal migration into joints. A genome-wide association study 
(GWAS) in 2017 revealed association of Janus Kinase-1 (JAK1) with 
oligoarticular JIA and RF-negative polyarticular JIA [15]. This is of special 
interest as there are JAK inhibitors available, for example Tofacitinib, which is 
consequently used for treatment in JIA [16]. If the different subtypes of JIA are 
studied as one group, it may decrease the chances of finding disease relevant 
genes. For sJIA it has been suggested that there is a distinctly different genetic 
background compared to other JIA subtypes such as oligoarthritis and 
polyarthritis [17]. 
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A difference between the type of immune cells involved in sJIA and the other JIA 
subtypes has also been found. The innate immune system is dominant in sJIA 
pathogenesis with neutrophils and monocytes infiltrating the tissues and 
causing inflammation [18]. Also in other JIA subtypes the innate immune system 
plays a role as low-density granulocytes (LDG) have been found in higher 
numbers than in healthy controls [19]. JIA pathogenesis is indeed considered to 
be driven by the adaptive immune system, and primarily by proinflammatory T-
helper cells (Th) called Th-17 due to their ability to produce Interleukin (IL)-17. 
The percentage of IL-17 producing cluster of differentiation (CD) 4 positive cells 
as well as CD3 positive cells is higher both in active and inactive JIA [20]. These 
cells produce IL-17A and Interferon (IFN) and the percentage of Th-17 cells in 
the synovium of JIA patients positively correlated with disease activity 
measured as C-reactive protein (CRP) [21]. This further supports the 
importance of this cell type. IL-17 is a cytokine triggering further inflammation 
by stimulation of tumour necrosis factor alpha (TNF) and IL-1 [22]. TNF 
plays an important role in the disease and its inhibition is used as for a 
treatment [23]. While inflammation is stimulated by Th-17 cells, T-cells which 
dampen immune responses called regulatory T-cells (Treg) are impaired [24].  
 
1.3 Juvenile-onset Systemic Lupus Erythematosus (JSLE)– A 
systemic autoimmune disease 
1.3.1 Clinical manifestation of JSLE 
Perhaps the most archetypal systemic autoimmune disorder is systemic lupus 
erythematosus (SLE) which is a disease with a wide range of symptoms. If a 
patient is diagnosed at an age younger than 17 the disease is considered 
childhood-onset of Juvenile-onset systemic lupus erythematosus (JSLE). 
Different clinical manifestations of JSLE are observed. These can vary widely 
between patients and can range from mild through to life-threatening severe 
complications. Skin manifestations are common, but all organ systems can be 
affected. JSLE patients particularly often have major haematological, renal or 
neurological involvement [25]. Consequently, it is named a systemic 
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autoimmune disease and the most common symptoms are summarised in 
Figure 1.1.  
Clinical parameters are characterised by antibodies against nuclear-
autoantigens including single and double stranded DNA (ssDNA and dsDNA), 
nucleosomes or nuclear proteins such as ribonucleoproteins (RNP) [26]. 
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Figure 1.1: Symptoms common for JSLE. 
 
1.3.2 Diagnosis of JSLE and assessment of disease activity 
For diagnosis of SLE the American College of Rheumatology (ACR) revised 
criteria for SLE classification are frequently used. If at least four of the criteria 
are met before the age of 17, a patient can be diagnosed with JSLE. Symptoms 
can be present simultaneously or over many years. There are eleven criteria in 
total, namely: malar rash, discoid lupus, photosensitivity, oral or nasal 
ulceration, non-erosive arthritis, serositis, nephritis, neurological symptoms 
(seizures or psychosis), haematological symptoms (leukopenia or lymphopenia 
on ≥ two occasions or thrombocytopenia), immunological symptoms (anti-DNA, 
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-Sm, -phospholipid antibodies, positive lupus anticoagulant, false positive for 
syphilis for > six months), abnormal titres of anti-nuclear antibodies [27].  
 
A more recent approach of diagnosis includes these symptoms as the basis as 
described in the 2012 proposed Systemic Lupus International Collaborating 
Clinics (SLICC) criteria [28]. The SLICC classification criteria include both 
clinical and immunological criteria (shown in Table 1.2) and in order to 
confirm a patient to have JSLE, at least four of them have to be met, with at least 
one immunological and one clinical criterion. Alternatively, it is sufficient for 
diagnosis if a patient is confirmed with lupus nephritis (LN) by biopsy while 
antinuclear antibodies (ANA) or anti-double stranded (ds)DNA antibodies are 
present [28]. SLICC criteria have been shown to be more accurate and sensitive 
compared to the ACR criteria [29]. Currently, there are new ACR-endorsed 
Criteria for Rheumatic Diseases, but they have not yet been assessed for JSLE 
compared to the older classification systems.  
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Clinical Criteria 
Acute cutaneous 
lupus 
Lupus malar rash  
Bullous lupus 
Toxic epidermal necrolysis variant of SLE 
Maculopapular lupus rash  
Photosensitive lupus rash 
Subacute cutaneous lupus 
Chronic cutaneous 
lupus 
Classical discoid rash 
Hypertrophic (verrucous) lupus 
Lupus panniculitis (profundus) 
Mucosal lupus 
Lupus erythematosus tumidus 
Chillblains lupus 
Discoid lupus/lichen planus overlap 
Oral ulcers Palate, buccal, tongue or nasal in the absence of other 
causes (e.g. infection with herpes) 
Nonscarring alopecia In absence of other causes e.g. iron deficiency 
Synovitis  Involving ≥ two joints, (swelling or effusion) OR 
tenderness in ≥ 2 joints and ≥ 30 minutes morning 
stiffness 
Serositis Typical pleurisy > one day OR pleural effusion OR rub 
Typical pericardial pain > one day OR pericardial 
effusion OR rub or pericarditis by ECG 
Renal Urine protein 500mg of protein/24 h 
Neurologic Seizures 
Psychosis 
Mononeuritis multiplex 
Myelitis 
Peripheral or cranial neuropathy 
Acute confusional state 
Haemolytic anaemia  
Leukopenia < 4000/mm3 at least once 
Lymphopenia  < 1000/mm3 at least once 
Thrombocytopenia < 100,000/mm3 at least once 
Immunological Criteria 
ANA  Above laboratory reference range 
Anti-dsDNA Above laboratory reference range (ELISA twice above 
laboratory reference range) 
Anti-Sm  
Antiphospholipid 
antibody 
Lupus anticoagulant OR false-positive RPR OR 
medium/high titre anticardiolipin OR anti-2 
glycoprotein I  
Low complement Low C3 OR C4 or CH50 
Direct Coombs test  
Table 1.2: SLICC criteria for diagnosis of SLE   
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The disease is characterised by periods of quiescence as well as periods of 
active disease which are called flares. During flares, patients may suffer from 
increased pain, fatigue or rashes, also increased sensitivity to ultraviolet (UV) 
light, headaches, fever or other organ manifestations. Multiple factors including 
stress, UV light exposure and intercurrent infections have been suggested to 
cause such flares [30]. 
The disease activity, which can affect any organ system, may be assessed using 
specific lupus disease activity scores. These include the British Isles Lupus 
Assessment Group (BILAG)-2004 index or the SLE disease activity index 
(SLEDAI)-2K disease activity score.  
The BILAG-2004 index evaluates the nine following organ systems: 
constitutional, mucocutaneous, central nervous system, musculoskeletal, 
cardiovascular/respiratory, abdominal, renal, ophthalmic and haematological. 
Each system is graded separately from A (active) to D (inactive now) or E (never 
been active). A total score (maximum score 108) is then calculated replacing the 
letters with numerical values (A=12, B=8, C=1, D=0, E=0) [31]. It is a 
comprehensive multi-organ assessment and linked to the clinician’s intention to 
treat, which shows inter-rater reliability and thus is a reliable tool for assessing 
disease activity [32]. The SLEDAI-2K is a sole numerical system and each 
symptom is weighed differently with a range of 0-55 as a total score. For 
example, while presence of fever equates with 1 point, low complement equates 
with 2 points and a seizure would receive a score of 8 points. If a symptom is 
present at the time of visit or was present the ten preceding days, its value is 
accounted for and the sum of all symptoms represents the SLEDAI-2K of the 
patient. The index focuses on disease activity and excludes previous disease or 
therapy caused damage [33]. 
 
1.3.3 Epidemiology of SLE and JSLE 
A recent study reported a reliable incidence of 4.91 per 100,000 people per year 
(from 1999-2012) and summarized broad disease categorisation data for SLE in 
the UK. SLE is considered a rare disease and it is 5.8 times higher in females 
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compared to males when looking across all age groups. The highest incidence 
appears to be in individuals between 40-49 for women and 60-69 for men. 
Furthermore, Black Caribbean ethnicity appears to have a higher incidence rate 
than white people [34]. Children were also included in this study and while only 
0.19 per 100,000 children were newly diagnosed at the ages 0-9, from the ages 
10-19 1.92 new cases per 100,000 children were found per year. [34]. Each 
country has different ways of registering patients and patients may be 
diagnosed incorrectly, both leading to incorrect and potentially low numbers. 
Incidence of JSLE has been reported to range from 0.47 for example in Japan to 
0.9 per 100,000 in Wisconsin in the United States [35]. 
 
1.3.4 Pathogenesis of SLE 
Reasons for SLE development are still not fully understood and environmental 
factors, genetic predisposition, hormonal influence as well as medication have 
been considered as causative factors. Sunlight is an example of a possible 
environmental trigger, as a higher risk to develop SLE was associated with 
outdoor working and being exposed to daylight for more than 20 h/week over 2 
months/year. Patients were also found to react more often with a blistering 
sunburn or a rash [36].  
Hormones have been considered relevant in the development of SLE due to the 
increased risk of the disease in females. Furthermore, this hypothesis is 
supported as oestrogen-receptor stimulation has been shown to shorten 
survival of lupus-prone mice [37]. In addition, some drugs have been found to 
induce SLE. Patients have, for example, developed SLE after procainamide 
treatment which is used as an anti-arrhythmic drug. The effects were not long-
lasting and disease ameliorated after the drug was discontinued [38].  
Almost 50 years ago, a genetic predisposition to SLE was found to be linked to 
the HLA Class I B8 [39]. Since then, many other risk alleles have been found. 
Genes with importance for the complement system such as C4A and C4B are 
present in lower copy numbers in SLE patients compared to in healthy controls 
[40], [41]. Furthermore, genes responsible for DNA processing, such as Three-
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prime repair exonuclease 1 (TREX1), an exonuclease which processes DNA [42], 
have been found to be changed in SLE. Deficiency of this protein could increase 
presence of single-stranded DNA. Monogenic diseases have given insight into 
genes important for JSLE such as DNASE1L3, responsible for clearance of 
chromatin [43] and Protein Kinase C Delta (PRKCD) which regulates 
lymphoproliferation and spontaneous cell death [44].  
SLE is a heterogenous disease according to symptomology, but also in the 
variety of immune cells involved in its pathogenesis. B-cells lose their tolerance, 
become autoreactive and produce autoantibodies. B-cell activating factor 
(BAFF) is overexpressed in SLE patients which stimulates the development of 
autoreactivity [45]. Therapeutically, anti-BAFF antibodies (Belimumab) are now 
used for treatment of SLE, but the disease still cannot be completely treated 
with this agent. In a continuation study of a Phase III Belimumab SLE cohort 
study 10% of patients had to be withdrawn from a Belimumab treatment and 
20.6% still experienced a severe flare despite receiving Belimumab [46]. 
Similarly, anti-CD20 antibodies called Rituximab, target B-cells and deplete 
them. SLE disease improvement was again not sufficient to consider B-cells the 
main actors in this disease [47].  
For SLE both the adaptive and the innate immune system are considered to play 
a role in disease onset and progression. Most published studies limit their 
research to a specific immune cell type, rather than on specific immune-
mediated processes including cell death (see Section 1.4.4.4) and especially the 
process of neutrophil-specific NETosis (see Section 1.4.4.4.3), the phagocytosis 
of pathogens and how the immune system deals with apoptotic debris (see 
Section 1.4.4.5). 
One of the challenges in studying the immunopathogenesis of JSLE, its causes, 
risk factors and disease progression is due to the heterogeneity and complexity 
of the disease and the different factors potentially influencing the outcome as 
summarised. 
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1.4 Strategies to stratify SLE patients 
For both investigation of the disease and in seeking to target and successfully 
develop novel drugs for treating SLE, it has been necessary to stratify patients 
into different SLE clinical subtypes. Strategies include looking only at specific 
organ involvement, for example LN, or categorising patients depending on 
disease activity score or ethnicity [48]. Other types of stratifications include 
separation into adult and juvenile-onset disease, or a more recent approach is 
division based on the patient’s IFN score (as will be discussed further below – 
see Section 1.4.2). 
 
1.4.1 Adult- and juvenile-onset SLE 
Depending on the age when the disease is diagnosed it is divided into two 
subgroups, which are adult-onset SLE and JSLE. The latter includes all patients 
who are diagnosed before 18 years of age [49]. Affected children typically show 
fever, renal involvement, haemolytic anaemia, and neuropsychiatric 
manifestations (such as encephalopathy) more often than in the adult-onset 
disease [50]. There are currently limited published data on the disease 
characteristics but in particular disease pathogenesis in childhood compared to 
the adult-derived literature. This needs to be addressed not only because the 
development of JSLE is generally more severe than for adult-onset SLE, but also, 
these patients make up 15-20% of all lupus patients. JSLE patients do not 
necessarily have the same cause of disease or disease progression. JSLE is 
associated with a higher risk of proteinuria, anti-dsDNA, arthritis and 
leukopenia and early development has a stronger association with risk alleles 
than adult-onset [51]. Leukopenia and arthritis are more present with 
advancing age, although this may simply reflect an average older population 
where the prevalence of arthritis would be higher (related to ageing) than in 
children [52]. However, levels of anti-dsDNA, anti-Smith (anti-Sm) and anti-
ribonucleoprotein (anti-RNP) autoantibodies, along with prevalence of 
nephritis, which is a very severe manifestation, are higher in JSLE compared to 
adult-onset SLE patients [52]. These and other studies describe increased 
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disease severity in the early-onset group. While being potentially a very 
damaging disease, fewer comorbidities in the younger age group makes 
juvenile-onset patients a good group to study the mechanism of SLE. 
Understanding the disease in children will provide important insights into 
disease pathogenesis and identify potentially more appropriate and safer 
treatments. This would help to improve lives of these patients as they suffer 
physiologically and psychologically lifelong from both the disease and the 
treatment [53]. Differences in disease development and progression make it 
essential that patients are distinguished between juvenile- and adult-onset 
groups.  
 
1.4.2 IFN induced gene signature stratification  
Recent interest has focussed on the potential for disease stratification based on 
the patient’s expression of IFN-induced genes (IG). In 2003, it was reported that 
peripheral blood mononuclear cells (PBMC) from 50% of the studied SLE 
patients were characterised to have an IFN-induced gene signature (IGS), which 
could not be confirmed to relate to IFN IFN or IFN levels in patients’ serum 
and plasma [54]. Patients with a high IFN score based on the IGS were classified 
as IFN high and patients with an IFN score similar to controls were considered 
IFN low. Furthermore, this study found that the IGS was indicative for a more 
severe manifestation of the disease as more IFN high patients were suffering 
from more renal and/or CNS involvement and hematologic involvement [54]. At 
the same time another paper was published about the IGS in PBMCs of JSLE 
patients [55]. The data showed that for most patients studied, their PBMCs 
displayed an IFN high signature and that this signature had similarities to IFN 
stimulated PBMCs of healthy adults. Interestingly, data arising from this study 
noted in addition an augmented granulopoiesis signature (increased expression 
of genes promoting granulocyte production and function) linked to IFN high 
patients, and showed an association between the presence of LDG and 
granulopoiesis signature. This suggested a link between neutrophils, also called 
polymorphonuclear cells (PMN), and the IFN high signature. The analysis 
included a JIA patient group, but an IGS could not be detected for these 
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individuals [55]. Later published data did identify an IGS in JIA patients, but only 
in a 30.8% of patients studied [56]. In this study of JIA patients, the IFN high 
signature was linked to neutrophils from whole blood which would include LDG 
[56]. Other studies have identified an IGS in patients with juvenile 
dermatomyositis, undefined interferonopathies and some autoinflammatory 
diseases [57]. Despite the suggested link to increased disease severity, there is 
still a significant gap in understanding the effects and causes of the IFN high and 
low signature in SLE. This is particularly interesting, as most studies to date 
have investigated IGs rather in relation to intercurrent viral infections.  
Importantly, JSLE patients with differing IGS subgroups (e.g. high or low 
expression) may have distinct pathoaetiological differences and therefore may 
potentially respond differently to different treatments. Understanding the role 
of the IGS in the aetiopathogensis of JSLE and its potential impact on treatment 
needs further investigation. 
Genes that were linked to IFN in the past or even used as part of an IGS were 
used as part of the IGS for this study. They were further selected based on high 
mRNA expression in our JSLE cohort (unpublished data). The genes included 
were: Interferon induced protein 44-like (IFI44L), 2’-5’oligoadenylate 
synthetase 2 (OAS2), IFN inducible protein 6 (IFI6) and Lymphocyte antigen 6 
family member E (LY6E). 
 
1.4.2.1 Interferon induced protein 44-like gene 
One of the key IGS genes is IFI44L. This gene has previously been used as part of 
an IFN score, a system to evaluate if a patient is IFN high or IFN low based on 
the average of several genes [57]. It has also been studied as a biomarker for 
renal damage in SLE as hypomethylation of the promoter region of IFI44L which 
increases its mRNA expression, has been found to be more common in SLE 
patients with renal involvement [58]. This coincides with the higher renal 
involvement found in IFN high patients compared to IFN low patients [54]. The 
function of IFI44L is still unknown, but its expression has been linked to 
response to viruses. Human monocyte-derived macrophages upregulate this 
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gene after infection with recombinant adenovirus expressing HIV-1 protein Vpr, 
although no specific function has been identified to date [59]. 
 
1.4.2.2 2’-5’oligoadenylate synthetase 2 gene 
In a similar manner to IFI44L, 2’-5’oligoadenylate synthetase 2 (OAS2) gene 
expression has been shown to be increased with infection, although this 
increase was less marked [59]. In contrast to IFI44L, the protein associated with 
OAS2 has been studied to some extent. It has been found, that OAS2 produced 
after IFN stimulation remains inactive until it encounters dsRNA [60]. The 
enzyme activates Ribonuclease L (RNase L) which is capable of degrading viral 
RNA but also mRNA and rRNA [61]. The OAS2 gene is considered an indicator 
for the IFN-pathway activation [62] and has previously been used as a predictor 
for response to IFN treatment in SLE patients, indicating its potential 
importance as part of the IGS [63].  
 
1.4.2.3 IFN inducible protein 6 gene 
The IFI6 gene, also called G1P3, has been proposed to be included as part of an 
IFN scoring system, which can distinguish SLE patients with high expression 
from rheumatoid arthritis patients with low expression [64]. In contrast, 
another study has demonstrated increased mRNA levels of IFI6 in early and 
chronic RA. Furthermore, autoantibody levels against carbamylated protein 
were correlated to gene expression [65]. IFI6 expression has been correlated to 
a pro-apoptotic effect in myeloma cells when treated with IFN-2b. It has 
therefore been proposed that it can stabilize the mitochondrial potential which 
would suggest a pro-apoptotic effect also for other cells [66]. 
 
1.4.2.4 Lymphocyte antigen 6 family member E gene 
Another IFN-induced gene is known as Retinoic acid induced gene E (RIG-E), 
thymic shared antigen 1 (TSA-1) or also Lymphocyte antigen 6 family member E 
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(LY6E). TSA-1 has been explored in mice as an important protein for T-cells and 
their development [67].  
LY6E has been used as part of an IFN score together with 2'-5'-Oligoadenylate 
Synthetase 1 (OAS1), 2'-5'-Oligoadenylate Synthetase Like (OASL), MX Dynamin 
Like GTPase 1 (MX1), and Interferon-stimulated gene (ISG15) and showed 
higher prevalence in peripheral blood of SLE patients compared to healthy 
controls and RA patients [68]. Patients who had active disease, a severe disease 
activity or who had anti-dsDNA antibodies were found to present with a higher 
IFN score. While the IFN score was higher in patients with kidney involvement, 
specifically LY6E was shown to increase with higher proteinuria and kidney 
manifestation, both inactive and even more so for active nephritis [68].  
 
1.4.3 “-Omics” approaches to investigating JSLE immunopathogenesis 
The term “omics” is used to describe a more universal approach to study the 
entirety of genes (genomics), mRNA transcripts (transcriptomics), proteins 
(proteomics) or metabolites (metabolomics) of a sample, cell or organism (see 
Figure 1.2). A vast amount of data becomes available with these technologies 
and techniques become faster and cheaper. Sections 1.4.3.1 to 1.4.3.5 will 
summarise the strength and limitations of each “-omics” approach. Further 
described is the information gained so far from studies using these methods to 
investigate JSLE.  
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Figure 1.2: Omics approaches can investigate the gene level (genomics), 
RNA level (transcriptomics), protein level (proteomics) or metabolite 
level (metabolomics) of a sample. 
 
1.4.3.1 Genomics and JSLE pathogenesis 
The genome is the genetic library coding for all transcripts and therefore 
proteins. Single nucleotide polymorphisms (SNP) in a gene can cause the 
resulting protein to be overactive, inhibited or even dysfunctional. SNPs and 
copy number variants (CNV) can give information about cell functions that are 
likely to be perturbed in a disease. While SNPs can alter the function of proteins, 
CNVs can change the amount of protein present. 
Different cellular actions have been indicated to play a crucial role in the 
immunopathogenesis of JSLE based on genomic observations. These include: 
abnormalities in apoptosis, IFN-signalling, phagocytosis, complement system, B-
cell signalling, T-cell signalling, or DNA-processing. Examples of these are given 
in Table 1.3.  
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CELL FUNCTION EXAMPLES FOR GENES SHOWN TO BE ALTERED IN 
SLE PATHOGENESIS (REFERENCE) 
APOPTOSIS ATG5, FAS, FASL [69], [70] 
INTERFERON-
SIGNALLING 
IRF8, IFIH1 [71] 
PHAGOCYTOSIS FCGRIIA, FCGRIIIA [72] 
COMPLEMENT 
SYSTEM 
 C4A, C4B [40], [41] 
B-CELL SIGNALLING BANK1, BLK [69], [71] 
T-CELL SIGNALLING CTLA4, PTPN22 [73], [74] 
DNA-PROCESSING DNASE1, TREX1[42], [75] 
Table 1.3: Different functions are suggested to be altered on the genome 
level in SLE. 
 
Nevertheless, despite CNV of genes or SNPs, transcription of these genes may be 
regulated via other genes and the functionality of the proteins they express 
needs to be assessed carefully before conclusions about the effect of them in any 
given disease can be made. Alterations in the genome may increase or decrease 
susceptibility but are not in themselves definite predictors that disease will 
occur during an individual’s life. Thus, knowledge derived from genomics has to 
be understood for what it can and cannot reveal and is not absolute; its 
interpretation needs to be treated with care.  
 
1.4.3.2 Transcriptomics and JSLE pathogenesis 
RNA is the transcript of the genomic information and can mirror need of a 
specific tissue, the response to the environment, or a specific physiological 
condition. Transcriptomic analysis can be achieved by a range of techniques 
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including microarray which uses a selected range of sequences or RNA-
sequencing (RNA-seq) which analyses all transcripts. 
Transcriptomics data in patients with adult-onset SLE and JSLE has identified 
clusters of genes expressed specifically, that indicate an increased IGS and the 
importance of neutrophils in the disease process (as described in 1.4.2).  
 
1.4.3.3 Proteomics and JSLE pathogenesis 
Transcripts can be degraded quickly or may be available longer for translation 
which is the process of protein synthesis arising from mRNA. Transcriptomics 
alone can therefore only give an indication of the state of a cell, but may not 
actually affect the cell or tissue if it is not translated into protein [76]. The 
function of many of the proteins expressed from the genes that comprise the IGS 
is also unclear. 
Hence, proteomics research can only detect the presence of a protein and not its 
function or activity. This approach is often used to identify biomarkers for both 
SLE as well as JSLE. In JSLE, urinary biomarkers have been found with this 
approach to identify renal involvement and active nephritis [77]. Several other 
studies have found biomarkers to predict active or inactive LN [78], [79]. While 
proteomics data could distinguish JSLE patients with nephritis from JSLE 
patients without, and active from inactive renal disease, biomarker peak 
intensities were not able to predict different subtypes of nephritis in JSLE 
patients [77]. Other studies found good sensitivity and specificity for the 
prediction of the class of nephritis if proteomics data was fed into an artificial 
network. The only exception was class V, which is the membranous form of LN 
[80]. Urine samples are less invasive and therefore preferred for biomarker 
search using proteomics. Nevertheless, organ damage and kidney involvement 
has also been assessed with plasma of SLE patients in a Czech cohort [81]. Most 
papers focus on biomarker discovery rather than further using this tool for 
exploration of SLE pathogenesis. Nevertheless, these discoveries have been very 
useful to patients as panels of proteins have been developed to identify 
nephritis in JSLE [82] as well as remission and flares in patients [83].  
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While protein expression can help inform what a cell or tissue is expressing, it is 
still not guaranteed that those proteins are having the specific function they are 
expected to, as an enzyme or a receptor’s activity can depend (for example) on 
the presence of inhibitors or activators. 
 
1.4.3.4 Metabolomics  
The study of metabolites, called metabolomics takes a very different approach 
to this problem, as it is focused on side and end products present in a fluid, 
tissue or specific cell type. They are the result of “reactions that have happened” 
rather than “reactions that can potentially happen” as it is the case in genomics, 
transcriptomics and proteomics. Despite this, it has to be considered though, 
that observations can be a result of accumulation of a continuous process, as 
well as a response to an immediate event. 
Two techniques are currently used in metabolomics to quantify metabolites: 
mass-spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy. 
Similarities and differences between these techniques are shown in Table 1.4 
[84]. 
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 Mass spectrometry NMR spectroscopy 
Processing of 
samples 
More time, destructive 
(ionization) 
Little time, non-destructive 
Detection Targeted, predefined Untargeted, unbiased 
Sensitivity High sensitivity, but 
potential loss of 
metabolites in ionization 
step 
Only metabolites with higher 
abundance 
Advantages Identifies specific 
metabolites 
Analysis of metabolic 
pathways, cost-effective, 
high-throughput possible 
Table 1.4: Differences between mass spectrometry and NMR spectroscopy 
as used for metabolomics. 
 
  
24 
 
While in MS the sample needs to be ionized first and is then detected according 
to its mass-to-charge ratio, samples used for analysis with NMR spectroscopy 
remain intact. For the latter, only a magnetic field is applied to the sample and it 
gets excited with radio frequencies. The resonance of the nucleus is then 
measured and noted as a chemical shift for each atom in parts per million 
(ppm). The chemical environment, which stands for the shielding against the 
magnetic field, defines the ppm of a nucleus. This can be influenced by 
electronegativity, hydrophobic interactions or chemical bonds. For example, 
alcohols are found at lower ppm compared to aldehydes or aromatic rings 
(Figure 1.3).  
 
 
 
Figure 1.3: Overview (simplified) of chemical shifts.  Different chemical 
groups are shown according to their chemical shifts in ppm. While for example 
amino acids such as alanine are found between 1-4 ppm, carboxylic acids are 
found on the far right towards 10-13 ppm. 
 
Nevertheless, even when metabolites are expressed as ppm, these are just a 
relative value as they are noted as a distance from a reference value and can 
therefore be different for the same atom measured with another reference 
compound. Only nuclei with an uneven number of nucleons which consists of 
neutrons and protons can be detected. Detection is restricted to these atoms 
with a so called ½ spin as for example 1H, 13C or 14N. The most abundant one in 
nature is 1H and it consequently is a more frequently measured atom. 
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1.4.3.5 Metabolomics of SLE 
Both MS and NMR have been used to a small extent to date to investigate SLE 
metabolite profiles. Predictive models for LN have been developed on NMR-
derived metabolomics data in which it has been suggested that nephritis can be 
distinguished from patients without renal involvement [85]. Spectra from urine 
samples can be further analysed to differentiate between specific sub-classes of 
LN [85], [86]. There are studies testing predictive models of metabolites to 
distinguish SLE patients from healthy controls or other diseases [87], but 
investigation of SLE pathogenesis with metabolomic approaches are neglected. 
Further, most studies focus on serum or plasma metabolites even though urine 
can be obtained in a less invasive manner. Urine is rather used in studies 
focusing on kidney involvement.  
Importantly, no studies to date have been published that have investigated 
metabolite profiles in JSLE.  
 
1.4.4 Potential causes for autoimmune development in JSLE 
1.4.4.1 Potential role of B and T-cells in JSLE 
T- and B-cells are part of the adaptive immune system and possess antigen 
specific receptors. Specialised antigen-presenting cells like dendritic cells (DC) 
or macrophages present exogenous proteins on MHC-II molecules and all cells 
within the body can present endogenous antigens on their surface with MHC-I 
molecules. This is followed by activation of T-cells once they meet the cell 
presenting a protein they recognize with their T-cell receptor (TCR). T-cells 
which recognize self-antigens should normally be removed in a selection 
process and remaining auto-recognizing cells can cause autoimmunity [88]. 
T-cells comprise a number of subtypes, and depending on the specific T-cell 
subtype they have different roles and react with a specific response. One type 
are, CD8+ cytotoxic T-cells which can directly kill infected or damaged cells by 
releasing granzyme B and perforin which mediate apoptosis of the target [89]. 
Cells present endogenous protein on the MHC-I on the cell surface and can 
thereby signal to the cytotoxic T-cells if they need to be eliminated. 
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Autoantigens should therefore be ignored by this type of T-cell. Even though 
information is scarce in autoimmunity, in SLE, cytotoxic T-cells have been found 
in higher proportion in blood of active patients compared to patients with 
inactive disease. The percentage of cytotoxic granzyme B and perforin positive 
cells correlated with the SLEDAI of the patients [90]. 
T-helper cells are another type of T-cells which regulate other immune 
responses with differing patterns of cytokine production. Regulatory T-cells 
(Treg) have a role in dampening an immune response and produce transforming 
growth factor  (TGF-) and IL-10. Proportion of these cells was reduced in 
active SLE patients compared to inactive patients and Tregs of SLE patients were 
more sensitive to Fas, a protein inducing apoptosis [91]. Increased sensitivity to 
apoptosis has not been observed for cutaneous lupus, but a decreased 
proportion of Tregs was detected in skin biopsies from cutaneous lupus patients 
compared to healthy control samples [92].  
Th1, Th2 and Th17 cells trigger further responses. Th1-cells produce IFN and 
IL-2 for the defence against microbes, whereas Th2-cells produce IL-4, IL-5 and 
IL-13 and fight helminths. Th17-cells cause an inflammatory response with the 
production of IL-17 and IL-22 [93], [94]. Th17 cells especially cause 
inflammation and impaired IL-2 production in SLE patients [95] may skew T-
cells to rather develop into inflammatory Th17 cells instead of Tregs [95]. Th17-
cells were further discussed for JIA (see Section 1.1.2) and may cause similar 
damage in JSLE. 
B-cells recognize antigens via a B-cell receptor (BCR) similar to the TCR and 
produce antibodies which protect the body from recurrent infections. After 
activation class switching ensures that different classes of antibodies can be 
produced such as IgE, IgA, IgM and IgG [96]. Production can be stimulated both 
with and without Th cell assistance [97]. During development B-cells undergo a 
selection process and those with high-affinity for autoantigens undergo 
apoptosis [98]. Dysfunctional selection increases the number of autoreactive B-
cells present and is found to be a problem in SLE and may explain autoreactive 
antibodies [99]. SLE is indeed characterised by the presence of autoantibodies, 
indicating a major importance of B-cell dysfunction in the pathogenesis of SLE 
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[100]. Survival of autoreactive B-cells may be supported by proteins stimulating 
proliferation of B-cells, such as BAFF. BAFF inhibits apoptosis and has been 
found to be significantly increased in SLE patients [45].  
B- and T-cells, together referred to as lymphocytes, trigger production of anti-
nuclear autoantibodies such as anti-chromatin/nucleosome or anti-dsDNA 
antibodies in autoimmunity. However, the origin of the antigens that cause 
antibody production has yet to be fully elucidated [100]. Lymphocytes express 
increased levels of Fas, also called Fas receptor or apoptosis antigen 1 which 
induces apoptosis. Higher expression on the cell-surface of SLE lymphocytes 
compared to healthy control lymphocytes indicates a higher rate of apoptosis 
and thereby potential presentation of autoantigens. On the other hand the 
expression of B-cell lymphoma 2 protein (Bcl-2), an anti-apoptotic protein, is 
upregulated in T-cells of JSLE patients, which might lead to restricted clearance 
of autoreactive cells [101]. 
All the aforementioned discoveries of B- and T-cell abnormalities suggest an 
important role of the adaptive immune system in JSLE. 
 
1.4.4.2 Cytokine abnormalities 
Investigation of the underlying pathogenesis of SLE has involved exploration of 
both the adaptive and to a lesser extent the innate immune system. 
Communication between all cell types including non-immune cells is achieved 
with small molecules called cytokines. Many of those are known to be abnormal 
and dysregulated in SLE patients. Here, the focus will be on three important 
cytokines relevant to in SLE pathogenesis, namely IFN, TNF and IL-17.  
 
1.4.4.2.1 Interferons  
Interferons are a class of cytokines that have been considered important for 
protection against viruses [59], but have also been found to play a role in 
autoimmune diseases. The class of IFNs consist of type I IFNs, which comprise 
IFN, , , , , and type II IFN which is restricted to IFN and type III IFNs 
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consisting of IFN. Stimulation of monocyte-derived dendritic cells with 
lipopolysaccharides (LPS), flu virus or polyinosinic:polycytidylic acid (poly I:C) 
triggers both type I ( and ) and type III IFN production [102]. Similar to type I 
IFNs, production of IFN activates STAT2 and thereby contributes to antiviral 
activity and inhibition of cell proliferation [103]. There are not many studies 
focusing on type III IFNs. Nevertheless, both mRNA and protein expression of 
type III IFNs have been found to be significantly increased in SLE patients, 
which included juvenile-onset cases, compared to healthy controls [104]. 
Furthermore, protein concentration of type III IFNs in serum was significantly 
higher in active compared to inactive patients. This study demonstrated a 
strong correlation between IFN and anti-dsDNA levels in patients, which could 
go some way to explaining the increased cytokine release [104].  
As already mentioned in Section 1.4.4.1, Th1 cells are producers of IFN, the 
only type II IFN. When IFN is injected into lupus-prone mice it stimulates 
lupus-like glomerulonephritis [105]. Similarly, in IFN-transgenic mice a lupus-
like phenotype developed with auto-antibodies and nephritis suggesting this 
IFN to have a higher involvement in the development of kidney disease in SLE 
[106]. A study investigating IFN in SLE patients found increased serum levels of 
this cytokine and noted that IFN levels preceded increased type I IFN activity 
[107].  
Type I IFNs have been investigated much more extensively in SLE to date, and 
IFN specifically has been included in a wide range of important studies. This 
cytokine possesses 13 subtypes and its main producers are plasmacytoid 
dendritic cells (pDCs) [108]. These cells have been found (among other tissues) 
in skin samples of SLE patients, especially at the sites where lesions were 
present, showing their probable involvement in the disease process itself [109]. 
pDCs produce IFN a cytokine important for JSLE (see Section 1.4.2 and 
1.4.4.2.1.). Among other stimuli, pDCs release IFN in the presence of poly I:C, 
which mimics dsRNA for example of Herpes Simplex virus type I (HSV) or 
plasmid DNA. A case of an IFN response that may be relevant to lupus disease 
was observed after stimulation with apoptotic and necrotic supernatants in the 
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presence of SLE IgG [110]. A more recent study has suggested that neutrophils 
are also capable of producing IFN in response to circulating chromatin. Even 
though neutrophils may produce less cytokine per cell than pDCs, due to the 
high abundance of neutrophils in the body, their effect may still exceed the 
overall effect of pDCs [111]. For some time, IFN serum levels have been found 
to be higher for disease active patients. In the first study in 1979 a positive 
correlation with anti-dsDNA antibodies was also found [112]. In this study, the 
cytokine was measured indirectly as assays detected antiviral activity and noted 
this to reflect IFN levels. Clearly, other factors may have also played a role in 
antiviral activity, rather than IFN alone. [112]. Since then, most other studies 
also focused on indirect measurement of IFN, for example by looking at IFN-
induced genes as described in Section 1.4.2 such as Baechler et al. in 2003 [54]. 
In SLE nephritis biopsies, mRNA staining of IFN was positive in renal epithelial 
tubular cells, suggesting that these cells can also produce the cytokine [113]. 
IFN has been shown to be present in SLE serum, but to be even higher in JSLE 
patients. Cytokine levels were shown to correlate with IGS for SLE, JSLE and 
other diseases, while JSLE patients had higher IFN levels than SLE patients 
[114]. Of note, in this study, one of the adult-onset SLE patients had an IFN high 
signature with low IFN levels and another one had an IFN low signature with 
high IFN levels which could not be explained. IFN levels above 300 fg/ml 
were further associated with high disease activity [114]. Discrepancies between 
IFN levels and the IFN signature could be explained by mutations in genes 
known to cause an IFN signature [57], or could indicate the influence of other 
cytokines.  
Most studies described above focus on adult-onset SLE leaving childhood-onset 
under-investigated in comparison. Furthermore, the impact on disease 
pathogenesis of patients dependent on whether they are IFN high or IFN low 
has not been investigated and may be essential for treatment of JSLE. 
 
30 
 
 Tumour necrosis factor-alpha (TNF) 
TNF is an important cytokine, considered to be proinflammatory, with 
multiple functions including apoptotic and proliferative effects [115], [116]. On 
one hand, TNF can help trigger apoptosis [116] when acting through TNF-
receptor 1 (TNFR1) via the Fas-associated protein with death domain (FADD) 
[117]. On the other hand TNF is proposed to have anti-apoptotic effect [118] 
when signalling through TNFR2 [119]. Furthermore, TNF treatment of T-cells 
has caused them to respond with stronger proliferation [120]. Similarly, B-cells 
require TNF to proliferate and in the presence of TNF enhanced proliferation 
is observed [121]. 
A link between SNPs in the TNF gene at position 308 and SLE and JSLE was 
observed, although this has not been explored further if this has an effect on the 
protein expression [122], [123].  
The pro-inflammatory effect of TNF in SLE pathogenesis is controversial as 
some studies suggest its importance and others indicate it may have no 
influence on the disease process. A positive correlation has been noted between 
the SLEDAI score of SLE patients in an Egyptian patient cohort and serum TNF 
concentration [124]. In contrast a different study measured high levels of 
TNF in disease inactive patients [125]. Lower disease activity was further 
marked by higher TNF concentrations than high disease activity [125]. 
Nevertheless, both studies found higher levels of this cytokine in SLE patients 
compared to healthy controls.  
Use of anti-TNF antibodies in the treatment of SLE is controversial. These 
agents, such as infliximab, have been shown to ameliorate manifestations 
including arthritis and nephritis in both SLE and JSLE patients, but results were 
not stratified according to the age of onset [126]. Interestingly, serum levels of 
TNF had more than doubled following six months of antibody treatment, 
although this did not differ significantly between those treated with 
conventional therapy and the infliximab-treated group [126]. 
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Importantly though, it has also been observed that anti-TNF treatment of 
arthritis patients with adalimumab, etanercept or infliximab has led to 
induction of lupus with cutaneous manifestation, fever, polysynovitis or even 
nephritis. The underlying diseases associated with arthritis were RA, psoriatic 
arthritis, JIA, Crohn’s disease ankylosing spondylitis. The study design related to 
each of these reports was unable to determine if the antibody treatment was the 
sole cause for lupus-related symptoms [127]. Animal models have shown that 
absence of TNF can enhance SLE development. One study for example knocked 
out the TNF gene in mice otherwise not susceptible to lupus and found them to 
develop disease similar to an established LN mouse model [128]. 
 
1.4.4.2.3 Interleukin-17 (IL-17)  
The family of IL-17 cytokines includes a number of sub-types, namely IL-17A, -
17B, -17C, -17D, -17E and -17F. However, the IL-17A form is most commonly 
referred to as IL-17 and will be discussed specifically here. 
IL-17 is produced generally by Th-17 cells and induces release of granulocyte-
colony stimulating factor (G-CSF) and IL-8 and thereby attracts neutrophils and 
stimulates their development [129]. Further, IL-17 together with TNF has 
been suggested to promote a pro-inflammatory and pro-apoptotic environment 
[130].  
As described in Section 1.1.2, IL-17 has been studied in JIA and is considered a 
main driver of the disease. In freshly isolated T-cells from SLE patients, the 
production of IL-17 has been found to be increased [131]. These cells were 
detected in the kidney biopsies of SLE patients suggesting attraction of 
neutrophils into the kidney and giving potential explanations for damage and 
induction of LN [131].  
IL-17 has been shown to correlate with a patient’s SLEDAI score in a group of 
SLE patients with an age range from 18-40. They were described as new-onset 
patients, but as diagnosis can take time this population may have included some 
JSLE patients, but this was not specified [132]. Nevertheless, JSLE patients have 
been described to have higher levels of IL-17A in plasma and in supernatant of 
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PBMCs stimulated with CD3/CD28 in vitro. However, IL-17A was higher in only 
a minority of JSLE patients than in healthy controls [133]. 
 
1.4.4.3 Potential role of neutrophils in JSLE pathogenesis 
Many reports indicate the innate immune system to be especially involved in 
the initiation of SLE pathogenesis, and to be a potential source for the nuclear 
autoantigens so characteristic of the disease. 
 
1.4.4.3.1 Neutrophils and their natural history 
One essential cell of the innate immune system is the neutrophil, a granulocyte 
which is the most abundant white blood cell or leukocyte in the blood. In 
response to infections they are the first actors in the defence machinery of the 
immune system. They were originally considered to only have a half-time in the 
blood of between 4-9 hours and a high turnover rate of 86-341x107/kg/day; 
they then are likely to die or migrate into tissue. In healthy individuals, both 
their half-time in the blood and turnover of neutrophils exhibits significant 
variability [134]. Their lifespan is still under discussion as a more recent study 
proposed that neutrophils have a half-life of 5.4 days in the peripheral blood. 
This study considered that the handling of the neutrophils may have an 
important impact on their perceived lifespan and the presumption of their rapid 
death was actually just an observation caused by an artefact of the original 
assay [135]. At the end of their life, neutrophils upregulate CXCR4 and migrate 
to the bone marrow where they undergo apoptosis [136]. This function appears 
to be dysregulated as neutrophil apoptosis in the peripheral blood is increased 
in JSLE [137]. The role of cell death especially of neutrophils in SLE is further 
discussed in Section 1.4.4.4. 
 
1.4.4.3.2 Neutrophil function 
As first guards of the immune system, neutrophils use several means to fight 
infections. These include phagocytosis (further discussed in Section 1.4.4.5), 
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meaning engulfing the pathogen and killing it with reactive oxygen species 
(ROS), degranulation, meaning releasing their toxic granules and NETosis 
(further discussed in Section 1.4.4.4.2), a special cell death that involves 
extruding their chromatin.  
Upon infection neutrophils get attracted to the site of infection, for example by a 
complement component such as C5, cytokines such as IL-8 or bacterial 
components such as N-Formylmethionyl-leucyl-phenylalanine (fMLP) [138]–
[140]. Reaching the targets they then detect them either directly via Toll-like-
receptors (TLRs) which recognize pathogen-associated molecular patterns 
(PAMPs) (more details found in Sections 1.4.4.5 and 1.4.5.1) or via molecules 
which opsonize the pathogen (further described in Sections 1.4.5.3 and 1.4.5.3). 
ROS production in the phagosome via nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase supports the killing of the pathogen inside the cell 
and dysfunction of this enzyme can lead to a serious disease called chronic 
granulomatous disease [141]. The killing of pathogens further requires 
degranulation, meaning release of the enzymes and peptides from the 
preformed granules into the phagosome [142]. Neutrophil granules are divided 
into primary (azurophilic), secondary (specific) and tertiary types. 
Myeloperoxidase (MPO), cathepsins, elastase and defensins are found in the 
primary granules which are the most toxic ones. Secondary granules contain 
lactoferrin as the main protein and tertiary granules contain gelatinase [143]. 
NETosis occurs when pathogens are too big to be phagocytosed. As proteins 
from primary granules can be released from the cells via NETosis they are 
considered to cause harm to the surrounding tissue in diseases like RA and SLE 
[144], [145]. Furthermore, antibodies against MPO have been found in SLE 
demonstrating the role of neutrophils in disease development [146].  
 
1.4.4.4 Cell death 
Depending on the stimulation and predisposing factors, there are different ways 
for a cell to undergo cell death. Also called a programmed cell death, apoptosis 
can be induced both from within e.g. by stress or DNA damage, but also from 
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outside the cells via the Fas-receptors. The aim of apoptosis is to clear cells in a 
non-inflammatory manner which makes it suitable for processes like tissue 
development or homeostasis. One of the key steps of apoptotic cell death is the 
condensation and fragmentation of chromatin, which might be a way of 
preventing immune responses [147]. Apoptotic cells release signals and present 
them on their cell surface, such as phosphatidylserine. This way they get cleared 
away and even though many cells undergo apoptosis every day only few are 
found in tissues or in circulation [148]. 
If apoptotic cells are not removed they start losing their membrane integrity 
leading to secondary necrosis. Direct induction of necrosis is possible, and both 
the cellular organs and cytoplasm swell until the cell membrane ruptures. This 
occurs if there is no chance for repair after significant cell damage and leads to 
an uncontrolled death. Over the last few years it has become clear that there is 
also programmed necrosis induced for example by TNF. These pathways are 
further divided depending on their intracellular signalling into necroptosis, 
mitochondrial permeability transition-regulated necrosis, and parthanatos 
[149]. Oxidative (also called) respiratory burst has been observed for both 
primary necrosis and secondary necrosis meaning that there is a release of ROS 
[150]. The rupture of the necrosing cells further releases larger molecules into 
the environment such as damage-associated molecular patterns (DAMP) and 
DNA [151].  
 
1.4.4.4.1 Apoptosis in JSLE 
Among the different types of cell death described (see Section 1.4.4.4), 
apoptosis has been found to be dysregulated in both T- and B-cells in JSLE [101]. 
Modifications of the chromatin, like citrullination or acetylation, occur during 
the programmed cell death and make DNA in combination with other molecules 
like High-mobility group box-1 protein (HMGB1) immunogenic. As long as 
apoptotic cells get removed the process is invisible to the immune system, but if 
they remain for longer, they become necrotic. Then the modified chromatin with 
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HMGB1 is available to dendritic cells (DC) for uptake, which can trigger auto-
antibody production [152].  
Autoantibodies in lupus can be directed against SS-A/Ro an extractable nuclear 
antigen (ENA) and Smith antigen (Sm). These proteins stay intact and are not 
cleaved by proteolysis during apoptosis or primary and secondary necrosis 
[153]. They therefore serve as ideal targets for the immune system to develop 
autoantibodies. More apoptotic cells are observed in SLE patients compared to 
healthy adults; an increase in apoptosis, a faulty signalling towards phagocytic 
cells, or dysregulation of phagocytosis could be a reason [148]. In JSLE, 
neutrophils themselves show a higher rate of apoptosis, and additionally the 
serum of these patients can promote apoptosis compared to serum from non-
lupus patients. Both Fas Ligand (FasL) and TNF-related apoptosis-inducing 
ligand (TRAIL) which are known to be pro-apoptotic factors are found to be 
elevated in JSLE serum [137]. 
 
1.4.4.4.2 Neutrophils and the Neutrophil Extracellular Traps (NETs) 
Neutrophils are part of the innate immune system and release as part of their 
defence cytotoxic contents. This serves as an effective protection against 
pathogens but can also cause tissue injury leading to non-infectious 
inflammatory diseases. 50-60% of patients with SLE develop neutropenia 
suggesting an important role for neutrophils in this disease [137]. Neutrophils 
are an abundant cell type and as they have a short life-span they may already be 
an apoptotic burden to the immune system. If control of neutrophil apoptosis or 
clearance is dysregulated, this may lead to the presentation of autoantigens to 
the immune system and may support development of autoimmune diseases 
[154]. One of the roles of neutrophils is clearance of pathogens by phagocytosis 
(further explained Section 1.4.4.5), but this process can be insufficient for the 
number of pathogens when they replicate too quickly or if the pathogen is too 
large to be taken up.  
In these circumstances, the release of neutrophil extracellular traps (NETs) in a 
process called NETosis is required, which is a cell type specific death that only 
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occurs in neutrophils. Activated platelets, bacteria, and also fungi can trigger 
this release of chromatin with antimicrobial, granule specific proteins attached. 
This defence mechanism involves perforation of the cell membrane and thereby 
the death of the neutrophils [155]. Upon stimulation, neutrophil elastase (NE), 
an enzyme usually located in the granules, transports into the nucleus where it 
is responsible for the degradation of the chromatin. Myeloperoxidase then 
breaks down the nuclear envelope and further processes the chromatin. After 
about 120 minutes the cell membrane ruptures and NETs are released to 
capture the pathogen. It should be noted that recent data also suggest that cell 
survival after NET release is possible [156]. 
 
1.4.4.4.3 NETosis in JSLE 
Besides apoptosis, NETosis also seems to be of great importance in the 
aetiopathogenesis of JSLE. As in programmed cell death (apoptosis), in NETosis 
chromatin also undergoes modifications but decondensation is necessary before 
it can be released into the extracellular environment. NETs can therefore 
become a source of auto-antigens and subsequent targets for immune 
complexes and complement. NETs can also cause direct tissue damage and can 
therefore be involved both in the development of the disease and its symptoms 
[157]. Increased NETosis and impaired NET removal seems to be involved in 
SLE as NETs have been found in SLE both in blood and in tissues [158]. Very 
recently our group has demonstrated that a subset of neutrophils, the so-called 
low-density granulocytes, is augmented in JSLE patients [159]. This cell type 
displays inflammatory capacity and is more likely to produce NETs [159]. 
Dysregulated apoptosis and NETosis might explain why more apoptotic cells 
and NETs are seen in JSLE patients. This apoptotic and inflammatory 
environment in turn also affect cells in patients and causes them to be 
dysregulated. 
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1.4.4.5 Phagocytosis 
Phagocytosis is a process of removing bacteria, debris and apoptotic material 
safely. Cells responsible for the removal of apoptotic cells or pathogens are 
called phagocytic cells. They can be divided into professional phagocytes, which 
are macrophages, monocytes, immature dendritic cells and neutrophils, and 
non-professional phagocytes like NK-cells, lymphocytes, and surrounding cells. 
To be removed the apoptotic cells send “find/eat me” signals to professional 
phagocytes. One example is sphingosine-1-phosphate which is released after 
stimulation of apoptosis and which then attracts cells such as monocytes or 
macrophages [160]. Another example of an attractant of professional 
phagocytes are nucleotides present in apoptotic supernatants with ATP or UTP 
being stronger attractants than ADP and UDP [161]. In addition, apoptotic cells 
can release signals to keep cells which would cause inflammation away. For 
example, neutrophil attraction could cause inflammation and it could therefore 
be beneficial for apoptosing cells to attract only monocytes/macrophages for 
removal. The presence of lactoferrin will repress chemotaxis only of neutrophils 
even in the presence of strong neutrophil-chemoattractants like IL-8 or fMLP 
[162]. When reaching the apoptotic cells further “eat me” signals such as from 
phospholipid phosphatidylserine on the cell surface are required to start the 
engulfment by the phagocytes [163]. 
Microorganisms on the other hand are recognized via PAMPs with pattern 
recognition receptors (PRR). Patterns on bacteria include cell wall components 
such as LPS, peptidoglycan or lipoproteins. Fungi possess components such as 
mannans, glucans, zymosan or chitins that can be recognized. The immune 
system possesses proteins which can detect these patterns. These include Toll-
like receptors (TLRs), lectins, nucleotide oligomerization domain proteins 
(NOD) or peptidoglycan receptors [164]–[166]. 
After engulfment phagocytes can either retain bacteria intracellularly to stop 
them from proliferating, which is a state called bacteriostasis, or can digest and 
thereby kill them. Digestion happens within the phagosome when fusing with 
the lysosome by acidification and breakdown by enzymes [167].  
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1.4.4.5.1 Phagocytosis in JSLE 
To date, there is a paucity of robust data available describing the phagocytic 
activity and control mechanisms in JSLE, even though dysregulation of 
phagocytosis can cause presentation of nuclear antigens. 
PBMCs, for example, provide evidence of reduced clearing of apoptotic material 
in in vitro experiments [168]. As the study of Ballantine et al. 2015 showed, 
serum from JSLE patients decreases phagocytosis of E.coli and apoptotic 
neutrophils by healthy macrophages, whereas monocytes from healthy 
individuals retained normal phagocytosis function when they were incubated 
with their own serum. The phagocytic ability of JSLE monocytes was also 
restored when they were incubated with healthy control serum. Tyro3, Axl and 
Mer were found to be decreased on the cell surface of monocytes and their 
soluble counterparts to be increased. These molecules are involved in removing 
apoptotic cells, and by their cleavage off of the surface the ability to phagocytose 
is diminished. This explains why the monocytes isolated from patients and 
incubated with patients’ serum display decreased capacity to remove bacteria 
[4]. Further research was undertaken on samples from adult-onset SLE patients. 
It was shown that their monocytes express less CD44 on their surface than the 
ones of healthy controls. This molecule seems important for the binding and 
phagocytosis of apoptotic cells [169]. Despite these findings, the mechanisms 
behind phagocytosis in JSLE remain poorly understood. 
 
1.4.4.5.2 Phagocytic clearance by Neutrophils in JSLE 
PBMCs are not the only cells responsible for phagocytosis and neutrophils play 
at least an equally important role. Reduced phagocytosis has been observed 
with decreased engulfment of albumin and polyglobin-coated beads in 60% of 
the adult-onset SLE patients [168]. A similar hypothesis was proposed by 
Chauhan et al. 2015 who investigated NET degradation and phagocytosis. 
Looking at a heterogeneous group of juvenile- and adult-onset SLE patients, 
they observed reduced dismantling of the NETs by their serum compared to 
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healthy controls. When the results were divided into subgroups it was shown 
that serum of patients with anti-dsDNA and anti-dsDNA plus ENA antibodies 
showed reduced degradation, whereas samples from patients with just anti-
ENA antibodies behaved no differently to healthy controls. Even though there 
seemed to be a difference in NET degradation between the groups, for all of 
their serum they saw an effect of reducing phagocytosis in healthy neutrophils 
[170]. Knowledge about efficacy of phagocytosis and processing of different 
bacteria by neutrophils of JSLE patients is very limited and the possible 
dysregulation within the neutrophils is not studied. This underlines the 
importance of investigating dysregulated phagocytosis in JSLE which may 
induce NETosis. 
 
1.4.5 Phagocytosis related genes in JSLE patient neutrophils  
Dysregulated phagocytosis might not only leave apoptotic debris behind as a 
source for auto-antibody production, but might also alter the reaction following 
phagocytic stimuli towards cell death like NETosis [171]. Therefore, phagocytic 
regulation needs to be investigated. While phagocytic genes have not been 
investigated as a group, several genomic studies have found phagocytosis 
related genes to be susceptibility genes. Low copy numbers of C4 were linked to 
a risk to develop SLE [40] and so were individuals with low copy numbers of 
FcRIIIb [172]. Transcriptomic data is rarer and especially neutrophil specific 
data are lacking. 
Transcriptomic data our group acquired from our JSLE cohort showed 
significant differences between control patients’ and JSLE patients’ gene 
expression profiles of neutrophils (unpublished data). For this present study, 
genes were chosen based on significance in the aforementioned unpublished 
study and on their involvement in phagocytosis. The functions of these genes 
are summarized in Figure 1.4. 
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Figure 1.4: Summary of functions of all phagocytosis related genes tested in this thesis.  Clockwise, from the left top is 
shown: TLR2, a pathogen-associated molecular pattern recognition receptor. Dectin-1 recognizing size of pathogens together 
with TLR2 and leading to NETosis if phagocytosis is not possible. CD3 detects complement opsonized bacteria. Low-affinity 
FcRIIIb recognizes antibody covered pathogens. S100A8/S100A9 heterodimer can stimulate phagocytosis in an endocrine and 
autocrine way. AnxA3 binds to phosphatidylserine of apoptotic cells. Inside the neutrophil: CamK1D, responsible for 
phagosome-lysosome fusion and ROS production to eliminate pathogens.
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1.4.5.1 Toll-like Receptor 2 
Toll-like receptor 2 (TLR2) is one of the pattern recognition receptors 
recognizing PAMPs and DAMPs (described in Sections 1.4.4.4 and 1.4.4.5). This 
specific receptor forms heterodimers with TLR1, Dectin-1 and TLR6. It is known 
that lipoprotein is a ligand for TLR2, but the receptor also recognizes zymosan, 
lipoteichoic acid or LPS. Pathogens containing any of these molecules or 
patterns, such as bacteria and yeast, will activate the receptor [173]. As for most 
TLRs, this is followed by recruitment of Myeloid differentiation primary 
response gene 88 (MyD88) and activation of nuclear factor-B (NF-B) [174], 
[175]. Signalling through TLR2 can lead to secretion of both anti- and pro-
inflammatory cytokines including IL-10, IL-12, IL-13 and IFN- [176], [177]. 
TLR2 can further localize in intracellular structures and induce type I IFNs and 
TNF production [178]. The main function of TLR2 is to create an inflammatory 
environment through triggering the release of cytokines [179]. It was reported 
that by adding macrophage-activating lipopeptide 2 (Malp2), which stimulates 
the TLR2/6 heterodimer, or Pam3CSK4, a synthetic triacylated lipoprotein 
stimulating TLR2/1, to human neutrophils, they are less likely to undergo 
apoptosis and showed more phagocytosis of bacteria. In this paper, the effect for 
Pam3CSK4 was only observed at high concentrations and therefore might not 
be relevant in physiological conditions [180]. Hellberg et al. 2011 also tested the 
influence of TLR2 on phagocytosis of apoptotic cells. Both Malp2 and Pam3CSK4 
incubation resulted in a significant increase of the phagocytic activity of 
neutrophils and thus demonstrated the link between TLR2 and phagocytosis. 
The activation by Pam3CSK4 was observed only at high concentrations [181]. 
 
1.4.5.2 Dectin-1 
Even though TLR2 forms heterodimers with other TLRs, it also interacts with a 
non-TLR-type receptor. This particular receptor is called Dectin-1 and is a C-
type lectin recognizing PAMPs, like -glucan or zymosan which can be found on 
fungi [171]. This protein is also known as CLEC7A and is part of the family of 
non-classical C-type lectins. After ligand binding, the immunoreceptor tyrosine-
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based activation motif (ITAM)-like motif of Dectin-1 becomes phosphorylated 
and activates spleen tyrosine kinase (SYK) [182]. The signalling leads to 
production of inflammatory cytokines, respiratory burst and phagocytosis 
[183]. Dectin-1 is important in neutrophils as it can sense the size of microbes 
and thereby alter the phagocytic process of the neutrophil. Fungi for example 
can be present both in small yeast but also in a large filamentous hyphae form, 
and it is important to distinguish between these states. While the yeast can still 
be phagocytosed, the size of hyphae triggers NETosis. Similar observations have 
been made with bacteria that form larger aggregations and therefore inhibited 
phagocytosis. Branzk et al. 2014 suggest that this discrimination and the 
following reaction of the cell is dependent on Dectin-1, as its deficiency leads to 
NET release in response to a pathogen independent of the size of the microbe 
[171]. Thus Dectin-1 is essential for phagocytosis and it has been found to be 
both defective and associated with fewer monocytes in SLE and rheumatoid 
arthritis compared to healthy controls. In active disease a significantly lower 
Dectin-1 protein expression has been found than for inactive SLE [184]. 
 
1.4.5.3 Complement receptor 3  
Both CD18 and CD11b are integrins and are the two subunits that make up 
complement receptor (CR) CR3. This heterodimer can bind to iC3b which 
opsonizes apoptotic cells. Stimulation of CR3 can alter cytokine production and 
phagocytosis so that the apoptotic cells are cleared [185]. Links between CR3 
and SLE have been observed, as mutations in the gene for this protein are highly 
associated with disease development. Some of the mutations studied were also 
tested for their functionality and revealed impaired phagocytosis [186], [187]. 
 
1.4.5.4 FcRIIIb 
IgM, IgA, IgE and IgG antibodies all have their specific receptors which are 
required to detect antibody-opsonized targets. The Fc receptor IIIb also known 
as CD16, is a protein which binds the constant region of IgG with low-affinity. 
CD16 can be found on other cells (CD16a), but CD16b is considered exclusive to 
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neutrophils linked to the cell membrane via glycosyl-phosphatidylinositol [188]. 
Each neutrophil possesses between 120,000 and 400,000 molecules on its 
surface [189]. The Fc receptor has been detected intracellularly from 
compartments which can quickly restore cell surface protein [190]. This is 
necessary, because besides the location on the cell surface and intracellularly, 
CD16b can be shed. Cleavage into the supernatant or blood from the surface 
requires ADAM metallopeptidase domain 17 [191]. This is caused for example 
by actin polymerization or cell death [192], [193]. 
Neutrophils are able to bind to IgG complexes and this process has been shown 
to be linked to CD16b as its blockade inhibited binding of complexes [189]. 
Targeting CD16 with antibodies also decreased phagocytosis of heat-killed 
opsonized S.aureus by neutrophils [194]. Fossati et. al supported the theory 
further when they depleted this protein. They demonstrated that a lack of 
FcRIIIb leads to a decrease both in phagocytosis of IgG-opsonized beads and in 
activation of the respiratory burst, which are both essential for efficient 
phagocytosis [195].  
 
1.4.5.5 S100A8 and S100A9 
The S100A9 and S100A8 proteins form heterodimers called calprotectin and 
upon Ca2+ binding they create a heterotetramer. Their expression in 
keratinocytes and epithelial cells is induced by inflammation, but they are found 
even under healthy conditions in monocytes and neutrophils. Activated 
phagocytes need the heterotetramer for their migration as it is part of the cross-
linking of the microtubules [196]. Calprotectin and S100A9 alone also stimulate 
the NADPH oxidase complex which is linked to the phagosome. That is probably 
why a knockdown of S100A8/A9 results in a decrease of phagosomal ROS-
production [197]. Simard et al. further investigated the influence of S100A9 on 
phagocytosis and found neutrophils to have stronger FcR- and CR-mediated 
uptake when S100A9 was added to the neutrophil medium. Upon activation 
with S100A9 neutrophils phosphorylate Syk, a kinase implied in phagocytosis. A 
cell can stimulate itself in an autocrine manner with S100A9 and thereby be 
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more prone to perform phagocytosis. This involves S100A9 in the process of 
phagocytosis [198]. 
 
1.4.5.6 Annexin A3 (AnxA3)  
The annexin family consists of proteins that are regulated by Ca2+-signalling and 
they are thought to be involved in exocytosis (transport out of the cell) and 
endocytosis (transport into the cell) [199]. Very little is known about the 
annexin family and even less is published about AnxA3. For Annexin A1 and A2 
it has been reported that they bind to S100 proteins and, besides trafficking, the 
protein family is also implicated in inflammation and apoptosis [200]. 
AnxA3 is found in cytoplasmic granules in resting neutrophils. When the cells 
are activated upon phagocytosis of opsonized zymosan, the protein localizes at 
the membrane of the phagosome instead [201]. Rosenbaum et al. demonstrated 
that mouse AnxA3 can interact with phosphatidylserine, which is presented by 
apoptotic cells. Binding of AnxA3 was shown on both early apoptotic, and 
secondary necrotic cells. This suggests an important function in the clearance of 
dying cells as annexins are found both on apoptotic cells and phagocytes [202]. 
Even though the study was performed with mouse AnxA3, the genetic 
differences with the human equivalent have been proposed to not result in 
differences in function [203]. 
 
1.4.5.7 CamK1D 
Ca2+/Calmodulin-dependent kinases are responsible for a downstream 
signalling and include the enzymes CamK1-4. For activation they either have to 
be phosphorylated or the auto-inhibitory domain in the protein has to be 
removed [204]. There are four different isoforms of CamK1, namely CamK1, , 
 and . A synonym for CamK1 (CamK1D) is CamK1-like kinase and it is also 
called CKLiK. The mRNA of CamK1D is found in granulocytes but is hardly 
expressed in monocytes and lymphocytes [205]. 
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Ca2+ levels change upon activation of neutrophils and Ca2+ being important for 
respiratory burst, phagosome-lysosome fusion and adhesion, suggests a role of 
CamK1D in these processes. For phagocytosis to be properly functional both 
adherence to the pathogen and the production of ROS, as well as the fusion of 
the phagosome with the lysosome, are essential. It has been shown that 
CamK1D can activate ERK1, a kinase regulating phagocytosis [205], [206]. In 
2005 the same group showed that by inhibiting the kinase function of CamK1D, 
ROS production and phagocytosis were reduced [207]. 
 
1.4.6 Summary 
Autoimmune diseases are conditions which affect patients’ lives in a very 
serious way. The impact of autoimmune disease is even greater for children 
who exhibit symptomology and disease burden over a longer life course, 
particularly as contemporary disease management offers a longer life 
expectancy. Furthermore, autoimmune disease often differs in children in 
important features and clinical characteristics, who cannot just be seen as a 
small adult. The specific needs of children and young people with autoimmune 
diseases such as JSLE and JIA need to be directly addressed. There is much to 
learn regarding the aetiopathogenesis of SLE from adult patients, but to date, 
less is known regarding the specific characteristics in JSLE patients. Stratifying 
patients into both juvenile-onset and adult-onset disease offers opportunities to 
learn specific aspects of disease mechanism in this wide spectrum of disease. 
While there have been several approaches to study these diseases to date 
including genetic, transcriptomic data and proteomic data, the contribution of 
metabolomic data to this process are still lacking, especially in paediatric 
autoimmune diseases including JSLE and JIA. 
In recent years there has been considerable attention given to exploring and 
understanding the role of the IGS in the aetiopathogenesis of JSLE, and in 
particular whether it can be another way of stratifying patients. Specific 
consideration has also focussed on the IGS and the importance of neutrophils in 
the evolving disease mechanisms. Patients can be divided into both IFN high and 
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IFN low expressing subgroups. However, to date, there have been no specific 
investigations undertaken to compare the metabolite profiles of these patient 
groups stratified by IGS expression. 
Within the different IGS patient subgroups, a phagocytosis-related gene 
signature (PRG signature, PGS) has also been detected in the transcriptomics 
data. Therefore, it can be hypothesised that phagocytosis is dysregulated which 
may lead to increased NETosis and that this process may be considered a 
potential cause for autoantibody production in JSLE patients. Understanding the 
role of these specific characteristics of neutrophil function and their 
involvement in the evolving disease mechanism of this archetypal autoimmune 
disease is therefore important. Several factors inhibiting phagocytosis in both 
adult-onset SLE and JSLE patients have been described, but a direct 
investigation of the ability of JSLE neutrophils to phagocytose has yet to be 
performed. Investigation to date of the triggers and causes of the PGS, and the 
IGS in JSLE, is very limited. 
 
1.4.6.1 Overarching hypothesis 
It is possible to stratify JSLE patients based on their metabolite profiles present 
in serum and urine or by phagocytic and IFN-induced gene signatures present in 
neutrophils from whole blood. The PGS should be visible in the phagocytic 
activity of PMN of JSLE patients and signatures are caused by the environment 
of PMN. 
 
1.4.6.2 Overarching aims 
Aim 1: To explore the ability to stratify patients with autoimmune diseases 
based on their IGS, including a metabolomics approach using urine and serum. 
Aim 2: To investigate the PRG and IG signatures in neutrophils of JSLE and 
healthy paediatric controls. 
Aim 3: To determine if the PGS is translated onto protein and functional level in 
neutrophils of JSLE patients. 
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Aim 4: To determine the influence of factors present in the neutrophil 
environment including TNF, IFN, nucleosomes and signal released from 
apoptosing cells, on the PGS.  
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 Materials and Methods 
This chapter describes materials and general methods used to achieve the aims 
stated in Section 1.8.2. At the beginning of Chapters 3-5 the methods specific for 
each chapter are described. 
2.1 Patients and sample collection  
2.1.1 Patient criteria 
Urine and whole blood samples were collected from patients who were part of 
the UK JSLE Cohort Study and Repository. The study was approved by the North 
West Liverpool East Research Ethics Committee (REC: 6/Q1502/77) (Appendix 
A 1). JSLE patients were diagnosed according to the revised American College of 
Rheumatology (ACR) criteria for SLE [27] before the age of 17 years. Patients 
were recruited from those attending the Department of Paediatric 
Rheumatology, Alder Hey children’s NHS Foundation Trust, Liverpool, UK. 
Whole blood and urine samples were collected with the support of the National 
Institute for Health Research (NIHR) Alder Hey Clinical Research Facility. 
Additional whole blood samples were received from the Central Manchester 
University Hospitals NHS Foundation Trust from the Royal Manchester 
Children's Hospital.  
JIA patients met the criteria for the International League of Arthritis and 
Rheumatism (ILAR) classification [5]. Samples from these patients were also 
recruited from the Department of Paediatric Rheumatology at Alder Hey, and 
collected with the support of the NIHR Alder Hey Clinical Research Facility. 
Paediatric non-inflammatory controls were defined as children attending Alder 
Hey NHS Foundation Trust for elective surgery where no inter-current infection 
was present, and with no history of paediatric autoimmune disorder.  
All patients and their parents were given detailed information regarding 
participation in the study (see Appendix A 3.3.3.1 and 3.3.3 for an example). 
Written informed patient/parental assent/consent was obtained in accordance 
with the declaration of Helsinki (see Appendix A 3.3.2, 3.3.4, 3.3.5, 3.3.7, 3.3.9 
and 3.3.10). 
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Volunteers for healthy adult control blood declared themselves as healthy and 
were aged over 18 years. These samples were used for specific experiments 
when higher cell numbers were needed than were obtainable from paediatric 
controls. Healthy adult controls were recruited from staff and students of the 
University of Liverpool or NIHR Alder Hey Clinical Research Facility following 
informed consent (information sheet Appendix A 3.3.11 and consent form 
Appendix A 3.3.12). Participation was approved by the University of Liverpool 
research ethics committee (Appendix A 2). 
 
2.1.2 Patient clinical phenotypic data  
All experiments were undertaken blinded to the patient’s clinical data. Patient 
data were fully anonymized, but demographic and clinical phenotype data were 
obtained at routine clinical appointments at the time of sample collection. These 
data were collected using standardised data collection sheets and then uploaded 
onto a database based at the University of Liverpool. Data collected included: 
age, gender, ethnicity, current medication and disease activity assessment, 
informed by routine clinical blood results. The latter includes: Erythrocyte 
sedimentation rate (ESR), C-reactive protein (CRP), serum C3 and C4 levels, 
anti-dsDNA titres, the patient’s Childhood Health Assessment Questionnaire 
(CHAQ), the BILAG global disease assessment score and specific organ system 
BILAG scores, and SLEDAI score. 
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2.2 Laboratory methods  
Plasticware was purchased from Fisher Scientific or Starlab, UK. All reagents, 
unless otherwise stated are from Sigma Aldrich, UK. 
 
2.2.1 Urine and serum collection 
Urine samples were collected in 25 ml universals and centrifuged at 300xg for 
20 min. The supernatant was aliquoted into 1.5 ml microcentrifuge tubes. 
Serum samples were collected in Micro tube 1.3ml Z (Sarstedt, Germany) to 
support blood clotting. After 30 min of clotting the sample was centrifuged at 
2,000 RPM for 10 min and the serum layer was transferred into microcentrifuge 
tubes. All samples were stored at -80°C until use. 
 
2.2.2 PBMC and neutrophil isolation from whole blood 
Whole blood was obtained with venepuncture and collected into lithium-
heparin vacutainers (Sarstedt, Germany). Samples were processed within 1.5 h 
of collection in the University of Liverpool Wolfson laboratories in the ‘Institute 
in the Park’, Alder Hey Children’s NHS Foundation Trust. Until their use, they 
were left at room temperature (RT, 20-25°C) on a SLS Lab Basics Tube Roller 
Digital (SLS Lab Basics). Lab reagents were warmed to room temperature 
before use. 
Five parts blood were mixed with one part HetaSep (Stemcell, UK) and were left 
to stand at RT for at least 30 min (Figure 2.1 A) until the red blood cells and 
plasma layer were equal (B). The upper layer was transferred into a fresh tube 
and washed with four times the volume PBS at 200xg for 10 min. The pellet was 
resuspended in 1 ml RPMI-1640 media with L-Glutamine (Lonza, Belgium) 
(referred to as RPMI-1640 from here) and layered onto 2 ml Histopaque-1077 
(C). The leukocytes were separated at 2,000 RPM centrifugation for 20 min with 
a density gradient into a pellet with granulocytes and a layer of PBMCs (D). All 
media and PBMCs were carefully removed with a Pasteur pipette and the pellet 
was resuspended in 1 ml RPMI-1640. PBMCs for incubations with apoptotic 
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supernatant were washed with 7 ml PBS at 2,000 RPM for 5 min and then stored 
at 4°C until use (Section 2.2.4.2). Remaining red blood cells were lysed with 9 ml 
ammonium chloride lysis buffer (155 mM ammonium chloride, 10 mM 
potassium bicarbonate and 127μM EDTA). To support lysis, the tube was 
inverted for 1 min and left at RT for further 2 min. After a 2,000 RPM 
centrifugation for 5 min the supernatant was decanted, and the cell pellet was 
resuspended in RPMI-1640 with or without 2%/10% FCS (Life Technologies, 
UK). If neutrophils were further used for ultra-purification they were 
resuspended in 1 ml EasySep™ Buffer (Stemcell, UK) (Section 2.2.3).  
 
 
 
Figure 2.1: Isolation of PBMCs and granulocytes from whole blood.  Five 
parts whole blood are mixed with one-part HetaSep and left for 30 min at RT 
(A). When the solution is separated equally into plasma layer and red blood cells 
(B), the upper layer is washed with four times the volume PBS for 10 min at 
200xg. The pellet is resuspended in 1 ml RPMI-1640, layered onto 2 ml 
Histopaque (C) and then centrifuged 2,000 RPM for 20 min. PBMCs can be 
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obtained from the upper ring whereas granulocytes are pelleted on the bottom 
of the tube (D).  
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The solution of neutrophils was counted as a 1:10 dilution with a 
haemocytometer (Hausser Scientific, USA) and purity was assessed by flow 
cytometry at a 1:100 dilution. A purity of 95% neutrophils was considered 
sufficient. 
 
2.2.3 Neutrophil ultra-purification by magnetic immunoselection 
The EasySep™ Human Neutrophil Enrichment Kit (Stemcell, UK) was used for 
neutrophil purification as this is an immunomagnetic negative selection cell 
isolation kit. Neutrophils therefore remain undisturbed to prevent activation. 
All other cells are removed by binding of Tetrameric Antibody Complexes with 
magnetic particles (simplified in Figure 2.2 A as bead-labelled antibody) 
followed by insertion into a magnet. All bound complexes are pulled towards 
the magnet and the desired fraction can be decanted (B). 
 
 
 
Figure 2.2: Purification of neutrophils by magnetic bead-separation using 
negative selection.  All cell types except for neutrophils are labelled with 
Tetrameric Antibody complexes bound to magnetic particles which are 
represented as bead-labelled antibodies (A). After insertion into the magnet all 
labelled cells will be pulled towards the side of the tube by the magnetic force 
(B). Neutrophils can be poured off while all other cells remain inside the tube.  
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Neutrophils were adjusted to a maximum of 50x106 cells/ml EasySep™ Buffer, 
transferred to test tubes and subsequently further purified with the EasySep™ 
Human Neutrophil Enrichment Kit according to the manufacturer’s instructions. 
50 l EasySep™ Human Neutrophil Enrichment Cocktail was added per 1 ml 
solution and mixed by pipetting. After a 10 min incubation at RT, the EasySep™ 
Magnetic Particles were pipetted vigorously five times and 100 l was added 
per 1 ml cell solution. The suspension was mixed well and incubated for 10 min 
at RT. The volume was filled up to a total of 2.5 ml with EasySep™ Buffer and 
gently pipetted up and down. The tube was inserted into the EasySep™ Magnet 
and left for 5 min at RT to separate cells bound to the antibodies. The desired 
fraction was decanted into a fresh tube and the tube left inverted for three 
seconds to recover the maximum possible number of cells. This step was 
repeated and finally the cells were counted at a 1:10 dilution and checked for 
their purity on the flow cytometer at a 1:100 dilution. 
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2.2.4 In vitro stimulation of neutrophils 
2.2.4.1 Incubation with TNF, IFN and GM-CSF 
1x106 neutrophils isolated from healthy paediatric control patients were 
incubated in RPMI-1640 with 10% FCS with or without 1ng/ml TNF 10 ng/ml 
IFN (PeproTech, UK) or 5 ng/ml GM-CSF (R&D Systems, UK) and incubated at 
37°C with 5% CO2 for 30 min for TNF otherwise 2 h for RNA expression and 1 
h for TNF otherwise 7 h for protein expression. Protein expression was 
measured every hour using flow cytometry as described in 5.4.3. 
 
2.2.4.2 Incubation with apoptotic supernatant 
1.5x106 neutrophils in 500 l RPMI-1640 were left for 24 h at 37°C with 5% CO2 
to undergo cell death. To fully assess the effect of factors released during cell 
death rather than effects from aged medium, “OVN medium” was used for 
untreated conditions. Thus, the same volume of RPMI-1640 alone was incubated 
for 24 h under the same conditions as the dying cells. The next day, all liquid 
was removed and centrifuged 200xg for 5 min. Supernatant from the 
neutrophils left overnight (referred to as “apoptotic supernatant”) was 
transferred into 1.5 ml aliquots and frozen at -80°C. 
The experimental set up of incubation with apoptotic supernatant is 
summarized in Figure 2.3. In detail, neutrophils were freshly isolated from 
healthy adult controls as described in 2.2.2 and mixed with PBMCs at a ratio of 
95:5 % or further isolated to be ultrapure (see 2.2.3). A total of 11.5x106 cells 
per condition were centrifuged at 1800 RPM for 3 min and resuspended in 
either OVN medium or apoptotic supernatant with 10% FCS at a concentration 
of 10x106 cells/ml. 4x106 cells were seeded in 24 well plates for RNA collection 
and 1x106 cells per well for the apoptosis assay and protein expression in a 96 
well plate. Changes in neutrophils were then analysed as described below. 
All plates were incubated at 37°C with 5% CO2 for 2 h and 6 h. At the first time 
point only, RNA was collected using TRIzol (Life technologies, UK see 2.2.5.1) 
and cell death was measured using Annexin V/PI as described in 2.2.6.1 
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Apoptosis assay with Annexin V/PI. In addition, at the latter time point, cell 
supernatant was collected and frozen for ELISA analysis (see 2.2.9) and cell 
death and protein expression were measured using flow cytometry. Protein 
expression of CD16b, TLR2 and S100A9 was quantified with flow cytometry as 
described in Section 2.2.6.2. 
 
 
 
 
 
Figure 2.3: Overview of the protocol for incubation with apoptotic 
supernatant.  Ultra-pure neutrophils were incubated with OVN medium 10% 
FCS or apoptotic supernatant 10% FCS. A mix of neutrophils (95%) and PBMCs 
(5%) was incubated with apoptotic supernatant and 10% FCS. After 2 h, 
apoptosis was measured and mRNA collected. At 6 h additionally supernatant 
was collected and neutrophils stained for TLR2, CD16b and S100A9 protein 
expression which was measured using flow cytometry.  
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2.2.5 Real-time Polymerase Chain Reaction (RT-PCR) using SYBR-Green 
With real-time polymerase chain reaction (PCR) the quantity of messenger RNA 
(mRNA) in a sample is measured as fluorescence at the end of each cycle. There 
is no requirement to load the samples on a gel as would be for a standard PCR. 
First RNA is transcribed into complementary DNA (cDNA) and then added to 
SYBR-Green dye, polymerase, nucleotides and primers specific for the gene of 
interest. The mixture is then placed in a thermal cycler and the amplification 
reaction starts with a denaturation of the cDNA and enzyme activation at 95°C 
as shown in Figure 2.4. At 60°C, primers bind to their target part of the cDNA 
and the polymerase elongates the targets so that a new double stranded product 
is made. This step is repeated 40 times and in each cycle the amount of target of 
interest is doubled. SYBR-Green dye intercalates into double stranded DNA 
(dsDNA) which results in the emission of fluorescence which can be detected by 
the PCR machine. The more target that is expressed in the sample, the earlier 
fluorescence will be detected. 
After the last cycle the PCR is concluded with a melting curve to identify if the 
correct product has been made. The amplified product should have one specific 
peak dependent on its length and composition of nucleotides as seen for 
example in Figure 2.5.  
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Figure 2.4: Schematic representation of real-time PCR using SYBR 
green. The amplification starts with a denaturation step at 95°C 
followed by binding of the primers and elongation at 60°C. With every 
repeat the amount of target doubles and SYBR-Green binds to the 
dsDNA which is then detected as a signal.  
 
 
 
 
Figure 2.5: Example of a dissociation curve showing that all 
samples amplified the same product.  PCR reactions are gradually 
heated up and change in fluorescence is shown on the graph for each 
degree Celsius. All peaks are overlapping at the same temperature, 
showing, that all samples contain the same product.   
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2.2.5.1 RNA extraction and clean-up 
Cells were pelleted at 8,000xg for 5 min at RT and homogenized in TRIzol by 
pipetting until no cell remnants were visible. After 5 min at RT, 200 l of 
chloroform was added to the tubes and they were vigorously shaken for 15 sec. 
This was followed by a 2-3 min incubation at RT and then the tubes were 
centrifuged at 12,000xg for 15 min at 4°C to separate RNA from protein and 
DNA. The upper clear layer containing RNA was transferred into a fresh tube 
and mixed with 500 l of isopropanol. RNA was left for precipitation for 10 min 
at RT, approximately 1 h on ice or OVN at –20°C dependent on suitability for the 
experiment. RNA was pelleted by centrifugation at 12,000xg for 30 min at 4°C 
and the supernatant was discarded. The pellet was washed with 500 l 70% 
ethanol and centrifuged at 12,000xg for 15 min at 4°C. After the supernatant 
was removed, the pellet was left to air dry for 1 min and then resuspended in 
100 l nuclease-free water.  
The clean-up of RNA was done with the RNeasy Mini Kit (Qiagen, Germany) with 
an on-column DNase digest step with the RNase-free DNase set from Qiagen to 
minimize the risk of contamination with genomic cDNA using the 
manufacturer’s instructions which are described below: 
Before the RNA was transferred onto the membrane of the RNeasy Mini Spin 
Columns it was mixed with 350 μl Buffer RLT and 250 μl ethanol (96–100%) 
and mixed well. The spin at ≥10,000 RPM for 15 sec (as used for the whole 
protocol unless stated otherwise), let the RNA bind to the membrane and the 
flow-through could be discarded. Afterwards, the column was transferred into a 
fresh collection tube and washed with 350 μl Buffer RW1 followed by a spin. 
The column was again placed in a fresh collection tube and a mixture of 10 μl 
DNase I stock solution and 70 μl Buffer RDD was added directly onto the 
column. After a 15 min incubation the membrane was washed with 350 μl 
Buffer RW1 and the column was placed in a fresh collection tube. Next, the 
membrane was washed twice with 500 μl Buffer RPE ending with a 2 min spin. 
The column was transferred into the final collection tube and 40 μl Nuclease-
free water was put on the membrane. The tube with the column was then 
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centrifuged for 1 min and the flow-through placed onto the membrane again. 
Finally, the tube was centrifuged for 2 min and the RNA was ready for 
measurements of concentration and purity (A260/280 and A260/230) on the 
ND-1000 Spectrophotometer (Thermo Fisher Scientific). 
 
2.2.5.2 cDNA synthesis 
cDNA was synthesised either with AffinityScript qPCR cDNA Synthesis Kit from 
Agilent Technologies or with PrecisionTM Reverse Transcription Premix 2 from 
Primerdesign. 
For the Agilent kit, 100ng RNA was topped up to a total volume of 12.5 μl with 
nuclease-free H2O. For the negative control, three RNAs were randomly selected 
and mixed equivalent to a total of 100ng RNA and filled up with nuclease-free 
H2O to 12.5 μl total volume. 3 μl random primers were added to each sample 
and all tubes were spun down and incubated at 65°C for 5 min. Meanwhile a 
mastermix was prepared with 2 μl 10x AffinityScript reverse transcriptase 
(RTase) buffer, 0.8 μl Deoxynucleotide Triphosphate (dNTP) mix, 0.5 μl RNAse 
block to prevent RNase activity and 1μl AffinityScript RTase per sample. For the 
negative control the same mix was prepared, but without the enzyme.  
 
The mastermix was added to the RNA-primer solution and incubated on the 
thermal cycler. First for 10 min at 25°C, then for 60 min at 42°C and stopped the 
reaction with 72°C for 15 min. 
The cDNA was stored at -20°C until used. 
Alternatively, the PrecisionTM Reverse Transcription Premix 2 from 
Primerdesign was used which contains an optimised blend of random nonamer 
primers and oligodT. The latter support mRNA transcription, while with the 
random nonamer primers even degraded mRNA can be transcribed.  
1-10 μl RNA containing 50/100ng RNA, was mixed with 20 μl PrecisionTM 
Reverse Transcription Premix 2 and topped up with nuclease-free water to 30 
μl total volume. For the negative control, three RNAs were chosen randomly and 
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mixed with 20 μl Reverse Transcription negative control premix which lacks the 
enzyme.  
Tubes were spun and incubated on the thermal cycler at 42°C for 20 min and 
72°C for 10 min. 
Resulting cDNA was stored at -20°C. 
 
2.2.5.3 Real-time PCR 
Primers for PCR were designed and validated by Primerdesign or were chosen 
based on papers published in PubMed and confirmed as being appropriate for 
the gene of interest with Primer-BLAST tool. The published primer sequences 
were purchased from Eurofins (France) and Invitrogen. All primers are listed in 
Table 2.1 and 100 μM stocks were diluted 1:10 for all reactions.  
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Target gene Primer with forward (fwd) and 
reverse (rev) sequence 
OAS2 fwd-CTCCTCCTTTTTCCTTCCAGTCT 
rev-AAGCACCGAGAGCAAGATCA 
IFI44L fwd-CCTAGCCATGTGTCCTTCCA 
rev-GCTTTCACAGCTAGTAAGAGGACT 
IFI6 fwd-CAAGGTCTAGTGACGGAGCC 
rev-TTTCTTACCTGCCTCCACCC 
LY6E fwd-AGGACAGGCTGCTTTGGTTT 
rev-AGCAGCACTGGCAAGAAGAT 
DNA modifying genes: SAMSN1, 
SAP30, SIGLEC14, SETD7, 
BRCA2, TREX1, XRCC4, SRCAP 
Designed and validated by Primerdesign 
Housekeeping genes Designed and validated by Primerdesign 
TLR2 for-GGCCAGCAAATTACCTGTGTG 
rev-AGGCGGACATCCTGAACCT 
S100A9 fwd-CACCCAGACACCCTGAACCA 
rev-GCATGATGAACTCCTCGAAGC 
FCGR3B fwd-AGTTTGAGATGCCTTGGGTTC 
rev-CCATCTTGGCTTGTCCTGGTA 
Dectin-1 fwd-AAGGATCGTGTGCTGCATCTC 
rev-TGGTACCCAGGACCACAGCTA 
AnxA3 fwd-CCCATCAGTGGATGCTGAAG 
rev-TCACTAGGGCCACCATGAGA 
CamK1D fwd-GACGCCGTGTACTATCTCCA 
rev-GAGGACTTCAGGAGCGACAT 
CR3 fwd-CCTGGTGTTCTTGGTGCCC  
rev-TCCTTGGTGTGGCACGTACTC 
b-actin (Invitrogen, USA) fwd-AGATCAAGATCATTGCTCCTCCTG 
rev-CATTTGCGGTGGACGATGGA 
Table 2.1: List of forward and reverse primers used for real -time 
PCR.  
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Brilliant II SYBR® Green QPCR Master Mix from Agilent Technologies and 
Precision®PLUS qPCR Master Mix for the Stratagene with SYBR-Green from 
Primerdesign were used for real-time PCR reactions. cDNA was used as a 1:10 
dilution. The reaction setup is summarized in Table 2.2: 
 
 
Agilent Technologies Primerdesign 
5 μl 2× Brilliant II SYBR® Green 
QPCR Master Mix 
5 μl Precision®PLUS qPCR Master Mix for 
the Stratagene with SYBR-Green 
0.3 μl ROX dye (1:1,000 dilution)  
0.25 μl forward primer 0.25 μl forward primer 0.5 μl primer mix 
if ordered from 
Primerdesign 
0.25 μl reverse primer 0.25 μl reverse primer 
0.2 μl nuclease-free H2O 2.5 μl nuclease-free H2O 
Total MM: 6 μl + 4 μl cDNA 
template/water  
Total MM: 8 μl + 2 μl cDNA template 
Table 2.2: Summary of components for real-time PCR mastermixes for 
both Agilent and Primerdesign kits. 
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Nuclease-free H2O served as a non-template control and all samples were run in 
duplicate. All liquid was pulled down with a short spin. The thermal profiles run 
on the thermal cycler from Stratagene with the MxPro software are summarized 
below in Table 2.3:  
 
 
 Agilent Technologies Primerdesign 
Denaturation/Hot start 95°C for 1 min 95°C for 2 min 
Denaturation 40x 95°C for 20 sec 95°C for 10 sec 
Annealing/Elongation 60°C for 20 sec 60°C for 60 sec 
Dissociation curve 95°C for 1 min 
Followed by dissociation curve starting at 55°C 
Table 2.3: Thermal profiles used for real-time PCR for Agilent and 
Primerdesign products.  Amplification was repeated for 40 cycles 
and all PCRs were followed by a dissociation curve to verify that all 
wells contain the same product.  
 
 
Resulting cycle threshold (CT)-values were used to calculate relative expression 
by normalising them to at least one appropriate housekeeping gene. This 
method is called the Delta CT (ΔCT)-method. How housekeeping genes were 
chosen is described in the specific methods of each chapter as this was 
dependent on the sample type and was determined with GeNorm kit from 
Primerdesign.  
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2.2.6 Flow cytometric analysis 
Cellular features such as size and granularity can be measured with a flow 
cytometer without fluorescence. Cells are either pulled up with a microcapillary 
(e.g. Guava® EasyCyte) or with a stream of liquid called sheath fluid (e.g. 
Beckman Coulter F500) in order to create a line of single cells as shown in 
Figure 2.6. A laser beam hits the cells at this stage and the diverted light is 
collected on the forward scatter (FS) and side scatter (SS).  
 
 
 
Figure 2.6: Mechanism of flow cytometry with either a 
microcapillary or sheath fluid.  Cells are sorted into a single file and 
all are excited by a laser. Filters direct the emitted light dependent on 
the wavelength towards photomultiplying tubes which convert it into 
an electronic signal.   
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This way granular neutrophils can be distinguished from PBMCs as shown in 
Figure 2.7.  
 
 
Figure 2.7: Dotplot resulting from flow cytometry measurement of 
forward (FSC) and sideward scatter (SSC) measurement.  Cells are 
displayed dependent on their granularity (SSC) and their size (FSC). 
More granular granulocytes can be distinguished from the less 
granular lymphocyte/PBMC fraction.  
 
 
 
 
Furthermore, cells can be stained with different fluorochromes which when 
excited by a laser can emit fluorescence. This signal is detected by sensors and 
can give information about characteristics of the cell including expression of 
specific proteins or their activity (e.g. uptake of pHrodo-stained bacteria). 
Dependent on the wavelength of the fluorochrome, different detectors collect 
the data which allows multiple staining to be performed at the same time.  
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2.2.6.1 Apoptosis assay with Annexin V/PI  
Discrimination between early/late apoptosis and necrosis can be determined by 
staining with FITC-labelled Annexin V and propidium iodide (PI) (Sigma, USA). 
Upon apoptosis the membrane translocates phosphatidylserine to the outside 
and Annexin V can bind to it. At later stages of cell death, the membrane 
becomes permeable and PI can penetrate up to the point when cells are only PI 
positive. They would then be considered secondary necrotic. 
Cells were centrifuged at 1,800 RPM for 5 min and resuspended in 200 μl 
1xAnnexin V binding buffer of which 50 μl were then distributed into each one 
well of a 96-well plate. An additional 50 μl of buffer was added followed by 1 μl 
Annexin-V and incubated at 4°C in the dark for 15 min. Following the 
incubation, PI was added to each sample at a 1:1,000 dilution for 2 min at RT. A 
further 100 μl HBSS was added and cells were analysed on the flow cytometer. 
Unstained and single-stained controls were used in every run alongside the 
samples. 
 
2.2.6.2 Antibody staining TLR2-PE, CD16b-FITC and S100A9-PE expression 
of neutrophils measured with flow cytometry 
Following counting, neutrophils were centrifuged at 300xg for 5 min and 
resuspended to a concentration of 0.2x106 cells per 50 μl in ice cold PBS/2% 
FCS per staining. Suspensions were left on ice for 20 min before cells for 
intracellular staining were fixed in 2% Paraformaldehyde for 15 min at RT. 
Without any further wash steps, 0.1% Triton-X 100 (BDH Limited Poole 
England, UK) in PBS was added with a final concentration of 0.05% which 
permeabilized the cells for 10 min at RT.  
One part 0.1% Triton-X was added to one part permeabilized cell solution. 
Unfixed cells were made up to the same volume with PBS 2%FCS. Tubes were 
centrifuged at 300xg for 5 min and resuspended in 50 μl ice cold PBS/2% FCS. 
Antibodies were added with dilutions described in Table 2.4. The tubes were 
incubated for 30 min in the dark at 4°C. Subsequently, cells were washed twice 
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with 500 µl PBS/2% with each a 300xg centrifugation for 5 min and the pellet 
was resuspended in 300 µl ice cold PBS/2% FCS. All tubes were kept on ice until 
analysis on the flow cytometer. 
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Antigen Dye Fc-part Dilution 
TLR2 PE IgG1, κ 1:40 
CD16b FITC IgG2a, κ 1:10 
Isotype  FITC IgG2a, κ 1:10 
Isotype (extracellular) PE IgG1, κ 1:80 
S100A9 PE IgG1, κ 1:20 
Isotype (intracellular) PE IgG1, κ 1:80  
Table 2.4: Antibodies used for extra- and intracellular staining 
for flow cytometry.  
 
2.2.7 Phagocytosis assay 
Neutrophils take up pathogens and digest them as a defence mechanism in a 
process called phagocytosis. pHrodo™ BioParticles® Conjugates from Life 
technologies (Molecular probes, UK) are pathogens or parts of pathogens and 
are labelled fluorescently. This can involve different phagocytic targets like 
gram-positive (S.aureus), gram-negative bacteria (E.coli) or even fungal 
particles (zymosan). Dependent on the acidity of the environment, the 
brightness changes which means particles are only emitting light if taken up 
into a phagosome where the pH is decreased. We used these particles for flow 
cytometric analysis and confirmed results with confocal microscopy. 
1.5x105 neutrophils were seeded per well in a 96 well plate in RPMI-1640 
media.  
The pHrodo™ BioParticles® Conjugate was resuspended in HBSS+HEPES (BDH 
Limited Poole England, UK) (20mM, pH 7.4) to a concentration of 1 (S.aureus, 
E.coli) and 0.5 (zymosan) mg/ml. The cells were incubated with 0.3 g S.aureus, 
E.coli or 0.5 g zymosan per 1x105 cells and with or without 10% 
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JSLE/paediatric control serum. After a 5 min or 20 min incubation at 37°C, 
5%CO2 (or on ice as a negative control), the plates were centrifuged at 1800 
RPM for 3 min and resuspended in HBSS + HEPES. They were kept on ice until 
analysis.   
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2.2.8 Assessment of phagocytosis using confocal microscopy 
Visualization for phagocytosis experiments was achieved with incubations on 
coverslips and analysis under the confocal microscope (Leica TCS SPE with the 
optical microscope Leica DM 2500) as detailed below. 
2x105 neutrophils were plated into 24 well plates on autoclaved cover slips and 
left for approximately 45 min to settle and adhere to the glass. Afterwards the 
cells were treated as described above in Section 2.2.7, but incubated for 20 min, 
having established that 5 min was insufficient time for all particles to settle to 
get comparable results between flow cytometry and confocal microscopy 
assays. After the 20 min incubation all medium was removed and 200 µl 1xTBS 
diluted from a 10x solution (100 mM Tris-Base (Fisher Scientific, UK), 1.5 M 
NaCl (Fisher Scientific, UK) (pH 7.5)) was added. Coverslips were removed from 
the liquid with forceps and mounted on a glass slide with ProLong™ Gold 
Antifade Mountant with 4',6-diamidino-2-phenylindole (DAPI, Invitrogen, 
Fisher Scientific, USA). The slides were left to set for at least 1 h and then 
examined under the confocal microscope. 
Using the technique of confocal microscopy as shown in Figure 2.8, 
fluorescence from antibody-bound fluorophores or from DAPI, a DNA staining 
dye, can be detected. The fluorochromes are excited with lasers, but instead of 
using a wide field as in conventional microscopy, samples are scanned with light 
beams. Out-of-focus light is prevented with pinhole apertures and only 
fluorescence of the sample that is in focus will reach the photomultiplier which 
generates a signal with low background noise. 
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Figure 2.8: Principles of confocal microscopy.  Light from a laser is 
directed through a pinhole aperture onto a mirror and reaches the 
sample through the objective. Fluorescence is emitted from 
fluorochrome labelled antibodies bound to proteins on the sample. 
Out-of-focus light is stopped by the detector pinhole aperture and 
only in-focus light will reach the photomultiplier.  
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2.2.9 Sandwich ELISA 
For a sandwich enzyme-linked immunosorbent assay (ELISA) (see Figure 2.9), 
primary antibodies against the specific antigen are first immobilized onto a 
polystyrene plate. The plate is then blocked against non-specific binding with 
bovine serum albumin (BSA). Serum, plasma or supernatants are then 
incubated on the plates alongside a serial dilution of standards. The antigen of 
interest present in these samples will bind to the antibodies on the plates. 
Afterwards, the secondary, biotinylated antibody is added, which is directed 
specifically against the antigen. The enzyme horseradish peroxidase (HRP) is 
coupled to avidin which binds to the biotinylated antibody. This ensures that an 
HRP substrate such as 3,3', 5,5' tetramethylbenzidine (TMB) turns blue if the 
specific coupled antibodies are present. This process needs to be stopped with 
H2SO4 which also turns the blue colour into yellow and the plate can be read at a 
wavelength of 450 nm. With the optical density values from the serial dilutions 
using a four-parameter logistic (4-PL) curve-fit, a standard curve is generated 
making it possible to calculate all sample concentrations. All results were 
analysed on http://www.elisaanalysis.com/. 
  
74 
 
 
Figure 2.9: Procedure to perform a sandwich ELISA.  At first wells 
are coated with capture antibodies, then the protein of interest and 
standards are bound followed by the detection antibody. The HRP 
conjugate binds to the second antibody and will ensure colour 
development when coming into contact with the HRP substrate. 
 
 
 
 
2.2.9.1 ELISA detecting CD16b 
The CD16b in serum or released into supernatant was measured with the Aviva 
systems biology FCGR3B ELISA kit and all reagents were brought to RT before 
use. Serum was diluted 1:160, all other samples 1:2 and standards were serially 
dilute. 100 l diluted samples were plated onto the precoated ELISA plates. An 
incubation of 12 h at RT was followed by incubation with 100 μl of 1X 
Biotinylated FCGR3B Detector Antibody for 1 h at 37°C and three subsequent 
washes. For all washes for CD16b ELISA, wash buffer was used which was 
supplied with the kit. 100 μl of 1X Avidin-HRP Conjugate were added into each 
well and incubated at 37°C for 1 h. The plates were washed five times and the 
reaction was started with 90 l of TMB substrate at RT and stopped after 15 
min with 50 l Stop solution.  
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Figure 2.10: Example for a standard curve resulting from CD16b 
standards displayed as 4-Parameter Logistic Regression.  
Standards were plated in duplicate and the R2 was calculated to be 
0.99. The resulting curve was used to determine concentrations of 
samples.  
 
 
2.2.9.2 ELISA detecting TNF, S100A9 and S100A8/S100A9 
ELISA kits for TNF, S100A9 and the S100A8/S100A9 complex were all 
purchased from R&D systems, UK and used as described. 100 μl of 1x Capture 
Antibody diluted in filtered PBS was plated on a 96 well plate and incubated at 
RT OVN. Plates were washed three times and then blocked for 1 h at RT with 
reagent diluent (1% BSA in PBS). The plate was washed three times and the 100 
μl of sample, either undiluted or diluted in reagent diluent, or serially diluted 
standards were plated out and incubated OVN at RT or for 2 h at 37°C. 
Subsequently, plates were washed three times and incubated with 100 μl 
working concentration of Detection antibody diluted in reagent diluent. Plates 
were washed three times before 100 μl of the working dilution of Streptavidin-
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HRP were added to each well. Subsequently, plates were incubated 20 min in 
the dark at RT and washed again three times. Finally, 100 μl of Substrate 
Solution (one-part H2O2:one-part TMB BD Biosciences, UK) were placed into 
each well and the reaction was stopped after 12-15 min with 50 μl of Stop 
Solution (2N H2SO4, BDH Limited Poole England, UK). 
 
 
 
 
Figure 2.11: Standard curve resulting from S100A9 standards displayed as 
4-Parameter Logistic Regression.  Standards were plated in duplicate and the 
R2 was calculated to be 0.992. The resulting curve was used to determine 
concentrations of samples. 
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2.2.10 Whole blood assays 
2.2.10.1 Nucleosome purification 
Nucleosomes were isolated from purchased chicken blood in Alsever’s solution 
(TCS Biosciences Ltd Botolph Claydon, UK) as avian erythrocytes still contain 
nucleosomes in contrast to mammalian erythrocytes. Two falcon tubes each 
with 50 ml of chicken blood were centrifuged for 10 min at 1800xg and after the 
supernatant was discarded the pellet was washed twice in buffer A (0.08 M 
NaCl/0.02 M EDTA, pH 7.5). Subsequently the erythrocytes were resuspended 
in 23 ml buffer A and lysed by adding 23 ml of 1.5% Triton X-100 (in buffer A 
diluted). Tubes were left on ice until the lysates were carefully layered onto 
sucrose gradients consisting of 2 ml 2.25M sucrose and 15 ml 1.7M sucrose in 
ultracentrifuge tubes. This was followed by ultracentrifugation at 113,000xg for 
90 min at 4°C. The sucrose solutions were removed carefully, and residues were 
removed with a Kimwipe using a metal spatula. Nucleosomes were carefully 
resuspended in 20 ml buffer A. Afterwards, nucleosomes were centrifuged for 
15 min at 2,000xg at 4°C and supernatants removed. Nucleosomes were then 
washed twice with 15 ml of 50 mM Tris-Cl (pH 7.9) at 2,000xg for 15 min at 4°C. 
After all the supernatant was removed, nucleosomes were resuspended in 15 ml 
cold distilled water and sonicated at 4°C until reaching a homogenous solution.  
The concentration of DNA was measured using the ND-1000 Spectrophotometer 
and adjusted to 1 g/µl with 0.1 mM EDTA. Nucleosomes were stored at -80°C 
until used. 
 
2.2.10.2 Whole blood stimulation 
1 ml of blood was taken by venepuncture and incubated with 1 µl Brefeldin A 
(1000x stock solution) with or without 20 g nucleosomes and with or without 
anti-IFN receptor (IFNAR)-antibody or isotype control for 5 h at 37°C with 5% 
CO2. Afterwards cells were stained for TLR2, CD16b and S100A9 (see 2.2.6.2). 
For RNA extraction the incubations without Brefeldin were used and processed 
as described in 2.2.10.3. 
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Blood was blocked with cold PBS/ 2% BSA in a 1:1 ratio in test tubes for 30 min 
on ice. Then 1 ml of 1x BD FACS™ Lysing Solution (BD Biosciences, UK) was 
added and the solution was thoroughly pipetted up and down to support red 
blood cell lysis continued by a 10 min incubation at RT. Tubes were centrifuged 
500xg for 3 min. All subsequent centrifugations were performed with these 
conditions. Subsequently, the pellet was washed with 1 ml PBS 2% BSA and 
cells were either stained extracellularly for TLR2, CD16b or isotype control (see 
2.2.6.2) or permeabilised with a concentration of 0.05% Triton-X 100 in PBS for 
10 min. Cells were spun down in a final concentration of 0.075% Triton-X and 
the supernatant was poured off. Subsequently, cells were stained for 
intracellular CD16b or S100A9 as described in 2.2.6.2 or cells were resuspended 
only in the remaining liquid and 5 µl IFN-FITC antibody or IgGK1isotype 
control (Miltenyi, UK). After 1 h incubation at RT cells were washed twice with 
each 1 ml PBS/2% BSA. For analysis using the flow cytometer cells were 
resuspended in 250 µl PBS/2% BSA. 
 
2.2.10.3 Whole blood RNA extraction 
Due to the very small volumes used for whole blood assays, a separation into 
neutrophils and PBMCs was not advisable prior to RNA extraction. Therefore, 
the blood not needed for antibody staining was mixed one-part HetaSep, five 
parts blood. After 30 min at RT the leukocyte-rich layer was transferred into a 
fresh tube and washed with PBS at 200xg for 10 min. The resulting pellet was 
resuspended in 1 ml RPMI-1640 and 9 ml ammonium chloride lysis buffer (155 
mM ammonium chloride, 10 mM potassium bicarbonate and 127μM EDTA) was 
added. The tube was inverted for 1 min to support red blood cell lysis followed 
by a 2 min incubation at RT. This was followed by a centrifugation at 2,000 RPM 
for 5 min and cells were further processed for RNA extraction as described in 
2.2.5.1.  
  
79 
 
2.3 Statistical Analyses  
Statistical analysis was performed with GraphPad Prism 6.  
Comparison between two non-parametric groups which were not-matched was 
analysed with the Mann-Whitney test. If the same conditions were given for 
more than two groups, the Kruskal-Wallis test followed by Dunn’s post hoc test 
was applied. For two matched groups that were non-parametric, a Kruskal-
Wallis matched-pairs signed rank test was performed and for multiple groups 
the Friedman test was used with Dunn’s multiple comparisons post hoc test. P-
values of <0.05 were considered significant in these tests.  
  
80 
 
2.4 Metabolomics using 1H NMR spectroscopy 
1H NMR is, as further described in Chapter 3, a technique often used for a non-
targeted screening for differences in metabolites. In this study it was used as a 
metabolic profiling tool to distinguish between different autoimmune diseases 
and further compare if JSLE IFN high and JSLE IFN low patients are similar 
enough to be classified as one disease or if they should be considered as 
separate diseases. 
If atomic mass and atomic number are both even the nucleus cannot be detected 
with NMR as only spinning nuclei can be observed. The 1H isotope is the most 
naturally abundant isotope (99.98%) and therefore often used for NMR 
spectroscopy. Nuclei spin and create a magnetic field with their electrical 
charge. When an external magnetic field is applied these spins are aligned to the 
field. This requires energy which is released once the magnetic field is turned 
off again and which can be detected. Dependent on the chemical environment of 
the proton, a frequency shift can be observed as electrons would shield the 
proton from the magnetic field. In real terms this means that 1H bonded to 
different chemicals have different resonance frequencies. These frequencies are 
measured in Mz (longitudinal magnetisation; z-direction), and converted into 
parts per million (ppm) and moving of positions along the ppm-axis are called 
chemical shifts. Electronegative groups, e.g. methyl, result in a low chemical 
shift and electropositive groups, e.g. aldehydes or aromatics, in a high chemical 
shift. 
As neighbouring nuclei can affect with their orientation the magnetic field force 
experienced by the proton, a so-called spin-spin coupling effect can be observed 
which causes a split in the signal causing multiple peaks known as doublets, 
triplets, etc.  
Different pulse sequences of the magnet can be applied to the nuclei and one of 
them is the 1D Carr-Purcell-Meiboom-Gill sequence (1D CPMG) which records 
resonances of low molecular weight molecules (<5000Da) whilst removing 
(attenuating) resonances from macromolecules such as lipoproteins. This 
sequence is very useful for biofluids such as serum which contains multiple 
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albumins and was also applied in our study. An example can be seen in Figure 
2.12. 
 
 
 
 
Figure 2.12: Examples of CPMG spectra obtained with 1H NMR.  
Range shown here covers 0 ppm on the right to 8 ppm on the left and 
each line represents a different sample.  
 
 
 
 
2.4.1 Serum  
Blood is a body fluid rich in immune cells and should therefore be rich in 
metabolites resulting from these cells. For investigations comparing JIA, JSLE 
and healthy paediatric control patients, serum samples were compared 
regarding their 1H NMR spectra. Samples were obtained and stored as described 
in Section 2.2.1. 
 
2.4.1.1 Sample preparation 
Healthy paediatric control, JIA and JSLE serum samples were thawed on ice and 
then mixed 1:1 with a phosphate buffer containing 19.75% 1 M Sodium 
8 4 6 2 0 
ppm 
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Phosphate pH 7.4 (19 parts NaH2PO43- and 81 parts Na2HPO43-), 79.75% 
distilled H2O and 0.5% 1.2 M NaN3. All samples were vortexed for 1 min and 
centrifuged 13,000xg for 2 min at 13°C. Trimethylsilylpropanoic acid (TSP) 
cannot be added as a reference standard to serum as it is a protein-rich solution. 
It would result in binding to protein and consequently in an attenuated signal 
that will also be shifted according to the amount of albumin present. 
 
2.4.1.2 Spectral acquisition, processing and referencing 
Sealed NMR tubes containing serum samples were run on the Bruker Avance III 
600 MHz equipped with CryoProbe at 37°C. Temperature was calibrated using 
the methanol thermometer [208]. Samples were locked onto 2H2O and 1D CPMG 
NMR spectra were acquired at 600.13MHz with 4s interscan delay. Serum were 
acquired with 32 and 256 scans, 4 dummy scans and a spectral width of 20 ppm 
(3.067s acquisition time per scan) and in 3 mm outer diameter tubes.  
All acquired spectra were processed using auto-routines in Topspin-3.1 
(Bruker, UK), time domain data was converted with Fourier transformation and 
the resulting resonance spectra were automatically phased and baseline 
corrected.  
Serum samples were then referenced to the glucose peak (left peak of the 
doublet at 5.244 ppm) to ensure precise alignment of peaks (alignment shown 
in Figure 2.13). This is a robust method frequently used for serum samples 
[209]. 
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Figure 2.13: All spectra for serum are referenced to glucose.  All 
samples were overlaid and show that they are all referenced to 
glucose with the left lobe at 5.24 ppm.  
 
  
5.4 5.3 5.1 5.2 ppm 
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2.4.1.3 Creating a pattern file using TopSpin® and Chenomx Profiler® 
(version 8.2 standard) 
Peaks within the spectra were assigned to ‘bins’, also known as buckets defined 
by left and right boundaries (example shown in Figure 2.14. As many peaks as 
possible were annotated with Chenomx Profiler® software and peak 
boundaries in ppm combined with annotations employed as pattern files 
(Appendix C 1.1). The Amix® software integrated the area under the peaks 
within the variable sized buckets and scaled the pattern region to region size 
and the peaks to the total intensity of the spectrum. These peak intensities are 
now summarized in a bucket table. All unidentified peaks were considered 
unknown and the annotated patterns were then integrated into the bucket 
table. These bucket tables were used for analysis with the computing software 
R. 
 
 
 
Figure 2.14: Selection of boundaries for all spectra showing 3.4 
ppm to 3.6 ppm as an example.  Each bucket is indicated by a 
dashed line.  
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Metabolites can create several peaks in a spectrum, depending on their chemical 
structure. Depending on the number of peaks for each metabolite and if these 
peaks were singlets or doublets etc., a metabolite could be annotated with more 
or less confidence. This is summarized in a confidence table in Appendix C 1.2. 
Furthermore, spectra annotated in Chenomx Profiler® were confirmed where 
possible by in-house library and level of identification recorded in the 
confidence table as recommended by the metabolomics society initiative [210].  
 
2.4.2 Urine 
Urine is a waste product of the body and should therefore be representative of a 
wide range of bodily processes and metabolic pathways. For investigations 
urine samples from JIA, JSLE and healthy paediatric control patients were 
compared regarding their 1H NMR spectra. Samples were obtained and 
prepared as described in 2.2.1. 
 
2.4.2.1 Sample preparation 
Urine samples from healthy paediatric were thawed on ice before they were 
centrifuged 6,000xg for 5 min. Compensation for variation of pH was achieved 
by 50% dilution of samples with urine buffer (1M phosphate, pH 7.4, 20% 2H2O, 
2.4mM NaN3, 200uM TSP) resulting in urine samples with final concentration of 
500mM phosphate , pH 7.4, 10% 2H2O, 1.2mM NaN3, 100M TSP. This results in 
precipitation of some metabolites but was still considered as suitable as peaks 
would be subjected to even stronger pH shifts otherwise. Urine is generally low 
in protein and can be spiked with TSP which can be used in downstream 
analysis as a reference peak. Samples were vortexed for 1 min, then centrifuged 
13,000xg for 2 min at RT and lastly pipetted into NMR tubes with 5 mm outer 
diameter. Until spectroscopy was performed tubes were left at 4°C.  
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2.4.2.2 Spectral acquisition and referencing 
Urine samples in sealed NMR tubes were run on the Bruker Avance III 600 MHz 
equipped with CryoProbe at 27°C, calibrated with a methanol thermometer. 
Samples were locked onto 2H2O and 1D CPMG NMR spectra were acquired at 
600.13MHz with 4s interscan delay. Urine were acquired with 32 and 256 scans, 
4 dummy scans and a spectral width 30 ppm (1.818s acquisition time per scan) 
in 5 mm outer diameter tubes. Processing of spectra was undertaken with 
Topspin-3.1 (Bruker, UK) using Fourier transformation, they were 
automatically phased and baseline corrected. All samples were referenced to 
the TSP peak at 0 ppm (Figure 2.15). 
 
 
 
 
 
Figure 2.15: All spectra for urine are referenced to TSP.  Samples 
were overlaid and show that they are all referenced to TSP at 0 ppm.  
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2.4.2.3 Creating a pattern file using Chenomx Profiler® (version 8.2 
standard) 
Despite buffering the urine samples, there was a wide variation in the sample 
pH and ionic strength which resulted in shifts in the peaks (Figure 2.16). 
Chenomx Profiler® software not only annotates peaks, but also deconvolutes 
the peaks (see Figure 2.17) and calculates the area of each metabolite that is 
annotated. As many metabolites as possible were annotated in every spectrum 
and for each sample the area for the metabolites was exported into Excel. These 
results were collated into one sheet and further used in the same way as the 
values obtained from bucket tables for serum and then analysed in R.  
As mentioned in Section 2.4.1.3, metabolites can create several peaks in a 
spectrum, depending on their chemical structure. Depending on the number of 
peaks for each metabolite and if these peaks were singlets or doublets etc. a 
metabolite was annotated with more or less confidence. Again, where possible 
metabolites were matched to those present in the in-house library and assigned 
an identification level as recommended by the metabolomics society initiative 
[210]. This is summarized in a confidence table in Appendix C 1.3. 
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Figure 2.16: Urine spectra showing strong variation between the 
samples due to pH differences and ionic strength.  Each line 
represents a different spectrum obtained from urine samples from 
different patients. Most peaks of the same metaboli tes are not 
overlapping.  
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Figure 2.17: Example for deconvolution of a peak.  The black line indicates 
the acquired spectrum. The red area represents the sum of all annotated 
metabolites and the blue area shows the selected metabolite. This peak here 
consists for example of 19.9% Isoleucine, 39.4% Leucine and 40.7% 2-
Hydroxyisocaproate. The total area for each metabolite can be extracted and 
used as a method for quantification.  
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2.4.3 Analysis using R 
For all analysis unidentified peaks were excluded to avoid false positive 
discovery solely due to metabolites potentially present in patient medication. 
The peak identified as “Ethanol” as described in “3 Metabolite profiles of serum 
and urine in autoimmune disease” was excluded. Statistical analysis as well as 
graphical representation of Principal Component Analysis (PCA) and partial 
least squares discriminant analysis (PLS-DA) was performed with statistical 
packages within R (Team R, Cranfield, UK) and scripts were kindly provided by 
the Computational Biology facility technology directorate from the University of 
Liverpool (UK).  
 
2.4.3.1 Normalization and scaling 
Statistical analysis could only be undertaken if spectra were normalized and 
scaled as this makes them comparable. While serum samples were normalized 
using probabilistic quotient normalization (PQN), the urine samples were 
normalized to their creatinine peak as applied in many papers (e.g. [211], 
[212]). Both serum and urine samples were pareto-scaled, meaning division by 
the square root of the standard deviation to prevent bias towards larger 
variables. 
 
2.4.3.2 PCA and PLS-DA 
PCA reduces the dimensions of variables with an algorithm and presents them 
as principal components (PC) in two dimensions to simplify analysis. Thereby it 
allows to compare similarities between samples visually and we assessed 
outliers with this type of analysis. Each PC has a value stating how much of the 
variation within the data set is explained by it (Figure 2.18A).  
PCA is considered a non-supervised approach as it clusters samples excluding 
knowledge about their categories/groups. In contrast, PLS-DA takes the 
different groups into account and tests with multiple linear regression 
techniques if it is possible to discriminate between the sample types by the 
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given variables. This effectively maximises the variance between groups while 
minimising the variance within groups. This is also visualized on a two-
dimensional map. Values between 0 and 1 give indications about robustness of 
the model (R2) and between -1 and 1 giving indications about predictive power 
(Q2) (B). Variable Importance in Projection (VIP) scores are also produced 
ranking the buckets/peaks which impacted the separation most and were 
therefore considered most influential for differences between the diseases (C).  
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Figure 2.18: Examples for PCA, PLS-DA and a VIP score.  PCA 
shows samples distributed on the plot depending on principal 
component (PC) 1 and PC2 (A). Together both principal components 
can explain 68.9% of the samples. The same samples were then 
analysed for their ability to be separated with PLS -DA (B). The black 
squares, red circles and blue triangles in PCA equal the red, green and 
blue circles respectively in PLS-DA. Two components give the best 
results for a PLS-DA with a R2 of 0.57 and a Q2 of 0.05. Dependent on 
their impact on the PLS-DA metabolites are listed in the VIP score 
with the most influential on the top.   
B 
VIP scores for 2-comp PLS-DA model 
C 
A 
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2.4.3.3 Univariate statistical analysis of metabolomics data 
Statistical significance was assessed between three groups using ANOVA. The 
appropriate post hoc test would be Tukey of Fisher, a multiple test adjustment 
was also applied using Benjamini-Hochberg false discovery rate adjustment. 
This method adjusts for multiple testing which occurs as there are many 
metabolites identified, but also each metabolite has at least one peak. As many 
metabolites have several peaks this adjustment can be very conservative and 
due to our small sample size, we might lose information. P-values were 
therefore used unadjusted with a value less than 0.05 as important.  
 
2.5 Summary 
In this chapter it was presented how this study used samples arising from the 
UK JSLE Cohort Study and Repository from patients and healthy controls to seek 
to improve stratification of JSLE patients and understand the role of PGS and IGS 
in these patients. How patients were recruited, what clinical data was collected 
and how samples were processed was presented. 
Furthermore, laboratory and metabolomic methods were explained, 
background of these methods described, and the general approach to analyses 
undertaken of results has been reported. 
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 Metabolite profiles of serum and urine in 
autoimmune diseases 
 Introduction 
So far, “-Omics” approaches to study pathogenesis of autoimmune diseases such 
as JSLE and JIA focus more on genomics and transcriptomics rather than 
metabolomics.  
 
3.1.1 Metabolomics 
There are different ways to investigate diseases, but each method is limited in 
the data that it creates and its interpretation (see Section 1.5). For example, 
transcriptional approaches (as described in Section 1.5.2 and Chapter 4 - IFN-
induced and phagocytosis-related gene signature in JSLE neutrophils) measure 
mRNA levels which give information about which proteins a cell is about to 
make and therefore what a cell is trying to do. Investigating protein expression 
of the cells and tissues is often necessary and common to confirm that 
transcriptional changes have an impact [4]. Activity assays are used for enzymes 
or functional assays to enable the action of cells to be investigated. This can 
make the influence of the studied genes clearer, but this is only an artificial 
condition with inhibitors or stimulants defined by the experimental conditions. 
Furthermore, most tests only look at a subset of proteins or cells and cannot 
evaluate the complete biological system with all its interactions. The 
environment created in the assay with cytokines added nutrients etc. and 
chosen cell types could be considered a biased system.  
The study of all metabolites present in a type of cell, tissue or body fluid is called 
metabolomics (see Section 1.5.4). Metabolomics (in both serum and urine) 
facilitates the measurement of side and end products of biochemical pathways 
to provide detail of the in vivo metabolic state. Metabolites may be the results of 
an immediate response to a stimulus or event, but can also indicate 
accumulation of metabolites from ongoing processes. 
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3.1.2 1H NMR spectroscopy of serum and urine  
Metabolomics methods can use either nuclear magnetic resonance (NMR) 
spectroscopy or mass spectrometry (MS) – see Section 1.5.4. The latter is a good 
tool for a targeted project such as the identification of biomarkers. It is used to 
quantify a class of molecules such as fatty acids or amino acids. Even though MS 
is a very sensitive technique, the required preselection of the targets leads to a 
loss of information. An initial separation with gas or liquid chromatography is 
usually applied before the ionization step necessary for mass-spectrometry. 
This causes increased preparation time which can cause a loss of metabolites 
due to instability of molecules [213].  
NMR spectroscopy on the other hand is an untargeted approach, but 
metabolites can only be detected if they are present in high abundance and this 
technique is therefore less sensitive than MS. Low abundance metabolites may 
be lost in the background noise. Nevertheless, because there is no separation 
step prior to the run on the spectrometer, generally a high abundance of 
molecules is reached. There is further preselection due to the choice of atom. 
The nucleus of atoms is made up of neutrons and protons called nucleons of 
which each has ½ spin. Only atoms with an odd number of nucleons can be 
detected with NMR as only these possess ½ spins which are affected by a 
magnetic field. 1H NMR is the most popular choice because of the richness of 1H 
compared to 13C or 14N. Other advantages of 1H NMR spectroscopy are 
reproducibility, cost-effectiveness, and it being an unbiased and non-destructive 
method [84]. 
Serum and urine are the body fluids that are relatively easy to obtain with urine 
collection being particularly non-invasive. Systemic fluids can offer information 
on entire biological systems rather than skewing results to a particular cell or 
tissue type, which may only show part of the biological response. Additionally 
they give insight and have been used to investigate drug treatments for a long 
time with 1H NMR ([214],[215]). Protocols have been more standardized over 
time and are now used to explore many different research questions [216]. 
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3.1.3 JIA and JSLE 
Even though both JIA and JSLE are autoimmune diseases, generally more 
prominent in females, that share symptoms including fatigue, fever or joint pain 
and autoantibodies, they also differ significantly and are two distinct diseases. 
At the same time, both reflect a spectrum of disease manifestations that can 
differ widely between individuals affected. JSLE is considered the archetypal 
multisystem autoimmune disease which can affect any organ system including 
the kidney, skin or brain for example (see Section 1.3). JIA comprises a group of 
disorders in which clinical manifestations are generally characterised by joint 
inflammation (such as oligoarticular and polyarticular forms of JIA, or 
enthesitis-related arthritis) joint involvement, but there is also a form in which 
systemic features are typically present (see Section 1.2).  
While investigations of disease mechanisms in JIA and JSLE using metabolomics 
are very limited (see Section 1.5.5), there have been several studies focusing on 
adult-onset arthritis or exploring metabolic changes due to treatments ([217], 
[218]). There have been a number of studies in adult-onset SLE patients where 
this approach has been used, for example using mass spectrometry or focusing 
on lupus nephritis ([87], [85]). Nevertheless, metabolomic investigation of a 
paediatric cohort is very limited for both JIA and JSLE and usually either focused 
on serum or urine metabolites.  
 
This chapter will focus on the metabolomics investigation of JSLE. In addition, 
JIA will be compared and contrasted as an alternative autoimmune disease 
characterised by tissue inflammation, and both these compared to healthy 
paediatric control patients, based on their metabolite profile both in urine and 
serum. JSLE patients will be further divided into those expressing an IFN high 
and an IFN low gene signature. By investigating metabolites that differ in 
expression to control patients (either increased or decreased) the aim is to 
detect potential dysregulated pathways that may provide further insight into 
inflammatory diseases such as JIA and particularly the autoimmune disease 
JSLE.  
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From past studies, it is known that neutrophils from JSLE and JIA patients 
behave differently compared to paediatric healthy control patients regarding 
their cell death or presence of LDGs ([137], [19]). Changes in metabolites may 
be detected in the serum or urine of patients with JIA or JSLE as neutrophils are 
the most abundant cell type in blood.  
 
 Chapter hypothesis 
The hypothesis for this chapter therefore is that JSLE and JIA patients can be 
distinguished from non-diseased individuals (healthy controls) by their 
metabolite profiles in urine and serum.  
 
Studies have previously indicated that patients can be distinguished, based on 
their IFN gene expression profile, which will be termed here IFN ‘high’ and IFN 
‘low’, dependent on their relative expression of their IFN-induced gene 
signature [56]. It is hypothesised in this study, that IFN low patients are more 
similar to control patients than IFN high patients and that a separation based on 
the IFN signature is possible. As metabolites are representative of processes 
occurring in the body, it is hypothesised that these analyses may provide 
additional evidence regarding dysregulated pathways in JSLE and JIA patients.  
 
 Objectives 
The objectives for this chapter were: 
• Objective 1: To determine if serum or urine is better for building a 
model to distinguish between metabolite profiles of JIA, JSLE and healthy 
paediatric control patients, and between the JSLE IFN high and low 
subtypes and healthy paediatric control patients. 
• Objective 2: To identify potential pathways differentially regulated 
between disease groups and healthy paediatric control patients, as well 
as between the IFN subtypes of JSLE patients.  
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 Chapter specific methods 
3.4.1 Experimental plan 
Serum and urine samples were obtained from children (disease onset before 
16th birthday) with JIA (n=5 for serum, n=4 for urine), with JSLE (n=13, n=8) 
and from paediatric healthy controls (n=9, n=4) – see Section 2.1. JSLE patients 
were subsequently separated into IFN low (n=4 for serum, n=3 for urine) and 
IFN high (n=6 for serum, n=4 for urine) dependent on their interferon (IFN) 
signature as described elsewhere [57], [219] [220]. The IFN signature for 
patients studied was obtained from transcriptomics analysis conducted by our 
group previously. The samples were run at 37°C for serum and at 27°C for urine 
on a Bruker 600 MHz AvanceIII spectrometer equipped with CryoProbe. 
Resulting 1H NMR spectra were analysed with Topspin, Chenomx NMR Suite 
and R. 
Resulting PC and PLS-D analyses (see Section 2.4.3.2) can help to establish 
disease models to predict disease groups and differences between metabolites 
can help to identify underlying mechanisms that may influence the development 
of the disease. Comparison of models based on serum or urine metabolites can 
identify which body fluid is more useful in the study of these diseases. 
 
3.4.2 Analysis of serum 
Acquisition and processing of the samples was performed as stated in “2.2.3 
Metabolomics using 1H NMR spectroscopy”. Serum was then referenced to 
glucose, a metabolite intrinsically present in all serum samples, normalized 
using probabilistic quotient normalization and afterwards pareto-scaled as 
described in “2.2.3.1.2 Spectral acquisition and referencing” and “2.2.3.3.1 
Normalization and scaling”. When analysing serum metabolites in JSLE, it is 
important to exclude patients who have been treated with Rituximab. B-cell 
depletion therapy has a major impact on metabolites in serum (Surace and 
Midgley et al., in preparation). To observe differences, it is therefore important 
to only use sera from patients who had not received Rituximab treatment in the 
last 12 months. 
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Table 3.1 lists the patients included in the comparison between JSLE, JIA and 
controls. The same patients of the JSLE and control group were used previously 
for transcriptomics analysis from our group and were able to be separated into 
interferon-induced gene signature high “IFN high” and low “IFN low” patients.  
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Study ID SLEDAI Age Gender Ethnicity Treatment 
C314a - 13 Female WB None 
C316a - 9 Female WB None 
C322a - 14 Female WB None 
C341a - 14 Male WB None 
C348a - 15 Female WB None 
C367a - 13 Male WB None 
C368a - 17 Male WB None 
C372a - 13 Female WB None 
C374a - 15 Female WB None 
J15d (O) - 12 Female WB Corticosteroid - joint injection 
J66b (P) - 9 Female WB Biologics 
J84a (P) - 9 Female WB Corticosteroid - joint injection 
J85a (O) - 9 Female 
Other Asian 
background 
DMARD 
J89a (P) - 9 Male WB No medication 
L30l 10 10 Male Bangladeshi 
HCQ 200, MMF 1500, Pred 5, 
Infliximab IV, Risedronale 35, 
Azithromycin 250, Omeprazole 
20, Calcichew D3, fluconazole 
250, diclofenac 50 
L43j 4 13 Female WB 
HCQ 200, MMF 2400, Pred 5, 
Omeprazole 20, folic acid 5 
L62i 16 14 Female WB HCQ 200 and MMF 1500 
L64i 7 17 Female WB Pred 10 
L65f 8 17 Female WB HCQ 400 MMF 1000 
L66i 4 16 Female WB HCQ 200 MMF 2000 
L67a 4 9 Female African MMF 500 
L68e 16 15 Female WB HCQ 400, MMF 2000, Pred 10 
L69a 12 17 Male Other 
HCQ 200, MMF 1500, Pred 15 
Cyclophosphamide IV 
L73a 4 14 Female No info HCQ 400 MMF 2000 
Table 3.1: List of patients included for serum analysis. Group (C=healthy 
control, J=JIA, L=JSLE), disease activity (SLEDAI) age, gender, ethnicity and 
medication is stated for patients. Brackets indicate subtype of JIA 
(O=Oligoarthritis, P=Polyarthritis, S=systemic arthritis). The most frequent 
medication were: Hydroxychloroquine (HCQ), Mycophenolate (MMF) and 
Prednisolone (Pred). Doses written after medication are in mg. The font of JSLE 
patients indicates IFN high (bold) and IFN low (italic) status. 
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Initial analysis revealed a strong difference between JSLE patients and the other 
groups due to peaks annotated in Chenomx Profiler® as “Ethanol”. Also some 
other studies found ethanol in their results [85] potentially as a contamination. 
As we found this mainly in JSLE patients, this was investigated further.  
A major difference between JSLE patients and JIA patients and paediatric 
controls, besides the disease itself, is the medication most patients receive. Most 
commonly given to JSLE patients is hydroxychloroquine, a DMARD 
administered to downregulate the immune system. This was run on the 700 
MHz AVANCE™III HD spectrometer. When analysing the obtained spectrum in 
Chenomx Profiler® it also recognized the “Ethanol” peaks as seen in Figure 3.1. 
Black lines indicate the acquired spectrum opened in Chenomx Profiler®. The 
blue line shows the triplet of ethanol around 1.2 ppm where it was also found in 
serum of JSLE patients. 
In order to avoid a model primarily due to separation by treatment, the peaks 
from ethanol (or ethanol-like molecules) have been excluded from further 
analysis. Additionally, analysis was only performed with annotated metabolites 
as we assumed unknown peaks could also be artefacts of medication and skew 
the analysis.  
 
 
 
Figure 3.1: "Ethanol" peak detected in the Hydroxychloroquine spectrum.  
Hydroxychloroquine was run on the 700 MHz AVANCE™III HD and the resulting 
spectrum is indicated by black lines. One of the metabolites detected within the 
hydroxychloroquine spectrum by Chenomx Profiler® was Ethanol as it was 
annotated in serum of JSLE patients. The triplet shown here at 1.2 ppm in blue is 
part of the predicted ethanol peaks.  
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3.4.3 Analysis of urine 
Urine is considered to be a waste product of the body and urinary metabolites 
can be indicators for processes that occur in excess. In investigating disease 
processes in children, and as a source of determining potential biomarkers of 
disease, it is a potentially ideal medium, as it is far easier to obtain than taking 
additional blood tests from patients. Urine has a lower content of protein 
compared to serum, so adding TSP as an internal reference peak is therefore 
possible. The single peak of TSP was set as 0 ppm and all other peaks were 
referenced to it. Variation in pH and ionic strength (salt content) between the 
samples can affect peak positions as measured for example by Platzer et al 
(2014). For assignment and analysis, it was therefore necessary to annotate 
metabolites in Chenomx Profiler® to overcome these problems. This process 
needs extreme care to match entire metabolite profile in a process of trial and 
error leading to deconvolution of peaks to give one relative abundance per 
metabolite as opposed to the multiple values per metabolite possible in 
homeostatic serum sample. The exported area under the peaks was used to 
measure relative abundance of metabolite a as described in 2.1.2. As no patient 
had acute kidney disease it was decided that creatinine is a valid peak to 
normalize for so that dilution factors could be taken into account [221]. 
Patients included in the study of urine are listed in Table 3.2. The three groups 
include healthy paediatric controls, JIA patients and JSLE patients. The 
classification of IFN high and IFN low JSLE patients is shown (as mentioned in 
Section 3.4.2) and further discussed in Chapter 4.  
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Study ID SLEDAI Age  Gender Ethnicity Treatment 
C316a - 9 Female WB None 
C367a - 13 Male WB None 
C368a - 17 Male WB None 
C372a - 13 Female WB None 
J9b (O)  20 Male WB 
Corticosteroids, 
biologics, NSAIDS and 
DMARDS 
J66b (P)  9 Female WB Biologics 
J90a (S)  9 Male WB Corticosteroid - oral 
J105a (P)  13 Female WB Biologics 
L34h (not 
tested on 
IFN) 
22 7 Male WB 
HCQ 400 and warfarin 
6 
L62h 0 12 Female WB 
HCQ 200, MMF 1500, 
Pred 2,5 
L64i 7 17 Female WB Pred 10 
L65f 8 17 Female WB HCQ 400, MMF 1000 
L66g 5 6 Female WB 
HCQ 200, MMF 2000, 
Pred 5, statin 
L68e 16 15 Female WB 
HCQ 400, MMF 2000, 
Pred 10 
L69a 12 17 Male Other 
HCQ 200, MMF 1500, 
Pred 15 
Cyclophosphamide -
no info on dose 
L73a 4 14 Female No info HCQ 400, MMF 2000 
L43s 16 16 Female WB 
HCQ 200, MMF 2000, 
Pred 5 
Table 3.2: List of patients included for urine analysis.  For each patient 
group (C=healthy control, J=JIA, L=JSLE), disease activity (SLEDAI) age, gender, 
ethnicity and medication is stated. Brackets behind JIA patients give information 
about the type of JIA (O=Oligoarthritis, P=Polyarthritis, S=systemic arthritis). 
The most frequent medication were: Hydroxychloroquine (HCQ), 
Mycophenolate (MMF) and Prednisolone (Pred). Doses written after medication 
are in mg. The font of JSLE patients is dependent on their classification as IFN 
high (bold) and IFN low (italic). 
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 Results 
3.5.1 Serum metabolomics 
3.5.1.1 Differences between the serum metabolome of JSLE patients, JIA 
patients and of healthy paediatric controls 
In this study, serum from JIA patients with mainly non-systemic onset subtypes 
was used to observe any differences between a systemic disease with neutrophil 
involvement (JSLE) and one with mainly joint involvement (JIA).  
Principal component analysis (PCA) looks at the entire variance within the 
spectra and clusters the patients according to the metabolites explaining most 
of the differences by grouping the variances into principal components (PC). 
Due to the differences between gender, age and ethnicity within the groups as 
well as between the groups, a high variance between the metabolites and no 
immediate clustering looking at the unsupervised PCA which is indiscriminate 
to patient diagnoses was expected. This type of analysis consequently was used 
to find outliers to prevent false positive detection by skewed data (see Figure 
3.2). Applying PCA to the data showed that for 63.5% of the variance (PC1 
51.6% + PC2 11.9%) there were no outliers detected. All samples were within 
the 95% confidence interval and as expected there was no clustering of the 
groups observed. 
The aim was to differentiate between the diseases and healthy controls based 
on metabolite profiles. Similarly, it would be possible to separate patients 
regarding their age, body-mass-index or other characteristics. Nonetheless, for 
this thesis the main question was if metabolites can cluster patients into their 
disease groups from a group of heterogeneous patients. Therefore, a PLS-DA 
was applied to investigate if a separation by the serum metabolome was 
possible (see Figure 3.3). The separation of JSLE, JIA and healthy paediatric 
control patients required three components. It was deemed very robust with an 
R2 of 0.82 (Figure 3.3 (A)). The R2 value ranges from 0-1 and a value of >0.5 is 
considered a strong model. At the same time, the predictive power is very low 
with a Q2 of only 0.18. The Q2 value can be between -1 to 1 and a value > 0.4 is 
considered acceptable for biological systems [222]. In the Variable Importance 
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in Projection (VIP) (B) score Arginine/N-Acetylserotonin.233 and 
Succinylacetone/UNID.194 are the two highest ranked metabolites. Both are 
overlapped peaks and hence, it cannot be distinguished which, or if possibly 
both metabolites are responsible for the differentiation between the study 
groups. Arginine, Asparagine and Succinylacetone are the main contributors to 
this separation as they have additional peaks in the spectrum which appear in 
the VIP score further down.  
The 10 most influential metabolites are listed in Table 3.3 also showing 
importance of Glucose and Hypoxanthine. These metabolites were increased in 
JSLE patients compared to controls but decreased or unchanged for JIA patients 
compared to controls. 
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Figure 3.2: PCA of serum spectra of JSLE, JIA and healthy paediatric control 
patients.  No outliers were observed for either JSLE (blue triangles, n=10), JIA 
(red circles, n=5) or healthy controls (black squares, n=9) as for each group the 
patients were within their 95% confidence interval indicated by a blue, red or 
black circle respectively. 63.5% of the overall variance could be explained with 
PC1 and PC2. 
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Figure 3.3: PLS-DA of serum metabolome of JSLE, JIA and healthy control 
patients.  Patients (JSLE n=10, JIA n=5, Control n=9) were separated with a 
supervised analysis (A) by the differences of their metabolites. Three 
components give the best separation with highest robustness (R2=0.82) and 
highest predictive power (Q2=0.18). Metabolites responsible for separation are 
shown in the VIP score for the first component (B). Metabolites are annotated 
by name and their unique identifying number to allow for multiple NMR peaks 
per molecule. 
 
  
A B 
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Metabolite and numbers of peaks within the TOP 20 VIP score with 
representative boxplot of control (red), JIA (green) and JSLE (blue) serum 
Arginine 
2 
Asparagine 
3 
Formate 
1 
Glucose 
4 
Glycerol 
1 (overlapped) 
Histidine/UNID 
2 
Hypoxanthine 
1 
Mobile lipids/ 
phosphocholine 
1 (overlapped) 
Succinylacetone 
3 
UNID/Histamine 
1 
Table 3.3: The ten most influential metabolites for PLS-DA of metabolites 
in JIA, JSLE and control serum.  The metabolites are listed in alphabetical 
order with one representative boxplot, but each metabolite may have several 
peaks within the VIP score. The number of peaks is stated after the metabolites. 
The boxplots show abundance on the Y-axis for the metabolite in serum of 
healthy paediatric control patients (red), JIA (green) and JSLE patients (blue). 
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Metabolites described in Table 3.3 are central to the separation between the 
three disease groups. Yet, there are more significant differences noted between 
the three groups as shown by one-way ANOVA between the three groups (see 
Table 3.4). Some of the metabolites are overlapping with the VIP score like 
Glucose, a main separator in PLS-DA was also found significant with ANOVA.  
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Annotated peak p-value 
adjusted 
p-value 
Significant for 
Tukey’s post hoc 
analysis between 
Acetoacetate.209 0.00033 0.02785 JIA-Ctrl, JSLE-JIA 
Alanine.244 0.00852 0.11871 JIA-Ctrl, JSLE-JIA 
Creatine_phosphate.79 0.04883 0.23243 
JIA – Ctrl (p=0.1), 
JSLE-Ctrl (p=0.08) 
Glucose.124 0.02813 0.15415 JIA-Ctrl, JSLE-JIA 
Glucose.127 0.00468 0.10618 JIA-Ctrl, JSLE-JIA 
Glucose.129 0.01509 0.15415 JIA-Ctrl, JSLE-JIA 
Glucose.98 0.03122 0.16152 JIA-Ctrl, JSLE-JIA 
Glucose.Glycerol.96 0.02765 0.15415 JSLE-JIA 
Glucose.UNID.128 0.00535 0.10618 JIA-Ctrl, JSLE-JIA 
Glutamine.UNID.219 0.01321 0.15415 JSLE-Ctrl 
Histidine.Arabinose.72 0.0285 0.15415 JSLE-Ctrl 
Leucine.Isoleucine.UNID.271 0.02648 0.15415 JSLE-Ctrl 
Lysine.163 0.02803 0.15415 JSLE-JIA 
Mannose.81 0.00898 0.11871 JIA-Ctrl, JSLE-Ctrl 
N-Acetylserotonin.15 0.00459 0.10618 JSLE-Ctrl, JSLE-JIA 
N-Acetylserotonin. 
Phenylalanine.14 
0.0007 0.02785 JSLE-Ctrl, JSLE-JIA 
Ornithine.158 0.01802 0.15415 JSLE-Ctrl 
Ornithine.160 0.02468 0.15415 JSLE-Ctrl 
Phenylalanine.12 0.02277 0.15415 JSLE-JIA 
Phenylalanine.UNID.17 0.0216 0.15415 JSLE-JIA 
Succinylacetone.UNID.194 0.00048 0.02785 JIA-Ctrl, JSLE-JIA 
Trimethylamine_N.oxide. 
Glucose.146 
0.02755 0.15415 JIA-Ctrl, JSLE-JIA 
UNID.Glutamine.188 0.00646 0.10982 JSLE-Ctrl 
UNID.Lysine.164 0.02848 0.15415 JSLE-JIA 
UNID.Valine.212 0.04871 0.23243 JSLE-Ctrl 
Table 3.4: Significant peaks of metabolites from serum of JSLE, JIA and 
healthy paediatric control patients.  Metabolites were tested with one-way 
ANOVA for their significance and p-values and adjusted p-values with 
Benjamini-Hochberg correction are stated in this table.  
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Most peaks were only significant for a “raw” p<0.05 rather than for an adjusted 
p-value. Usually the adjusted p-value is used to diminish the false-positive rate 
due to multiple testing. In metabolomic analyses, this can be restrictive as 
several peaks can be due to one metabolite and typically, when 280 or more 
variables are present this leads to a rather conservative adjustment. A thorough 
annotation of metabolites and assignment of many peaks would therefore 
decrease the chance to identify differences. For this reason, for all following 
results only the p-value was used as a significance level and the adjusted p-value 
will be stated only. 
From PCA (Figure 3.2) and PLS-DA (Figure 3.3) the JIA group showed a higher 
variance than the other two groups. Clear differences between JIA and JSLE and 
healthy controls were noted, and the higher variance within the JIA patient 
group would indicate potential differences between JIA sub-groups themselves. 
Further analyses of the JIA serum samples are therefore warranted, but beyond 
the scope of this present analysis. 
For going forward therefore, in order to reduce the variance and focus 
specifically on the characteristics of the metabolome in JSLE, JSLE patient 
samples were compared directly against the healthy control group only.  
 
3.5.1.2 Differences between the serum metabolome of JSLE patients and of 
healthy paediatric controls 
JSLE is a disease with many different manifestations from skin involvement to 
joint damage or nephritis. Patients may receive medication with higher and 
lower concentrations of DMARDs, steroids or immunosuppressants, but also 
other treatments like biologics. All these variables are explanations for a high 
variance to be observed within the JSLE cohort. PCA with PC1 and PC2 for JSLE 
and control patients gave 64.9% of the overall variance but leaving patient 
“L30l” as an outlier (Figure 3.4 A). As Figure 3.4 (B) shows, PC1 and PC3 are 
still accounting for 62.3% of the overall variance and “L30l” is not an outlier 
anymore. Therefore, all samples were considered for further analysis. PLS-DA 
created a more robust (R2=0.95) and more predictive (Q2=0.34) model (C) than 
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when comparing JIA, JSLE and control patients (Figure 3.3). Metabolites, e.g. 
Arginine, myo-Inositol and Hypoxanthine, are influential on component 1 and 
listed in the VIP score (Figure 3.4D).  
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Figure 3.4: PCA and PLS-DA of metabolites present in JSLE and control 
serum.  PCA of JSLE (red circles, n=10) and control (black squares, n=9) serum 
for PC1 and 2 explaining 64.9% of the overall variance in (A) indicated that 
patient L30l (indicated in blue square) is an outlier. PC2 and 3 in (B) make up 
62.3% and include L30l which is included in analysis. A separation of the two 
groups with PLS-DA can be visualized with two components (C) but the best 
model is achieved with four components. The robustness of the test reaches an 
R2 of 0.95 and the predictive power Q2 is 0.34 with the VIP score of the most 
influential metabolites listed in (D).  
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Significant difference between disease and healthy controls was observed with 
a Kolmogorov–Smirnov test assuming non-parametric distribution and unequal 
variance in the two groups  
Table 3.5). Due to small sample size a parametric distribution and equal 
variance could not be proved. The peaks are listed from lowest to highest p-
value.  
 
 
 
Metabolites p-values BH adjusted p-values 
Mannose.81 0.0027 0.18 
N.Acetylserotonin.Phenylalanine.14 0.0037 0.18 
UNID.Glutamine.188 0.007 0.18 
Ornithine.160 0.012 0.18 
Asparagine.169 0.018 0.18 
mobile_unsaturated_lipids.42 0.018 0.18 
myo.Inositol.139 0.018 0.18 
N.Acetylserotonin.15 0.018 0.18 
Propylene_glycol.261 0.018 0.18 
UNID.Valine.212 0.018 0.18 
UNID.Valine.213 0.018 0.18 
Glutamine.UNID.219 0.021 0.18 
Histidine.Arabinose.72 0.021 0.18 
UNID.Glutamine.223 0.021 0.18 
Creatine_phosphate.79 0.045 0.31 
Leucine.269 0.045 0.31 
 
Table 3.5: Statistical analysis using Kolmogorov-Smirnov-test to assess 
difference between healthy paediatric control and JSLE serum 
metabolites.  P-values are stated as well as Benjamini-Hochberg (BH) adjusted 
p-values. 
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PCA as seen in Figure 3.4 A indicates high variation within both controls and 
the JSLE cohort. Our group has previously obtained transcriptomics data from 
patients whose sera were used in this metabolomics analysis. Grouping samples 
into “Control”, “IFN high” and “IFN low” resulted in tighter clustering for the two 
JSLE subgroups (Figure 3.5A). These subgroups still indicated significant 
differences with ANOVA as seen in Table 3.6. For Asparagine, N-
Acetylserotonin and Ornithine even several peaks are coming up as significant 
supporting that the observed results are true. 
PCA of IFN high, IFN low and control patients (Figure 3.5A) displays a compact 
confidence interval with no outliers for IFN low patients strongly supporting the 
hypothesis that IFN low and IFN high patients are different subgroups of JSLE. 
Also, for IFN high patients a smaller confidence interval can be reached for PCA 
(A, red circles n=7) compared to the PCA obtained separating JSLE against 
control patients (Figure 3.4). This is further visualized with a PLS-DA which 
separates IFN low patients from both IFN high and control patients (Figure 
3.5B). Even though the robustness R2 is reaching values up to 0.99 this model 
does not reach a positive predictive power. PLS-DA diagnostics show R2 and Q2 
for one to eight components (C). It shows that separation is very robust with 
increased number of components (R2 reaching up to 0.99), but that predictive 
power remains very low with even negative values. Our analysis only included 
three IFN low patients, a positive predictive power is therefore not likely, and 
this model needs a larger cohort for effective validation (n≥6 required before 
PLS-DA can be effective). For this reason, metabolites responsible for PLS-DA 
separation were not considered for further analysis. 
  
116 
 
Metabolites p-value BH adjusted 
p-value 
Different 
between 
Acetoacetate.209 0.030 0.36 IFN low-IFN high 
Asparagine.169 0.036 0.36 IFN low-Control 
Asparagine.174 0.020 0.34 IFN low-IFN high 
Asparagine.176 0.048 0.40 IFN low-IFN high 
Glutamine.UNID.219 0.012 0.24 
IFN high-Control,  
IFN low-Control 
Histidine.Arabinose.72 0.0058 0.17 IFN high-Control 
Leucine.Isoleucine.UNID.271 0.035 0.36 IFN high-Control 
Mannose.81 0.0099 0.24 
IFN high-Control,  
IFN low-Control 
N-Acetylserotonin.15 0.0058 0.17 
IFN high-Control,  
IFN low-Control 
N-Acetylserotonin. 
Phenylalanine.14 
0.0014 0.08 
IFN high-Control,  
IFN low-Control 
Ornithine.158 0.028 0.36 IFN high-Control 
Ornithine.160 0.039 0.36 
IFN high-Control 
n.s. p=0.06 
UNID.Glutamine.188 0.00084 0.082 
IFN high-Control,  
IFN low-Control 
UNID.Histamine.140 0.039 0.36 IFN low-IFN high 
Table 3.6: Results of ANOVA for serum metabolites which are significantly 
different between the patient groups  Control, IFN low and IFN high. P-values 
are stated as well as Benjamini-Hochberg (BH) adjusted p-values. n.s. (not 
significant). Groups are stated different if p<0.05 for Tukey’s post hoc analysis. 
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Figure 3.5: PCA and PLS-DA of serum metabolites of JSLE IFN high and low 
and control patients.  PCA in (A) shows that PC1 summarises 84.0% of the 
variance within the samples and that PC1 and PC2 together reach over 90%. IFN 
low patients (blue, n=3) cluster closely together in both PCA (A) and PLS-DA 
(B). PLS-DA diagnostics (C) show that separation is very robust with increased 
number of patients (R2 reaching up to 0.99), but that predictive power remains 
very low with negative values indicative of no predictive capabilities.  
 
  
A B 
C 
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3.5.2 Urine metabolomics 
3.5.2.1 Differences between the urine metabolome of JSLE patients, JIA 
patients and healthy paediatric controls  
PCA of urine, similar to serum, did not show separation of JSLE, JIA and healthy 
paediatric control patients and PC1 together with PC2 only explained 55.9% of 
the variance (Figure 3.6A). Furthermore, no outliers were observed for any of 
the groups. Using PLS-DA of urine metabolites (B) as a model only two 
components were needed to reach a robustness of 0.91 and a predictive power 
of 0.41. Additionally, ANOVA showed significant differences of metabolites 
between the three groups. The main differences were between JSLE and JIA 
including Allantoin, Glucarate, Malate and Phenylalanine (Table 3.7).  
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Figure 3.6: PCA and PLS-DA of urine metabolites of JSLE, JIA and healthy 
control patients. Patients were evaluated with unsupervised analysis (A) 
dependent on variance within samples. Control (black squares, n=4), JIA (red 
circles, n=4) and JSLE patients (blue triangles, n=8) do not separate when 
looking at 55.9% overall variance with PC1 and PC2. A robust (R2=0.91) 
separation of Control (red), JIA (green) and JSLE (blue) patients can be reach 
with a model of two components (B) which achieves a predictive power (Q2) of 
0.41. Variables contributing to these Component 1 and 2 are displayed in (C). 
 
  
C 
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Metabolites p-value 
BH 
adjusted 
p-value 
Different between 
3,4-
Dihydroxybenzeneacetate 
0.015 0.72 JIA-Control, JSLE-Control 
3-Phenylpropionate 0.013 0.72 JSLE-Control, JSLE-JIA 
Allantoin 0.039 0.72 JSLE-JIA 
Glucarate 0.023 0.72 JSLE-JIA 
Malate 0.0059 0.72 JSLE-JIA 
Phenylalanine 0.036 0.72 JSLE-JIA 
Table 3.7: Urinary metabolites showing a significant difference with 
ANOVA between JSLE, JIA and control patients.  Adjusted p-values calculated 
with Benjamini-Hochberg (BH) are stated besides p-values and groups with 
differences after Tukey’s post hoc analysis are listed in the last column. 
 
 
Similar to serum samples also urine metabolites result in the overlap of 
confidence intervals of JIA and control patients in the PLS-D analysis (Figure 
3.5B). Differences of ANOVA are mainly seen between JSLE and JIA patients.  
A comparison of JSLE and control patients resulted in a better model between 
disease and healthy controls when serum metabolites were compared (as 
described in Section 3.5.1.2). For these reasons, analysis with only these two 
groups was also conducted for urine samples. 
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3.5.2.2 Differences between the urine metabolome of JSLE patients and of 
healthy paediatric controls  
PCA for urine metabolites of JSLE and healthy paediatric control patients did not 
show outliers but a high overlap of the 95%-confidence intervals of JSLE and 
control patients (Figure 3.7A). With PLS-DA a model with a clear separation 
was achieved with two components and a R2 of 0.92 and a Q2 of 0.28 (B). 
Metabolites influencing this model are shown in the VIP score (C). The accuracy 
of the model meaning its robustness and predictive power are comparable to 
the model obtained from serum with R2 of 0.95 and Q2 of 0.34. This is somewhat 
surprising to see as the urine sample size (n=12) was smaller compared to 
serum (n=19).  
Further separation of JSLE patients into IFN high and IFN low is difficult as in 
the cohort studied only two patients who donated urine were IFN low patients. 
Nevertheless, a PCA Figure 3.8 of these three groups was undertaken and PC1 
and PC2 covered 46.5% of variance. While there were no outliers observed with 
PCA, a separation between IFN high and low patients was clearly visible already 
with this unsupervised analysis. Isolation of IFN low patients resulted in a 
tighter confidence interval. PLS-DA at this stage was not possible with n=2 for 
IFN low patients. Interestingly, comparing this PCA with the PCA in Figure 3.7 
there was a similar pattern with two JSLE samples being further away from the 
other 6. The samples used for this separation included an additional sample of 
L34h. When labelling the samples with their study number the two IFN low 
patients indicated with a blue square were separated further away from all 
other patients (Figure 3.8B). The additional sample of L34h is located in the 
middle of the cluster of IFN high patients. Consequently, it seems likely that this 
patient is an IFN high patient which raises the possibility of using PCA of urine 
metabolites as a tool for differentiation of IFN high and low patients. 
With this striking separation it is crucial to get information about differences in 
urine and as PLS-DA could not be performed and only results from ANOVA were 
available. These results need to be treated with caution due to the small sample 
size particularly with in the IFN low group. It is possible to calculate a p-value 
for a group containing only two samples, but importance in a wider cohort 
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would need to be validated. Metabolites are listed in Table 3.8. The metabolites 
in this table are mainly different between IFN high and IFN low, including 
Formate, 2-Hydroxyisobutyrate, Uridine-diphosphate (UDP) glucose, Valine and 
Acetate. Sarcosine, Sucrose and Fumarate are examples of metabolites being 
different for IFN high and IFN lows and also IFN low and control patients which 
is supporting the division between IFN low and IFN high patients seen in Figure 
3.8A. 
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Figure 3.7: PCA and PLS-DA of metabolites present in JSLE and control 
urine.  PCA of JSLE (red circles, n=9) and control (black squares, n=4) urine for 
PC1 and 2 explaining 44.8% of the overall variance in (A) did not indicate 
outliers. A separation of the two groups with PLS-DA can be visualized with two 
components (B) which is also the most accurate model with a robustness of R2 
of 0.92 Q2 of 0.28 with the VIP score of the most influential metabolites 
displayed in (C). 
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Figure 3.8: PCA of urine metabolites of IFN high, IFN low and control 
patients and of JSLE and control patients with indication of IFN subgroup. 
PC1 and PC2 together made up 46.5% of variance and separated the two disease 
subgroups of IFN low patients (blue triangles, n=2) and IFN high patients (red 
circles, n=5) in (A). Unsupervised analysis of JSLE (red circles, n=8) and control 
patients (black squares, n=4) in (B) revealed that IFN low patients indicated 
with blue squares do not fall within IFN high patients. L34h (black arrow) was 
not part of the transcriptomics study and is therefore not classified as IFN high 
or low, but the sample falls within the IFN high patient group.  
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Metabolite p-value 
BH adjusted 
p-value 
Different between 
2-Hydroxyisobutyrate 0.035 0.37 IFN low-IFN high 
2-Oxoglutarate 0.047 0.37 
n.s. (0.052 for IFN 
low –Control) 
3,4-
Dihydroxybenzeneacetate 
0.024 0.37 IFN high-Control 
3-Hydroxy-3-
methylglutarate 
0.0086 0.21 
IFN low-Control, IFN 
low-IFN high 
Acetate 0.011 0.23 
IFN low-Control, IFN 
low-IFN high 
cis-Aconitate 0.0015 0.11 
IFN high-Control, IFN 
low-Control, IFN 
low-IFN high 
Erythritol 0.0069 0.20 
IFN high-Control, IFN 
low-Control, IFN 
low-IFN high 
Ethanolamine 0.045 0.37 IFN low-Control 
Formate 0.038 0.37 IFN low-IFN high 
Fumarate 0.033 0.37 
IFN low-Control, IFN 
low-IFN high 
Glycolate 0.032 0.37 IFN low-IFN high 
Leucine 0.045 0.37 IFN low-IFN high 
Mannitol 0.0040 0.15 
IFN low-Control, IFN 
low-IFN high 
Pyruvate 0.025 0.37 
IFN low-Control, IFN 
low-IFN high 
Sarcosine 0.0038 0.15 
IFN low-Control, IFN 
low-IFN high 
Sucrose 3.03E-07 4.46E-05 
IFN low-Control, IFN 
low-IFN high 
UDP-glucose 0.040 0.37 IFN low-IFN high 
Valine 0.021 0.37 IFN low-IFN high 
Table 3.8: Urine metabolites showing a significant difference with ANOVA 
between JSLE IFN high, IFN low and control patients.  Both the p-value and 
the Benjamini-Hochberg (BH) adjusted p-values are stated. n.s. (not significant). 
Groups are stated different if p<0.05 for Tukey’s post hoc analysis.  
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3.5.3 Pathway analysis 
PCA and PLS-DA as well as ANOVA indicated strong distinctions between the 
two diseases JSLE and JIA compared to control patients for both serum and 
urine. JSLE IFN high and IFN low subgroups were only described based on their 
genetic signature so far and consequently pathway analysis with these groups 
can show additional differences.  
Observed differences need to be looked at from a biological perspective and 
hence pathway analysis of the data was conducted. For this, metabolites with a 
significant p-value and the ten metabolites most influential on the VIP score 
were used.  
 
3.5.3.1 Pathways important for JSLE, JIA and control patients 
Metabolites that were included for analysis are listed in Table 3.9 with their 
number for the human metabolome database (HMDB), PubChem database and 
Kyoto Encyclopaedia of Genes and Genome database (KEGG). 
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Query Match HMDB PubChem KEGG 
3,4-Dihydroxy-
benzeneacetate 
3,4-Dihydroxy-
benzeneacetic acid 
01336 547 C01161 
3-Hydroxyiso-
valerate 
3-Hydroxyisovaleric 
acid 
00754 69362 NA 
3-Phenylpropionate Hydrocinnamic acid 00764 107 C05629 
Acetoacetate Acetoacetic acid 00060 96 C00164 
Alanine L-Alanine 00161 5950 C00041 
Allantoin Allantoin 00462 204 C01551 
Arginine L-Arginine 00517 6322 C00062 
Asparagine L-Asparagine 00168 6267 C00152 
Creatine-phosphate Phosphocreatine 01511 587 C02305 
Dimethylglycine Dimethylglycine 00092 673 C01026 
Formate Formic acid 00142 284 C00058 
Glucarate Glucaric acid 00663 33037 C00818 
Glucose D-Glucose 00122 5793 C00031 
Glycerol Glycerol 00131 753 C00116 
Hypoxanthine Hypoxanthine 00157 790 C00262 
IMP Inosinic acid 00175 8582 C00130 
Kynurenate Kynurenic acid 00715 3845 C01717 
Lysine L-Lysine 00182 5962 C00047 
Malic acid L-Malic acid 00156 222656 C00149 
Mannose D-Mannose 00169 18950 C00159 
Mobile lipids NA NA NA NA 
N-Acetylserotonin N-Acetylserotonin 01238 903 C00978 
N-Methylhydantoin N-Methylhydantoin 03646 69217 C02565 
Ornithine Ornithine 00214 6262 C00077 
Phenylalanine L-Phenylalanine 00159 6140 C00079 
Succinylacetone Succinylacetone 00635 5312 NA 
Threonate Threonic acid 00943 151152 C01620 
Xanthine Xanthine 00292 1188 C00385 
Table 3.9: List of metabolites included in pathway analysis of JIA, JSLE and 
control patients.  Results from ANOVA as well as from PLS-DA VIP scores were 
integrated. Metabolites were inserted into Metaboanalyst pathway analysis with 
the indicated HMDB, PubChem and KEGG number. Lipids are not included in 
this type of analysis and therefore not recognized by the program and marked 
as not available (NA).  
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Metaboanalyst pathway analysis yielded 35 pathway “hits”, but only seven of 
them had a significant p-value with Fisher’s exact test and are therefore stated 
here. These pathways included Aminoacyl-tRNA biosynthesis, arginine and 
ornithine metabolism, nitrogen metabolism, arginine and proline metabolism, 
galactose metabolism, alanine, aspartate and glutamate metabolism and 
pyruvate metabolism (see Table 3.10). 
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Pathway 
Matched 
metabolites 
Total number 
of 
metabolites 
p-value 
(Fisher’s 
exact 
test) 
Aminoacyl-tRNA 
biosynthesis 
L-Asparagine, 
L-Phenylalanine, 
L-Arginine, 
L-Lysine, L-Alanine 
75 8.38E-04 
D-Arginine and D-
ornithine metabolism 
L-Arginine, 
Ornithine 
8 0.0027918 
Nitrogen metabolism 
L-Phenylalanine, 
L-Asparagine, 
Formic acid 
39 0.007071 
Arginine and proline 
metabolism 
L-Arginine, 
Ornithine, 
Phosphocreatine, N-
Methylhydantoin 
77 0.0073479 
Galactose metabolism 
D-Glucose, Glycerol, 
D-Mannose 
41 0.0081356 
Alanine, aspartate and 
glutamate metabolism 
L-Asparagine, 
L-Arginine 
24 0.02486 
Pyruvate metabolism 
L-Malic acid, Formic 
acid 
32 0.042476 
Table 3.10: List of significant pathways for metabolites of JIA, JSLE and 
control patients.  Ten most influential metabolites of the VIP score for PLS-DA 
and significant metabolites of ANOVA were used in metaboanalyst to identify 
pathways. Fisher’s exact test was used to identify significance.  
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Combining these pathways and further investigation of the role of these 
metabolites indicated a potential biological role of these metabolites in JSLE and 
JIA patients. These metabolites are summarized in a pathway containing 
glycolysis, Pentose phosphate pathway (PPP), Krebs and urea cycle as shown in 
Figure 3.9. Differences in these pathways for JSLE and JIA patients is 
summarized in Figure 3.10. Both the PPP as well as the Krebs cycle appear to 
be fed by glucose in JSLE patients with a preference for the PPP which is 
increased compared to healthy control patients. JIA patients do not have 
increased glucose levels and appear to use it only for the PPP indicated by high 
IMP and xanthine levels as observed for JSLE patients. Metabolites of the Krebs 
cycle are increased for JIA patients but appear normal in JSLE. The increased 
need of energy in the rheumatic patients is satisfied with input of acetoacetate 
from triacylglyceride and acetoacetate and fumaric acid resulting from 
phenylalanine degradation. Arginine is increased in both disease groups and 
with it, ornithine. This observation is supported by higher guanidinoacetate 
levels resulting from ornithine production. Glutamine synthesis is increased in 
JIA patients, but inhibited in JSLE patients due to higher concentrations of 
alanine. Glutamine is also feeding into the urea cycle which seems upregulated 
in both diseases.  
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Figure 3.9: Connections between metabolic pathways potentially important for autoimmune diseases.  Glycolysis, the 
Pentose Phosphate Pathway, the Krebs cycle and the Urea cycle are all connected, and metabolites feeding into this pathway or 
being released from them are shown here.
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Figure 3.10: Altered metabolic pathway in JIA and JSLE patients compared to control. The pathway includes Glycolysis, 
Pentose Phosphate Pathway, Krebs cycle, and the Urea cycle with their starting and end products. Metabolites that were 
detected either in serum or urine are shown with squares for JIA on the left and JSLE on the right, under the name of the 
metabolites. Concentrations compared to control are indicated with  for higher than control,  similar to control and    for 
lower than control. If a metabolite was significantly different with ANOVA (p<0.05) then this is indicated with *
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3.5.3.2 Pathways important for JSLE IFN low, JSLE IFN high and healthy 
control patients 
Sections 3.5.1.2 and 3.5.2.2 described differences in serum and urine 
metabolites between subsets of JSLE patients which were suggested to be 
separable by their IFN signature. JSLE IFN low patients are very rare and PLS-
DA for serum showed a negative result for Q2 which is again due to the low 
number in the experimental sample. For urine, PLS-DA could not be conducted 
due to the low numbers. Therefore, for pathway analysis only metabolites which 
were significantly different with ANOVA were inserted into Metaboanalyst. 
Metabolites used for analysis are listed in Table 3.11 with their HMDB, 
PubChem and KEGG ID. The resulting pathways are stated in Table 3.12. 
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Metabolite HMDB PubChem KEGG 
3,4-Dihydroxybenzeneacetic acid 01336 547 C01161 
3-Hydroxymethylglutaric acid 00355 1662 C03761 
Acetic acid 00042 176 C00033 
Acetoacetic acid 00060 96 C00164 
Alpha-Hydroxyisobutyric acid 00729 11671 NA 
cis-Aconitic acid 00072 643757 C00417 
D-Mannose 00169 18950 C00159 
Erythritol 02994 222285 C00503 
Ethanolamine 00149 700 C00189 
Formic acid 00142 284 C00058 
Fumaric acid 00134 444972 C00122 
Glycolic acid 00115 757 C00160 
L-Asparagine 00168 6267 C00152 
L-Leucine 00687 6106 C00123 
L-Valine 00883 6287 C00183 
Mannitol 00765 6251 C00392 
N-Acetylserotonin 01238 903 C00978 
Ornithine 00214 6262 C00077 
Oxoglutaric acid=-ketoglutarate 00208 51 C00026 
Pyruvic acid 00243 1060 C00022 
Sarcosine 00271 1088 C00213 
Sucrose 00258 5988 C00089 
Uridine diphosphate glucose 00286 53477679 C00029 
Table 3.11: Serum and urine metabolites which were significantly 
different between IFN high, IFN low and control patients. 
Pathway Matched metabolites Metabolites p-value 
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(total) (Fisher’s 
exact test) 
Citrate cycle 
(TCA cycle) 
Oxoglutaric acid, 
cis-Aconitic acid, 
Pyruvic acid, 
Fumaric acid 
20 2.3073E-5 
Alanine, 
aspartate and 
glutamate 
metabolism 
L-Asparagine,  
Pyruvic acid, 
Oxoglutaric acid, 
Fumaric acid 
24 4.9399E-5 
Glyoxylate and 
dicarboxylate 
metabolism 
cis-Aconitic acid, 
Oxoglutaric acid, 
Formic acid, 
Glycolic acid, 
Pyruvic acid 
50 6.3699E-5 
Butanoate 
metabolism 
Acetoacetic acid, 
Pyruvic acid, 
Oxoglutaric acid, 
Fumaric acid 
40 3.8582E-4 
Valine, leucine 
and isoleucine 
biosynthesis 
Pyruvic acid, 
L-Leucine, 
L-Valine 
27 0.0016827 
Pyruvate 
metabolism 
Pyruvic acid, 
Formic acid, 
Acetic acid, 
32 0.0027699 
Tyrosine 
metabolism 
3,4-Dihydroxy-
benzeneacetic acid, 
Pyruvic acid, 
Fumaric acid,  
Acetoacetic acid 
76 0.0043584 
Arginine and 
proline 
metabolism 
Ornithine; 
Fumaric acid 
Pyruvic acid 
Sarcosine 
77 0.0045695 
Valine, leucine 
and isoleucine 
degradation 
L-Leucine, 
Acetoacetic acid, 
L-Valine 
40 0.0052619 
Galactose 
metabolism 
Sucrose, 
UDP- glucose, 
D-Mannose 
41 0.0056437 
Ascorbate and 
aldarate 
metabolism 
UDP-glucose, 
Pyruvic acid, 
Oxoglutaric acid 
45 0.0073367 
Taurine and 
hypotaurine 
metabolism 
Pyruvic acid, 
Acetic acid 
20 0.013719 
Pantothenate 
and CoA 
L-Valine, 
Pyruvic acid 
27 0.024384 
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biosynthesis 
Aminoacyl-tRNA 
biosynthesis 
L-Asparagine, 
L-Valine, 
L-Leucine 
75 0.029237 
Glycolysis or 
Gluconeogenesis 
Acetic acid, 
Pyruvic acid 
31 0.031601 
Vitamin B6 
metabolism 
Oxoglutaric acid, 
Pyruvic acid 
32 0.033523 
Propanoate 
metabolism 
Acetoacetic acid, 
L-Valine 
35 0.039557 
Nitrogen 
metabolism 
L-Asparagine, 
Formic acid 
39 0.048196 
Table 3.12: List of significant pathways for metabolites of JIA, JSLE and 
control patients.  Ten most influential metabolites of the VIP score for PLS-DA 
and significant metabolites of ANOVA were used in metaboanalyst to identify 
pathways. Fisher’s exact test was used to identify significance.  
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Some metabolites including acetoacetic acid, formic acid or ornithine, are 
observed for both JIA and JSLE patients when comparing them to paediatric 
healthy controls. However, many of the other significant metabolites between 
JSLE subsets and healthy control patients differed to the JIA, JSLE and control 
patient comparison shown in Figure 3.10. 
 
The connections were therefore adjusted to the metabolites for JSLE IFN high, 
IFN low and control patients in Figure 3.11. The PPP shunt was visible in both 
JSLE subgroups, but otherwise they strongly differed. The Krebs cycle appears 
to be highly active in IFN low patients with high glucose and pyruvate, but also 
acetoacetate supporting energy production. Ornithine is increased in both IFN 
high and IFN low patients, but only IFN high patients have high glutamine levels. 
IFN high patients seem to utilize arginine for citrulline production and not for 
ornithine synthesis as the by-product guanidinoacetate is decreased. Ornithine 
in JSLE IFN high patients might results rather from glutamine and could then 
result in citrulline production. This cannot be confirmed with 1H-NMR of serum 
and urine as these liquids have too many strong signals from high concentration 
metabolites which could mask signals from citrulline. 
Overall the IFN low patients have a very different metabolic signature compared 
to IFN high patients and presented pathways are upregulated compared to 
controls.  
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Figure 3.11: Altered metabolic pathway in JSLE patients with IFN high and IFN low signature compared to control.  The 
pathway includes Glycolysis, Pentose Phosphate Pathway, Krebs cycle, and the Urea cycle with their starting and end products. 
Metabolites that were detected either in serum or urine are shown with squares for JIA on the left and JSLE on the right, under 
the name of the metabolites. Concentrations compared to control are indicated with  for higher than control,   similar to 
control and    for lower than control. If a metabolite was significantly different with ANOVA (p<0.05) then this is indicated 
with *. 
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 Discussion  
This study aimed to look at differences between metabolites in serum and urine 
of JIA, JSLE and healthy control patients. Additionally, an objective was to 
compare IFN high and IFN low JSLE patients who were characterised based on 
results of their IFN induced gene signature from previously obtained 
transcriptomics data. It was hypothesized that changes in metabolite profiles 
could be potentially used as diagnostic tools for disease groups and therefore 
wanted to test which body fluid would provide a better prediction model. 
Furthermore, metabolites and altered pathways might indicate dysregulations 
in a disease or a disease subgroup.   
JSLE is a disease where many organs can be involved [53] and it is therefore 
called a multisystem disease. Most JIA subtypes are mainly affecting joints, but 
there is also a systemic form. The serum samples used for this study were solely 
from oligo- and polyarticular JIA subtype patients (Table 3.1). In the set of 
urine samples as seen in Table 3.2 one JIA patient with systemic disease was 
included due to the limited sample numbers available for this study. PCA of JIA, 
JSLE and control patients showed (Figure 3.6A) that all samples including the 
urine of the systemic JIA patient fell within the 95% confidence interval and was 
hence not considered an outlier. The sample was consequently used for all 
analyses. 
PCA for serum reached a higher percentage of variance adding PC1 and PC2 
compared to PCA of urine metabolites. Several peaks were annotated for each 
metabolite in serum and change in one metabolite should change all or at least 
most peaks of this metabolite. Urine on the other hand only had one variable per 
metabolite due to analysis using Chenomx Profiler® as described in 3.4.3. When 
serum and urine were used to distinguish in a model with PLS-DA between JIA, 
JSLE and control patients’ urine was found to be the more informative body 
fluid. While in serum a R2 of 0.82 and a Q2 0.18 was reached, urine achieved a R2 
0.91 R2 and Q2 0.41 (Figure 3.3 and Figure 3.6) with a smaller sample size. A 
comparison of the JSLE subgroups was not possible since the sample size was 
too small to create a PLS-DA. Yet, these results suggest that urine is the more 
140 
 
informative body fluid to distinguish between JIA, JSLE and healthy controls. 
Studies for NMR techniques are often focused on serum even in diseases with 
kidney involvement which is expected to have more impact on the urine rather 
than the serum [85]. A reason for this could be that sample preparation for 
urine is more difficult than serum as it has to be buffered because of variation in 
the pH values [216]. Even with pre-treatment it is usually not possible to 
achieve equivalent pH between samples, and the acidity can alter the state of 
protonation of a metabolite like an amino acid which results in a different 
chemical shift [223]. For this reason, analysis by comparison of the area under 
peaks within certain ppm ranges was not possible. It was necessary that 
metabolites had to be annotated for each sample in Chenomx Profiler® which 
reduced the number of variants as each metabolite only resulted in one variant 
instead of several because of multiple peaks per metabolite. This might have 
influenced the ability of urine to be a good model builder, but due to the higher 
levels of intervention by the analyst, it may have limited use for large sample 
sets. 
It has to be noted, that profiles obtained by these PLS-D analyses need to 
include all metabolites which contribute to Component 1 and Component 2 in 
order to cluster diseases or disease subtypes. The predictive power cannot be 
obtained for each single metabolite by this type of analysis and the VIP score 
only indicates which are the most influential metabolites. The overall predictive 
power of the PLS-DA models is the only predictive power which can be 
discussed. Due to the very small sample size the predictive power has been 
found low for most analyses in this thesis and all results need additional 
validation and need to be treated with caution. Furthermore, despite excluding 
unidentified metabolites, impact of medication on urine and serum may still be 
present in this analysis. A correlation analysis of all metabolites with the 
medication patients were treated with may find that some treatments affect 
certain metabolites. It cannot be distinguished though if these metabolites 
result from altered or less active disease or from processing medication. For a 
true understanding of impact of medication on serum and urine metabolite 
profiles a separate study with the same patients before and very shortly after 
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treatment would have to be conducted ideally with increasing doses. This 
however was beyond the scope of this project. 
Using both body fluids enabled us to perform a more thorough pathway analysis 
as some metabolites were only detected in serum or only in urine. Metabolites 
important for PLS-DA or significantly different with ANOVA were included in 
initial pathway analysis and a more general overview was created afterwards in 
Figure 3.10 for JIA, JSLE and healthy paediatric control and Figure 3.11 JSLE 
IFN high, IFN low and healthy paediatric control comparison. The three major 
interactions were glycolysis, the PPP, Krebs and urea cycle.  
For both JIA and JSLE IFN low patients the Krebs cycle showed increased 
activity as intermediates like -ketoglutarate and fumarate were increased. 
These metabolites have been shown to support inflammation by regulating 
hypoxia-inducible factors (HIF) which are transcription factors ([224], [225]). 
HIF1 upregulates IL-1, a pro-inflammatory cytokine that is considered to play 
an important part in SLE [158].  
When comparing JIA and JSLE patients, glucose levels showed a strong 
difference with JSLE patients seeming to be high in glycolysis using resulting 
products for both the PPP as well as the Krebs cycle. High glucose consumption 
has indeed been observed for example in CD4 cells from SLE patients for both 
naïve as well as activated T-cells, suggesting already an intrinsic effect [226]. 
JIA patients appear to have high acetoacetate levels which can support Krebs 
cycle activity. It has been suggested, that CD4-Tcells from RA patients use their 
glucose immediately for the PPP instead of for glycolysis which would support 
the observed need for ketone bodies to provide for the energy demands. In 
consequence ROS levels have been shown to be decreased in these cells [227]. 
Interestingly, in SLE T-cells mTORC1 activation was found leading to 
overreactivity of the PPP as observed in our JSLE cohort [228]. The PPP was 
found to be increased in all the three studied conditions which were JIA, JSLE 
IFN high and JSLE IFN low patients. 
This pathways leads to nucleotide and NADPH production with the latter being 
a substrate for the NADPH oxidase [229]. The enzyme supports phagocytes in 
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ROS production and neutrophils additionally in NET production, suggesting 
importance of these cell types in disease [230].  
Significance of phagocytes is further supported with mobile lipids and glycerol 
being low for JSLE as well as JIA patients. 1H NMR is not able to distinguish well 
enough between fatty acids, therefore the previously described 
“dyslipoproteinemia” could not be confirmed [231]. Nevertheless, other studies 
showed decrease in glycerides in RA and SLE [232]. Phagocytes have been 
linked to the use of fatty acids as they have a high demand for lipids in order to 
generate membranes [233]. Future studies may additionally wish to employ 
orthologous approaches such as mass spectroscopy to investigate differences in 
lipids. 1H NMR has only very limited capabilities regarding detection of fatty 
acids and their distinction. 
The third pathway linked to the investigated disease was the urea cycle. Also, 
here IFN low patients showed similarities to JIA patients with a higher ornithine 
production. IFN high patients seem to not use the conversion of arginine to 
ornithine, but instead a direct shunt to citrulline as products resulting from this 
conversion have been found low. Citrulline has been shown to be important in 
RA, NET production and is a common modification on lupus autoantigens [234]. 
Based on the comparison of their metabolite profile JSLE IFN low patients have 
many similarities to JIA patients. The majority of paediatric arthritis patients 
have been found to have an IFN low profile and the cause for the underlying 
signature could therefore be a strong contributor to the metabolic profile as 
well [56]. 
Analysis of different body fluids is not commonly used and may therefore need 
refinement for future use. Additionally, not all urine and serum samples were 
paired which would be a better approach to validate the ability to combine 
these data sets. Nevertheless, as metabolites were obtained by groups which did 
not have any outliers they are to some extend a homogenous group. Validity of 
these results is still not guaranteed and different disease activity status and 
medication of different episodes may influence results. Similar changes of the 
same metabolite in both serum and urine observed in our dataset for many 
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metabolites is yet a reassurance to some extent that the inclusion of the chosen 
samples is valid. 
 Conclusions 
In conclusion this study has demonstrated that 1H NMR is a useful tool to 
distinguish patients based on their metabolome into JIA, JSLE and paediatric 
control patients with urine being the optimal biofluid for separation. Separation 
of JSLE patients based on their IFN signature could not be evaluated due to the 
very small sample size. Nevertheless, pathway analysis revealed that 
metabolites from the Krebs cycle are increased which plays a vital role in 
inflammation. Further, the PPP was shown to be elevated in both diseases and 
both JSLE subgroups. In combination with glycerides being increased, this 
suggests increased production and use of NADPH, an invaluable substrate for 
phagocytes and especially in neutrophils for phagocytosis and NETosis. Their 
importance particularly in IFN high patients seems likely as the pathway 
analysis undertaken suggests that citrulline production is directly supported 
from arginine without ornithine as an intermediate. For most metabolites JSLE 
IFN low patients appear similar to JIA patients which could be due to the fact 
that JIA patients being more likely to be IFN low patients. Therefore, a specific 
comparison between JSLE IFN low and IFN high with focus on phagocytes might 
be an important approach to take forward.  
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 IFN-induced and phagocytosis-related gene 
signature in JSLE neutrophils 
 
4.1  Introduction 
JSLE is a very heterogenous disease (see Section 1.3) with a wider variation in 
clinical characteristics but also potential biologically-defined disease subtypes 
based on their interferon gene signature (IGS) have been found and described 
[57]. Yet, little is known about why some patients have an IFN low and others an 
IFN high signature, and also about the differences between the IGS subgroups in 
the disease.  
In Chapter 3 within the metabolomic analysis, differences between IFN low and 
IFN high JSLE patients were observed (albeit not demonstrating statistical 
significance, in part at least due to sample size limitations). Nevertheless, these 
results indicated important potential differences in pathways regulating 
phagocytosis between these groups. 
Neutrophils are important for detection and phagocytosis of pathogens which is 
concluded with digestion in the phagosome and phagolysosome. Molecular 
patterns expressed on or by a microorganism can be directly recognized with 
pattern recognition receptors such as TLRs [180] and Dectin-1 [171] – see 
Section 1.7.1 and 1.7.2. Targets can also be opsonized with complement or 
antibodies and are then recognized by Fc- or complement receptors on the 
surface of neutrophils ([235], [236]) – see Section 1.7.5 and 1.7.6.  
After uptake, the phagosome needs to fuse with the lysosome which involves 
changes of Ca2+-levels by CamK1D [207] so that the enzymes from the cell can 
break down the pathogen (see Section 1.7.4). To improve phagocytosis 
efficiency neutrophils can release proteins such as S100A9 (see Section 1.7.7) to 
stimulate themselves in an autocrine manner [198]. 
It is considered that dysregulation in phagocytosis can lead to increased 
NETosis [171], a process found to cause cell and tissue damage in SLE patients 
[237] – see Section 1.6.4.2. As this type of cell death is specific to neutrophils 
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and thought to be a source of autoantigens it is essential to understand the 
ability of neutrophils to perform phagocytosis in JSLE. 
Despite the potential importance of this mechanism in JSLE pathogenesis there 
is little research and understanding of this process in neutrophils of patients. To 
date, there are very limited data investigating the role of neutrophil 
phagocytosis in JSLE (see Section 1.6.5.2). Nevertheless, one study observed no 
significant impairment of phagocytosis of bacteria in neutrophils, but only 
against LPS derived from Salmonella [238]. Within the aforementioned study, 
there is no indication of the time points involved or whether serum from 
patients or controls were used. Therefore further investigation is required so 
that the effect of opsonisation and saturation of the neutrophils can be 
determined as this may play a part in why no difference was observed. 
 
Data presented in Chapter 3 have indicated that one of the key functions that 
may be important are the pathways regulating phagocytosis. Neutrophils from 
JSLE patients may have dysregulated phagocytosis based on both genetic as well 
as on a functional level, resulting in increased NET formation. 
 
4.2  Chapter hypothesis  
The hypothesis that will be investigated here is that JSLE IFN high and IFN low 
patients not only differ in their IFN-induced gene signature, but also differ in 
their phagocytosis-related gene signature.  
 
4.3  Objectives 
The specific objectives for this chapter are: 
Objective 1: To determine an appropriate IGS to differentiate between JSLE IFN 
low and JSLE IFN high patients. 
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Objective 2: To measure the expression of genes that are involved in the 
modification of DNA and phagocytosis-related genes (PRGs) in neutrophils of  
JSLE patients with their respective IFN subtypes and healthy controls. 
Objective 3: To compare protein expression of PRGs in JSLE neutrophils, and 
their respective IFN subtypes, and healthy paediatric control patient 
neutrophils. 
Objective 4: To investigate the phagocytic ability of JSLE neutrophils compared 
to healthy control neutrophils. 
 
4.4  Chapter specific methods 
4.4.1 Real-time PCR using SYBR Green 
For the Sections in this chapter cDNA and qPCR kits from Primerdesign were 
used unless stated otherwise. qPCR was performed as described in Sections 
2.2.5.2 and 2.2.5.3. mRNA was obtained from neutrophils of healthy paediatric 
control patients and JSLE patients (see Section 2.1 and 2.2.5.1). Characteristics 
of both groups and the JSLE groups split into IFN high and low expressing 
patients are summarised below: 
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 Control 
(n=13) 
JSLE (n=13) 
JSLE IFN high 
(n=10) 
JSLE IFN low 
(n=3) 
Age 14.54±1.1 14.23±2.9 14.5±2.4 13.33±4.7 
Female 62% 77% 80% 67% 
WB 100% 62% 60% 66% 
M
ed
ic
a
ti
o
n
 
none 
HCQ (9/13)  
Mycophenolate 
(8/13)  
Prednisolone 
(6/13)  
Azathioprine 
(1/13)  
Aspirin (1/13)  
Bisphosphonate 
(1/13)  
CP (2/13)  
ARB (1/13)  
Statin (1/13) 
no info (2/13) 
HCQ (6/10) 
Mycophenolate 
(6/10) 
Prednisolone 
(3/10) 
Azathioprine 
(1/10) 
Aspirin (1/10) 
Bisphosphonate 
(1/10) 
CP (1/10) 
ARB (0/10) 
no info (2/10) 
HCQ (3/3)  
Mycophenolate 
(2/3)  
Prednisolone 
(2/3)  
Azathioprine 
(0/3)  
Aspirin (0/3)  
Bisphosphonate 
(0/3)  
CP (2/3)  
ARB (1/3)  
no info (0/3) 
D
is
ea
se
 a
ct
iv
it
y
 
ESR 13.1±13.8 15.6±14.36 3.0±2.8 
CRP 5.5±4.7 5.9±4.7 4.0±0.0 
C3 1.16±0.48 1.18±0.54 1.13±0.13 
C4 0.24±0.15 0.26±0.18 0.20±0.11 
dsDNA 19.10±50.9 27.23±58.0 0±0 
SLEDAI 6.17±5.9 4.22±5.1 12.00±3.6 
Renal 
BILAG 
A (1/13)  
C (1/13)  
D (4/13)  
E (6/13)  
no info (1/13) 
C (0/10)  
D (4/10)  
E (5/10) 
 no info (1/13) 
A(1/3)  
C(1/3)  
D (0/3)  
E (1/3)  
Table 4.1: Demographic and clinical data about patients whose blood was 
used for real-time PCR.  Abbreviations: White British ethnicity (%WB), 
Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Complement 
component 3 (C3), Complement component 4 (C4), anti-dsDNA titres (dsDNA), 
SLE Disease Activity Index (SLEDAI), British Isles Lupus Assessment Group 
(BILAG), Hydroxychloroquine (HCQ), Angiotensin II receptor blocker (ARB), 
Cyclophosphamide (CP) 
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4.4.2 Selection of housekeeping genes using GeNorm kit 
The amount of cDNA added into a PCR reaction is quantified beforehand and 
should be equal between the tested samples, but normalization to housekeeping 
genes allows normalization of variations in starting material. In molecular 
biology, housekeeping genes are typically constitutive genes expressed in all 
cells of an organism under normal conditions and are generally required for the 
maintenance of basic cellular functions. Housekeeping genes however need to 
be selected carefully as even genes considered to be housekeeping genes may 
vary between treatment conditions or cell types.  
The GeNorm™ reference gene selection kit from Primerdesign contains the 
following primers for testing:  
18S, ACTB, ATP5B, B2M, CYC1, EIF4A2, GAPDH, RPL13A, SDHA, TOP1, UBC, 
YWHAZ. 
qPCRs with six cDNA samples were performed with different conditions as for 
example neutrophil and PBMC cDNA samples or control and JSLE patients.  
Results were then analysed with qbasePLUS (Biogazelle), which gives the M- 
and V-value as results. The M-value expresses variability of each gene between 
the conditions with a cut-off of 0.5 considered as stable. Genes are presented 
from the weakest (high M-value) to the strongest gene (lowest M-value) from 
left to right. The V-value determines how many housekeeping genes are 
required for optimal normalization with a cut-off of 0.15. Results are shown in 
step-wise inclusion of the next most stable gene. 
Analysis revealed that optimal PCR of neutrophils and PBMCs requires four 
housekeeping genes, namely UBC, ACTB, TOP1 and GAPDH to reach a V-value of 
0.15 which is shown in Figure 4.1. 
In neutrophils from control and JSLE patients, M-values were lower showing 
that there is less variation (Figure 4.2). The M-value is further reduced when 
comparing the housekeeping gene expression between control and the two IFN 
subtype lupus patients. Furthermore, any combination of housekeeping genes is 
far below the V-value of 0.15 (Figure 4.3). Yields of RNA from neutrophils are in 
general very low, and due to small blood sample volumes from paediatric 
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patients and JSLE patients frequently having low neutrophil counts, RNA 
availability is very limited. As RNA content was limited in patient samples and 
housekeeping genes were very stable, it was decided that for neutrophils alone, 
only one housekeeping gene was measured. PBMCs analysed together with 
neutrophil cDNA varied stronger in housekeeping gene expression and it was 
therefore decided to use the three most stable genes which were UBC, ACTB and 
TOP1. As the same neutrophil RNA was used for PBMC-neutrophil and control-
JSLE comparison we chose ACTB as the housekeeping gene for neutrophil 
comparison.   
150 
 
 
Figure 4.1: Reference target stability and optimal number of housekeeping 
genes for neutrophil and PBMC comparison. In total six cDNA samples of 
neutrophils and PBMCs were tested for their expression of 12 housekeeping 
genes. Stability of each gene is shown in (A) with the least stable gene on the left 
and the most stable gene on the right. GeNorm V in (B) shows how many genes 
are required to reach V<0.150 by performing pairwise variation. Four genes 
(UBC, ACTB, TOP1 and GAPDH) are required for optimal normalization. 
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Figure 4.2: Housekeeping gene stability comparing control against JSLE 
patients and control against IFN high and low JSLE patients.  In total six 
cDNA samples of neutrophils were tested for their expression of 12 
housekeeping genes. Stability of each gene is shown as a value M with the least 
stable gene on the left and the most stable gene on the right. For both groups 
control and JSLE (A), and control with the JSLE IFN subtypes (B) all 
housekeeping genes show little variation as for each the value is below 0.5. 
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Figure 4.3: Determination of the optimal number of reference genes for 
control, IFN high JSLE and IFN low JSLE patients’ neutrophils. Six cDNA 
samples of IFN subgroups and controls patients were used for analysis with 
qbasePLUS. The V-value has a cut-off at 0.15, but is very low for samples already 
with three housekeeping genes. From left to right an additional housekeeping 
gene is added and a new V-value calculated. Three housekeeping genes would 
consequently be the best option. 
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4.4.3 Determination of protein expression in serum using ELISA 
Shed CD16b or released S100A8/S100A9 protein in supernatants and serum 
were measured using sandwich ELISA. CD16b was measured with an Aviva 
Systems Biology kit and release of S100A8/S100A9 was measured using 
DuoSet® ELISA DEVELOPMENT SYSTEMs from R&D systems. The protocol for 
the ELISA kits is described in Section 2.2.9. 
 
For serum analysis patients were selected purely based on sample availability 
and knowledge of IFN high or low status as this could only be tested if RNA was 
retrievable. Used samples are summarised in Table 4.2 for CD16b in Table 4.3 
for S100A8/S100A9.  
  
154 
 
 
Control 
(N=8) 
JSLE (N=11) JSLE IFN high 
(N=6) 
JSLE IFN low 
(N=5) 
Age 11.4±3.4 15.3±5.7 16.2±6.9 14.3±4.3 
Female 50% 78% 86% 75% 
WB 100% 75% 75% 75% 
M
ed
ic
a
ti
o
n
 
none HCQ (10/11) 
Mycophenolate 
(9/11) 
Prednisolone 
(4/11) 
Azathioprine 
(1/11) 
Methotrexate 
(1/11)  
no info (1/11) 
HCQ (5/6) 
Mycophenolate 
(4/6) 
Prednisolone 
(1/6) 
Azathioprine 
(1/6) 
Methotrexate 
(1/6)  
no info (1/6) 
HCQ (5/5) 
Mycophenolate 
(5/5) 
Prednisolone 
(3/5) 
Azathioprine 
(0/5) 
Methotrexate 
(0/5)  
no info (0/5) 
D
is
ea
se
 a
ct
iv
it
y
 
ESR 17.5±18.2 23.2±22.7 10.4±8.1 
CRP 2.9±2.7 1.6±1.4 4.5±3.2 
C3 1.0±0.4 1.0±0.5 1.0±0.16 
C4 0.14±0.07 0.13±0.08 0.16±0.06 
dsDNA 15.9±23.4 31.3±29.6 3.6±8.0 
SLEDAI 6.4±5.0 4.0±2.2 8.8±6.1 
Renal 
BILAG 
D (4/11)  
E (6/11)  
no info (1/11) 
D (2/6)  
E (3/6)  
no info (1/6) 
D (2/5)  
E (3/5)  
no info (0/5) 
Table 4.2: Demographic and clinical data about patients whose serum was 
used for CD16b ELISA.  Abbreviations: of White British ethnicity (%WB), 
Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Complement 
component 3 (C3), Complement component 4 (C4), anti-dsDNA titres (dsDNA), 
SLE Disease Activity Index (SLEDAI), British Isles Lupus Assessment Group 
(BILAG), Hydroxychloroquine (HCQ). 
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 Control 
(n=13) 
JSLE (n=13) 
JSLE IFN high 
(n=8) 
JSLE IFN low 
(n=5) 
Age 9.4±3.6 14.9±5.2 15.7±5.9 13.5±4.4 
Female 62% 80% 83% 75% 
WB 92% 70% 67% 75% 
M
ed
ic
a
ti
o
n
 
none 
HCQ (12/13) 
Mycophenolate 
(11/13) 
Prednisolone 
(6/13) 
Azathioprine 
(1/13) 
Methotrexate 
(1/13)  
Aspirin (1/13) 
no info (1/13) 
HCQ (7/8) 
Mycophenolate 
(6/8) 
Prednisolone 
(2/8) 
Azathioprine 
(1/8) 
Methotrexate 
(1/8) 
 Aspirin (1/8) 
no info (1/8) 
HCQ (5/5) 
Mycophenolate 
(5/5) 
Prednisolone 
(4/5) 
Azathioprine 
(0/5) 
Methotrexate 
(0/5) 
Aspirin (0/5) 
no info (0/5) 
D
is
ea
se
 a
ct
iv
it
y
 
ESR 13.8±16.8 17.6±20.5 8.5±8.2 
CRP 3.15±2.4 2.3±1.7 4.4±2.8 
C3 1.0±0.5 0.9±0.6 1.1±0.2 
C4 0.18±0.12 0.19±0.15 0.17±0.06 
dsDNA 14.3±21.9 25±26.8 3.6±8.0 
SLEDAI 6.2±5.0 4.3±3.3 8.8±6.1 
Renal 
BILAG 
D (5/13) 
E (7/13) 
no info (1/13) 
D (3/8) 
E (4/8) 
no info (1/8) 
D (2/5) 
E (3/5) 
no info (0/5) 
Table 4.3: Demographic and clinical data about patients whose serum was 
used for S100A8/S100A9 ELISA.  Abbreviations: White British ethnicity (WB), 
Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Complement 
component 3 (C3), Complement component 4 (C4), anti-dsDNA titres (dsDNA), 
SLE Disease Activity Index (SLEDAI), British Isles Lupus Assessment Group 
(BILAG), Hydroxychloroquine (HCQ).  
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Neutrophils defend the body against invading pathogens by uptake followed by 
digestion. This process had been shown to be dysregulated in lupus and was 
therefore investigated for this thesis – see Section 1.6.5 ([170]; [168]).  
pHrodo™ BioParticles® Conjugates can represent different phagocytic targets 
like gram-positive (S.aureus), gram-negative bacteria (E.coli) or fungal particles 
(zymosan). Their fluorescent label changes brightness, dependent on the pH of 
the environment and they therefore emit light upon uptake into the phagosome 
which has a decreased pH.  
Preliminary experiments were conducted in a POLARstar Omega plate reader 
(BMG Labtech) with a plate prepared as described in Section 2.2.7. Plates were 
then incubated for 85 min on the plate reader at 37°C and fluorescence was 
measured every 5 min. Under these conditions phagocytosis of neutrophils was 
observed of one control and one JSLE patient both with control and JSLE serum. 
Surprisingly, JSLE neutrophils incubated with control serum showed higher 
uptake of particles at earlier time points (Figure 4.4 S.aureus A, E.coli B and 
zymosan C) than in neutrophils of control patients.  
Previously, phagocytosis has been observed at later time points where the effect 
of serum is more prominent on cells, but also has more effect on opsonization 
[170]. 
It was therefore decided to look at an early time point with a 20 min incubation. 
Bead uptake was analysed with a flow cytometer to ensure that fluorescence 
was not dependent on PBMCs, potentially present as contaminants in the 
sample, by gating the PMN population. Confocal microscopy was used to 
confirm the results visually. 
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Figure 4.4: Phagocytosis assay of control and JSLE PMN taking up pHrodo-
coated bioparticles.  Neutrophils of one control (circle) and one JSLE patient 
(square) were tested for their ability to phagocytose pHrodo coated S.aureus 
(A), E.coli (B) and zymosan (C) bioparticles in the presence of control (unfilled) 
or JSLE serum (filled). Fluorescence was measured with a POLARstar Omega 
plate reader every 5 minutes for 85 minutes, fluorescence of particles alone and 
cells alone were subtracted, and results shown. In the presence of control 
serum, phagocytosis was higher in JSLE than control neutrophils, particularly at 
earlier time points. JSLE neutrophils with JSLE serum showed inhibited uptake 
for most time points. 
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4.4.4 Flow cytometry for analysis of phagocytosis assay and antibody 
staining for protein detection  
Phagocytosis of pHrodo coated bioparticles was analysed with flow cytometry 
as described in methods in Section 2.2.7. 
Neutrophils of JSLE patients (n=9) and control patients (n=8) were analysed for 
protein expression of TLR2, extra- and intracellular CD16b and S100A9 and 
patient information is summarised in Table 4.3. They were stained with 
antibodies as described in Section 2.2.6. 
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 Control 
(n=7) 
JSLE (n=9) 
JSLE IFN high 
(n=6) 
JSLE IFN low 
(n=3) 
Age 11.4±3.4 15.6±6.1 17.0±7.8 14.3±4.3 
Female 50% 100% 100% 100% 
WB 100% 83% 75% 100% 
M
ed
ic
a
ti
o
n
 
none 
HCQ (8/9) 
Mycophenolate 
(7/9) 
Prednisolone 
(2/9) 
Azathioprine 
(1/9) 
Methotrexate 
(1/9) 
no info (1/9) 
HCQ (5/6) 
Mycophenolate 
(4/6) 
Prednisolone 
(1/6) 
Azathioprine 
(1/6) 
Methotrexate 
(1/6) 
no info (1/6) 
HCQ (3/3) 
Mycophenolate 
(3/3) 
Prednisolone 
(3/3) 
Azathioprine 
(0/3) 
Methotrexate 
(0/3) 
no info (0/3) 
D
is
ea
se
 a
ct
iv
it
y
 
ESR 17.5±18.2 23.2±22.7 10.4±8.1 
CRP 2.9±2.7 1.6±1.4 4.5±3.2 
C3 1.0±0.4 1.0±0.5 1.0±0.16 
C4 0.14±0.07 0.13±0.08 0.16±0.06 
dsDNA 15.9±23.4 31.3±29.6 3.6±8.0 
SLEDAI 6.4±5.0 4.0±2.2 8.8±6.1 
Renal 
BILAG 
D (3/9) 
E (5/9) 
no info (1/9) 
D (2/6) 
E (3/6) 
no info (1/6) 
D (1/3) 
E (2/3) 
no info (0/3) 
Table 4.4: Demographic and clinical data about patients whose 
neutrophils was analysed for protein expression with flow cytometric 
analysis. Abbreviations: White British ethnicity (WB), Erythrocyte 
sedimentation rate (ESR), C-reactive protein (CRP), Complement component 3 
(C3), Complement component 4 (C4), anti-dsDNA titres (dsDNA), SLE Disease 
Activity Index (SLEDAI), British Isles Lupus Assessment Group (BILAG), 
Hydroxychloroquine (HCQ). 
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4.4.5 Analysis using confocal microscopy 
As a visual representation, phagocytosis assays were also performed on cover 
slips and viewed under the confocal microscope. Assays were performed as 
described in Section 2.2.7. 
 
4.4.6 Determination of overall CD16b expression or IGS by ranking  
While the IGS consists of several genes, CD16b protein can be expressed 
intracellularly, on the cell surface or can be shed into serum. Therefore samples 
need to be investigated for each part of the IGS and CD16b individually, but to 
get an idea of the overall presence a scoring system was necessary in this thesis. 
As an example, scoring of CD16b is shown below in Figure 4.5. From left to 
right: All samples were ranked depending on their expression separately for cell 
surface CD16b and intracellular CD16b, measured with flow cytometry and 
results are shown in geometric mean fluorescence. They were also ranked for 
CD16b concentrations shed into serum which was measured with ELISA. The 
average rank was then calculated by: 
 
𝑟𝑎𝑛𝑘 𝐶𝐷16𝑏 𝑐𝑒𝑙𝑙 𝑠𝑢𝑟𝑓𝑎𝑐𝑒+𝑟𝑎𝑛𝑘 𝐶𝐷16𝑏 𝑖𝑛𝑡𝑟𝑎𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟+𝑟𝑎𝑛𝑘 𝐶𝐷16𝑏 𝑠𝑒𝑟𝑢𝑚
3
. 
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Figure 4.5: Example for the used scoring system with CD16b as an 
example.  At the top, from left to right, are samples ranked for CD16b cell 
surface and intracellular expression and shed CD16b. Expression of cell surface 
CD16b and intracellular CD16b were measured with flow cytometry and results 
are shown in geometric mean fluorescence. All sample were also ranked for 
CD16b concentrations shed into serum which was measured with ELISA. The 
average rank is then calculated as the sum of all three ranks for each sample 
(e.g. JSLE1 CD16b cell surface+JSLE1 CD16b intracellular+JSLE1 CD16b serum) 
divided by three. 
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4.5  Results 
Transcriptomics analysis of PMN by our group had revealed that within our 
JSLE cohort there are patients who can be distinguished by an IGS. Further 
analysis showed that there are differences in several other genes between 
patients classified as IFN high and low depending on their signature. The NCBI 
gene library (https://www.ncbi.nlm.nih.gov/gene/?term=phagocytosis) and 
NCBI PubMed library (https://www.ncbi.nlm.nih.gov/pubmed/) was used to 
search for functions of genes with significant difference. Two main functions 
were observed, which were modification of DNA and phagocytosis related genes 
(PRGs). IFN induced, DNA related and phagocytosis related genes were 
investigated and validated with real-time PCR. 
 
4.5.1 The IFN-induced gene signature in JSLE patients 
4.5.1.1 Presence of IGS in neutrophils and PBMC 
IFN signature was described in whole blood of JSLE patients [57], but was also 
found in different subpopulations of cells in RA [56]. The latter described 
neutrophils to be especially sensitive to IFN signalling. A validation of IGS 
expression in neutrophils compared to PBMC’s was necessary within our 
paediatric cohort as the previous study was based on adult RA patients.  
As Figure 4.6 shows, OAS2, IFI44L, LY6E and IFI6 were expressed more in the 
neutrophil (PMN) population compared to the PBMC fraction. OAS2, IFI44L and 
LY6E was expressed less in the PBMC fraction in all patients. IFI6 mRNA, 
however, was higher in one patient’s PBMCs compared to the respective 
neutrophils. These results were sufficient to decide that neutrophils were the 
more sensitive cell type to investigate the influence of the IGS. 
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 Figure 4.6: Expression of IFN-induced genes in neutrophils and PBMCs of 
JSLE patients. Neutrophil (PMN) and PBMC mRNA of four patients was 
measured for expression of OAS2 (A), IFI44L (B), LY6E (C) and IFI6 (D) which 
can be induced by IFN. Real-time PCR using SYBR green showed higher 
expression of IFN-induced genes for neutrophils in all genes and all samples 
expect for one sample which had higher levels of IFI6 in the PBMC fraction. 
Relative expression was calculated taking the deltaCt-value of the gene of 
interest and the geometric mean of the three house keeping genes UBC, ACTB 
and TOP1. Statistical analysis was not applied to these data as only n=4 were 
compared.  
164 
 
4.5.1.2 Changes of IFN-induced genes over time 
Even though the IGS has been described before ([56],[57]), there are no data 
comparing how the signature changes over time in a JSLE cohort. The cohort of 
patients in this study have recurrent hospital visits, so in addition to their study 
number they also get an episode number unique to each hospital visit. This 
enables us to compare the changes in IFN-induced genes longitudinally. We 
monitored five patients (Figure 4.7) of which patients L43 and L62 were 
considered IFN low when they were initially classified by transcriptomics data. 
RNA of three episodes for L43 and two episodes for all other samples was 
analysed. Disease activity was not consistent over time and especially worth 
mentioning, L43 and L62 had both high and low disease activity over the time 
course. The later L62 time point corresponded to the patient having a SLEDAI of 
0 whereas at the earlier time point the patient had a SLEDAI of 16. Additionally, 
to our knowledge none of the patients had infections. The expression of IFN-
induced genes had changed strongly when comparing the different episodes for 
the IFN high patients L54, L68 and L73. For L54 at the later episode even a 
decrease was observed, but for all patients the signature remained a high one 
throughout. While L43 of the IFN low patients did not show any changes in the 
IGS, L62 developed higher IFI6 expression.  
This raises the question if in fact, all of these four genes are actually good 
indicators to decide between an IFN high and IFN low signature. 
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Figure 4.7: Relative expression of IFN-induced genes in different episodes 
of five patients.  mRNA expression of OAS2 (A), IFI44L (B), LY6E (C) and IFI6 
(D) in neutrophils (n=5 JSLE patients) was measured using SYBR green qRT-
PCR and results were normalized to ACTB as a house keeping gene. For L43 
three time points were tested whereas for all other patients only two episodes 
were available. L43 remains with very low IFN-induced gene expression. L62 
previously also classified as an IFN low patient shows increase in mainly IFI6. 
L54, L68 and L73 were classified as IFN high patients and remained with this 
signature for the analysed time-point. L54 showed a decrease in all genes, but 
still remained an IFN high patient. 
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4.5.1.3 Evaluation of IFN low and IFN high patients 
Having confirmed that neutrophils are an appropriate and important cell type in 
which to study the IFN gene signature, we wanted to confirm expression of the 
selected genes OAS2, IFI44L, LY6E and IFI6 in additional patients from the JSLE 
cohort. Through this method, patients could be classified as being IFN high or 
IFN low.  
We therefore compared IFN-induced genes between paediatric control patients 
and an additional number of JSLE patients in which samples were available. 
Notably, there was a significant increase of all selected IFN-induced genes in 13 
JSLE patients compared to 13 controls (Figure 4.8A-D) with the most 
significant difference in OAS2 expression (p=0.0006). This was followed by 
IFI44L (p=0.0051) and LY6E (p=0.003) with the smallest difference in IFI6 
(p=0.0499). Two lupus samples fell within the 95% confidence interval of the 
control group (cut-off indicated as a dashed line) for all four genes, but for IFI6 
and IFI44L there were additional patients within the control range. We 
therefore used all four genes as a panel to evaluate the IGS of the patients. 
Samples were ranked for each gene and then the average of ranks was 
calculated for each sample with the result shown in Figure 4.8 (E). Significantly 
higher ranks were observed for JSLE patients (p=0.0027). Four JSLE patients 
were found to be lower than the minimum of the 95% confidence interval and 
were also below the maximum of the 95% confidence interval of control 
patients. The patients were therefore classified as overall “IFN low” patients. 
Even though it is classified as one “IFN-induced gene signature”, genes may be 
influenced by different or at least additional signals. Gene expression of all four 
genes in different episodes of five JSLE patients was measured with qRT-PCR. 
Comparing the expression of the genes in pairs can reveal correlation. High 
correlation would indicate that they might be influenced by the same stimulus 
or have an impact on each other. As shown in Figure 4.9, we found significant 
correlation (Spearman correlation test) between OAS2 and IFI44L (A, r=0.955, 
p=2.8x10-5), OAS2 and LY6E (B, r=0.945, p=4.9x10-5) and IFI44L and LY6E (C, 
r=0.86, p=0.001). None of the genes showed significant correlation with IFI6 
(with IFI44L r=0.132 p=0.698, OAS2 r=0.246 p=0.463, LY6E r=0.246 p=0.463). 
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The chosen IGS, comprising OAS2, IFI44L, LY6E and IFI6, appears to cover 
different stimuli. IFI6 was therefore excluded from the classification criteria for 
an “IFN signature” in this work. 
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Figure 4.8: Increased expression of IFN induced genes in JSLE patients 
compared to healthy controls and separation of patients into IFN low and 
IFN high patients.  mRNA expression of OAS2 (A), IFI44L (B), LY6E (C) and IFI6 
(D) (n=13 each JSLE and control patients) was measured using SYBR green qRT-
PCR (Agilent Lifetechnologies) and results were normalized to ACTB as a house 
keeping gene. Results are presented as individual samples with circles (control) 
and squares (JSLE), with the geometric mean and 95% confidence interval (CI). 
The dashed line indicates the maximum of the control CI. Samples were then 
ranked for each gene and plotted as the average rank for all genes to determine 
if patients were IFN high or IFN low (E). Cut-off was the minimum of the JSLE 
95% CI. *p<0.05 ** p<0.01 *** p<0.001 Mann-Whitney test 
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Figure 4.9: Significant correlation of IFN-induced genes OAS2, IFI44L and 
LY6E.  mRNA expression of five JSLE patients was measured at two or three 
different episodes allowing a comparison of n=11 using qRT-PCR with SYBR 
green. Values are presented as relative expression, calculated by normalizing 
the gene of interest to ACTB. Correlation was observed between OAS2 and 
IFI44L (A), OAS2 and LY6E (B) and IFI44L and LY6E (C) (regression r=0.955, 
r=0.945 and r=0.86 respectively). ** p<0.01 *** p<0.001 Spearman correlation 
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4.5.2 Expression of genes of DNA-related proteins in JSLE 
The IGS has been described in several papers [56], [57], but patients were not 
further characterized. Transcriptomics data from our group showed more 
differences between IFN high and IFN low patients. Several changes, for 
example, indicated genes of DNA-related proteins to be altered. Gene expression 
of these proteins between not only control and JSLE patients but also the IFN 
subgroups was therefore compared. 
Some of the proteins resulting from these genes can modify histones to alter 
transcription. One example is the SET domain containing lysine 
methyltransferase 7 (SETD7) which causes methylation of lysine-4 on histone 3 
leading to activation of transcription [239]. It can also methylate non-histone 
proteins and is, for example, involved in ROS signalling [240]. Another example 
is SAM domain, SH3 domain and nuclear localization signals 1 (SAMSN1) which 
interacts with Sin3A Associated Protein 30 (SAP30) and histonedeacetylase 1 
increasing deacetylase activity and thereby inhibiting transcription [241]. 
Other genes are important for DNA repair such as TREX1 for proofreading [242] 
or X-Ray Repair Cross Complementing 4 (XRCC4), Snf2-Related CBP Activator 
Protein (SRCAP) and Breast Cancer 2 (BRCA2) for double strand break repair 
[243], [244] [245].  
As seen in Figure 4.10, there were no significant differences between control 
and JSLE or the IFN subtypes in SAMSN1, SAP30, SETD7, XRCC4 and SRCAP 
mRNA expression. A significant increase of BRCA2 was found for JSLE patients 
compared to healthy paediatric controls patients. This difference was very much 
influenced by the IFN high group. While the IFN low group was not different to 
the controls, the IFN high group showed increased (p=0.06) BRCA2 expression. 
Similar results were found for TREX1 which was significantly higher in JSLE 
patients and in IFN low patients was similar to the control group whereas IFN 
high patients were responsible for the observed increase (p=0.003). Overall, 
there were no strong differences between JSLE and control patients or after 
separation into IFN high and low patients.  
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 Figure 4.10: mRNA expression of DNA related proteins in JSLE, IFN stratified JSLE patients and healthy paediatric 
control patients.  mRNA expression of DNA related proteins namely SAMSN1 (A), SAP30 (B), SETD7 (C), BRCA2 (D), TREX1 (E), 
XRCC4 (F) and SRCAP (G) was measured using SYBR Green real-time PCR. All results were normalized to TOP1 and EIF4A2 as 
suggested by GeNorm analysis and shown as relative expression. Only for BRCA2 and TREX1 significant increase was observed 
for the JSLE cohort (n=13). JSLE IFN high (n=10) patients caused these changes with a non-significant increase of BRCA2 
(p=0.06) and a significant increase in TREX1. IFN low patients (n=3) showed expression like the control cohort (n=8). Mann-
Whitney test for JSLE-Control comparison, Kruskal-Wallis test for IFN low, IFN high, Control comparison *p<0.05 **p<0.01
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4.5.3 Phagocytosis related genes are differentially expressed in JSLE 
The transcriptomic analysis from our group also suggested PRG to be 
differentially expressed.  
Beginning with binding of the pathogen, phagocytosis involves several separate 
processes which are equally important for an efficient clearance of infection. 
These steps include targeting material with proteins such as AnxA3 [202], 
recognition via receptors like TLR2, FcRIIIb, CR3, and Dectin-1 ([180], [195], 
[236], [171]) processing of the phagosome via CamK1D [207] and stimulation of 
phagocytosis via S100A9 [198]. If any of these genes are dysregulated, 
neutrophils could become incapable of phagocytosis and instead produce NETs. 
In order to analyse relevant phagocytic genes, the expression of TLR2, FcRIIIb, 
CR3, AnxA3, Dectin-1, CamK1D and S100A9 was measured. For this purpose, 
RNA from neutrophils of control and JSLE patients was extracted with TRIzol, 
cleaned up and transcribed into cDNA as described in Section 2.2.5 Gene 
expression was then measured with qRT-PCR using SYBR Green I, a dye that 
intercalates into double-stranded DNA (dsDNA) and only then emits 
fluorescence [246]. Amplification of the target gene results in increased quantity 
of dsDNA and therefore a stronger fluorescent signal.  
As Figure 4.11 shows, there is a trend in neutrophils of JSLE patients to express 
more FcRIIIb, CR3 and AnxA3 compared to healthy paediatric control patients. 
TLR2 was 1.84-fold (p=0.003) and S100A9 1.56-fold higher (p=0.012) in JSLE 
patients. While there was no difference for Dectin-1 between the two groups a 
trend for decrease in CamK1D (p=0.17) was detected. 
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Figure 4.11: The majority of phagocytic genes is increased in JSLE patients 
compared to paediatric healthy control patients.  mRNA expression of 
phagocytic genes in JSLE and control neutrophils was measured using SYBR 
Green qRT-PCR (Agilent Lifetechnologies). Each gene was normalized to ACTB 
and is presented as mean of the relative expression with SEM for each group. 
Results represent for both groups 13 patients. *p<0.05 **p<0.01, performing a 
Mann-Whitney test 
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OAS2, IFI44L and LY6E RNA expression was tested for all samples to distinguish 
between IFN low and IFN high patients as described in Section 4.5.1 and PRGs 
compared between healthy paediatric controls patients, JSLE IFN high and JSLE 
IFN low patients Figure 4.12. IFN low patients did not show significant 
difference between any of the genes and only AnxA3, TLR2 and S100A9 showed 
a trend for increased expression. However, patients with an IFN high signature 
were significantly higher for TLR2 (p=0.022) with a 1.90-fold, S100A9 
(p=0.047) with a 1.66-fold and FcRIIIb (p=0.012) with a 1.88-fold change 
compared to the healthy paediatric control patient group. Additionally, in IFN 
high patients, FcRIIIb was significantly upregulated compared to IFN low 
patients (p=0.017). A non-significant reduction for CamK1D (0.67-fold 
decrease) was observed in the IFN high compared to the control group. IFN high 
patients are therefore differently regulated than controls, whereas IFN low 
patients resemble the control group.  
Three of the PRGs were noted to be differentially expressed compared to two 
DNA related genes and metabolomics analysis as described in Chapter 3 
suggested importance of phagocytosis in JSLE. The PGS was therefore chosen for 
further investigation. 
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Figure 4.12: IFN high patients differ more from control patients in their 
phagocytic gene profile than IFN low patients. mRNA expression of 
phagocytic genes in JSLE and control neutrophils was measured using SYBR 
Green qRT-PCR (Agilent Lifetechnologies). Each gene was normalized to ACTB 
and is presented as mean of the relative expression with SEM for each group. 
Results represent 13 control, three IFN low and 10 IFN high patients. *p<0.05, 
performing a Kruskal-Wallis test 
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4.5.4 Protein expression 
In Section 4.5.3, it was noted that phagocytosis related genes are differentially 
expressed in JSLE and that mRNA of TLR2 and S100A9 were differently 
expressed in the neutrophils of healthy paediatric control patients and JSLE 
patients. When splitting the patients into IFN subgroups these differences were 
mainly due to high expression in IFN high patients whereas IFN low patients 
appeared to be more similar to healthy control patients. After this separation it 
also became clear that FcRIIIb is high in IFN high patients, but not in IFN lows. 
Changes observed in mRNA levels do not give certainty about translation into 
protein and therefore the protein expression of TLR2, S100A9 and CD16b, the 
protein of FcRIIIb, was measured. TLR2 was analysed for cell surface 
expression, S100A9 for intracellular and CD16b for both cell surface and 
intracellular protein expression. As S100A9 can be secreted and is most 
commonly found in complex with S100A8. For quantification of the bioactive 
form, the presence of the S100A8/S100A9 heterodimer was measured in serum 
using ELISA. CD16b can be shed from the cell surface and was therefore also 
quantified with ELISA. 
Protein expression of TLR2 was significantly higher in the JSLE cohort 
compared to healthy controls (p=0.02, Figure 4.13(A)) The IFN low group was 
primarily responsible for the TLR2 increase in the JSLE cohort being 
significantly higher (p=0.01) compared to the control group, whereas the IFN 
high group was only increased non-significantly. Intracellular S100A9 (B) was 
significantly increased between the control and JSLE group with the lupus 
cohort expressing more protein. The S100A8/S100A9 heterodimer (C) was 
found to be non-significantly increased (p=0.11) for the JSLE cohort which again 
was mainly caused by the IFN low group.  
The protein expression of CD16b (Figure 4.14) needs to be measured intra- 
(A), extracellularly (B) as well as in serum (C) to obtain a full picture of the 
protein expression. For each assay samples were ranked and then the average 
rank for each sample was calculated (D) as described in 4.4.6.  
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CD16b did not show a significant difference between JSLE and healthy 
paediatric control patients (p=0.72 extracellular, p=0.07 intracellular, p=0.81 
serum and p=0.21 scored CD16b expression). No significant difference was 
observed between the IFN groups and the control group, potentially due to the 
low numbers of IFN low patients (p=0.71 extracellular, p=0.12 intracellular, 
p=0.81 serum and p=0.36 scored CD16b expression). Nevertheless, these data 
show a trend for lower CD16b expression in IFN low patients compared to IFN 
high patients for intracellular CD16b as it was suggested in the qPCR data.  
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Figure 4.13: Protein expression of TLR2, S100A9 in JSLE and control 
neutrophils and released S100A8/S100A9 in serum.  Protein expression of 
TLR2 (A) and S100A9 (B) was measured using flow cytometry in healthy 
controls (n=8), and JSLE patients (n=9) of which three were IFN low and six 
were IFN high patients. The presence of the heterodimer S100A8/S100A9 in 
patients’ sera was measured with ELISA (C) for n=13 healthy controls and n=13 
JSLE patients of which n=5 were IFN low and n=8 were classified IFN high. 
Significant higher protein expression was found in JSLE patients compared to 
healthy controls for both TLR2 and S100A9. Additionally, TLR2 expression was 
significantly higher in the IFN low group compared to healthy controls. No 
significant difference was observed for S100A8/S100A9 in serum. Mann-
Whitney test for JSLE-Control comparison, Kruskal-Wallis test for IFN low, IFN 
high, Control comparison *p<0.05  
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 Figure 4.14: CD16b protein expression in healthy paediatric control 
patients and JSLE patients, as well as their IFN subtypes.  Cell surface CD16b 
(A) expression was measured with flow cytometry for n=8 and intracellular 
CD16b (B) for n=7 healthy paediatric control patients. The same measurement 
was undertaken for n=9 JSLE patients of which n=3 were IFN low and n=6 were 
IFN high. Serum CD16b levels (C) were measured using ELISA in serum of n=8 
healthy controls and n=11 JSLE patients of which n=5 were IFN low and n=6 
were IFN high subtype. For the samples where data was available for all three 
assays, samples were ranked from 1 to 16 (total number of samples) for each 
assay and then the average of the ranks was calculated for each sample as 
displayed in (D). Mann-Whitney test for was performed for JSLE-Control 
comparison, Kruskal-Wallis test for IFN low, IFN high, Control comparison 
p<0.05 was considered significant 
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4.5.5 Phagocytosis of pathogens 
To fully assess whether the mRNA and protein expression of these factors may 
have any effect on the functions of cells or if other proteins may compensate for 
this dysregulation, the phagocytic activity of neutrophils was investigated.  
Neutrophils have different receptors for specific types of microorganisms. These 
tests need to cover a range of pathogens as a faulty or dysregulated receptor 
targeting a certain pathogen may not affect uptake of other microbes. Most 
studies restricted the comparison of lupus and control patients’ ability to 
phagocytose on one to two microorganisms ([170], [4]). Selected targets should 
include pathogens both from bacterial, with the subgroups of gram positive and 
gram negative strains, as well as fungal origin in order to ensure that different 
recognition and uptake mechanisms are tested.  
The efficiency of phagocytosis was measured with pHrodo coated S.aureus, 
E.coli and zymosan (Molecular Probes) particles. These particles emit 
fluorescence once taken up into the phagosome due to the more acidic 
environment. This effect can be detected with flow cytometry as cells which 
have not engulfed any bacteria are non-fluorescent and can be distinguished 
from pHrodo positive cells. To confirm the results observed with flow 
cytometry, cells were seeded onto coverslips before incubation with particles 
and were visualised with confocal microscopy. 
To minimise the effects of a potential complement deficiency in the serum and 
observe only the neutrophil intrinsic ability, phagocytosis assays were 
performed without pre-opsonisation and only for 20 minutes at 37°C. 
Furthermore, the cells were incubated in parallel with JSLE and control serum 
or without serum. 
Phagocytosis with little effect of serum would suggest that mainly TLR2 and 
S100A9 are involved in this process which are a receptor for pathogen 
recognition and a phagocytosis stimulator, rather than CD16b a receptor mainly 
responsible for immune complexes. No difference was observed comparing the 
IFN subgroups for TLR2 and S100A9 and we therefore did not split the patients 
into IFN low and IFN high for this assay. 
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4.5.5.1 Phagocytosis of S.aureus by neutrophils 
After 20 min there was no difference of uptake observed between any of the 
incubations and about 100% of cells have phagocytosed (Figure 4.15 ()). 
Confocal pictures suggested a slightly higher uptake for healthy paediatric 
control patients (C+D) compared to PMN of JSLE patients (E+F). Particles need 
to settle first to reach the neutrophils which were left to adhere for 45 min 
before stimulation with particles. This suggests that at an even earlier time 
point may be needed to observe a difference for flow cytometry.  
For this reason, we also looked at the 20 min incubation at 37°C without any 
serum as this should slow down phagocytosis and might give a suggestion if 
there is a difference between the neutrophils of JSLE and control patients 
(Figure 4.16). Indeed, JSLE neutrophils showed an enhanced (non-significant 
(p=0.18)) uptake of S.aureus particles without serum. 
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Figure 4.15: JSLE neutrophils can phagocytose S.aureus as efficiently as 
those of control patients.  Phagocytosis of pHrodo coated S.aureus particles in 
PMN from JSLE and control patients with JSLE (L) and control (C) serum was 
measured with flow cytometry (A) and pictures were taken with a confocal 
microscope (B-F, showing one representative JSLE and one control patient) 
after a 20 min incubation at 37°C. (A) Fluorescence of PMN was measured using 
flow cytometry and cells were considered positive if the emitted light was 
stronger than for cells without particles. N=6 JSLE patients and n=7 control 
patients were tested. Control PMN without serum or particles are shown in (B). 
Control PMN with L serum (C) and control PMN with C serum and S.aureus (D) 
showed more cells with particles, than JSLE PMN with L serum (E) or JSLE PMN 
with C serum and (F) S.aureus which instead had more and brighter particles 
per cell. Blue shows DAPI staining of nuclei, arrows indicate phagocytosed 
S.aureus (red) and conditions were compared with a Kruskal-Wallis-test. 
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Figure 4.16: Neutrophils of JSLE patients phagocytose more S.aureus 
particles than healthy paediatric control patients when no serum is 
present.  Phagocytosis of pHrodo coated S.aureus particles without any serum 
after 20 min at 37°C was measured with flow cytometry for n=7 healthy 
paediatric control patients and n=6 JSLE patients. Comparing the two groups 
with a Mann-Whitney U test there was no significant difference between the two 
groups. Nevertheless, a trend of p=0.18 for a higher uptake in JSLE patients was 
observed. 
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4.5.5.2 Phagocytosis of E.coli by neutrophils 
Phagocytosis of E.coli particles by neutrophils of JSLE patients compared with 
controls was higher but not significantly different (p=0.08) (Figure 4.17). PMN 
of JSLE patients showed increased uptake equally with JSLE and control serum, 
compared to control cells with either JSLE or control serum.  
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Figure 4.17: Uptake of E.coli by neutrophils of JSLE and control patients.  
Phagocytosis of pHrodo coated E.coli particles in PMN from JSLE and control 
patients with JSLE (L) and control (C) serum was measured with flow cytometry 
(A) and pictures were taken with a confocal microscope (B-F, showing one 
representative JSLE and one control patient) after a 20 min incubation at 37°C. 
(A) Fluorescence of PMN was measured using flow cytometry and cells were 
considered positive if the emitted light was stronger than for cells without 
particles. N=6 JSLE patients and n=7 control patients were tested, but only a 
trend of p=0.08 found JSLE neutrophils to be more effective in phagocytosis. 
JSLE PMN without serum or particles are shown in (B). Control PMN with L 
serum and E.coli (C) or with C serum and E.coli (D) showed lower uptake of 
particles, than JSLE PMN with L serum and E.coli (E) and JSLE PMN with C 
serum and E.coli (F) showed more uptake than). Arrows indicate ingested E.coli 
(red), blue shows nuclei with DAPI staining. Results of flow cytometry were 
compared with a Kruskal-Wallis-test. 
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4.5.5.3 Phagocytosis of zymosan by neutrophils 
Similar to E.coli, zymosan particles observed phagocytosis in JSLE PMN was 
higher at 20 min than in healthy paediatric control patient neutrophils (Figure 
4.18). Statistical analysis using the Kruskal-Wallis test showed a significant 
difference between all groups with a p-value of p=0.04, but after adjustment for 
multiple comparison, there is only a trend (p=0.07) between control PMN with 
JSLE serum and JSLE PMN with control serum. Control PMN with control serum 
and JSLE PMN with control serum have a p-value of 0.28. Results further 
suggested that for zymosan the control serum had a beneficial effect on uptake 
even at this short incubation time.  
Comparison with lupus serum had been conducted before and it had been 
demonstrated that control serum can restore phagocytosis in JSLE PMN. The 
novelty in our data is the investigation of the phagocytic ability of JSLE 
neutrophils compared to healthy paediatric control patients PMN in a healthy 
environment. The important comparison is therefore between control and JSLE 
PMN incubated with control serum. There was significantly higher uptake 
observed of E.coli particles (p=0.04) and non-significantly higher uptake of 
zymosan particles (p=0.05) in JSLE PMN compared to healthy paediatric control 
patients PMN (Figure 4.19). S.aureus particles did not show a difference in 
phagocytosis. 
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Figure 4.18: Increased uptake of zymosan for JSLE PMN compared to PMN 
of healthy control patients.  Phagocytosis of pHrodo coated zymosan particles 
in PMN from JSLE (n=6) and control patients (n=7) with JSLE (L) and control (C) 
serum was measured after a 20 min incubation at 37°C with flow cytometry and 
found to be significantly different (p=0.04) between the groups (A) 
Fluorescence of PMN was measured using flow cytometry and cells were 
considered positive if the emitted light was stronger than for cells without 
particles. Pictures were taken with a confocal microscope (B-F, showing one 
representative JSLE and one control patient). JSLE PMN without serum or 
particles were negative for uptake (B). Control PMN with L serum (C) and C 
serum (D) showed a trend for lower uptake of zymosan than control PMN with 
L serum (E) or C serum (F). Blue represents DAPI, a DNA staining dye and red 
indicated ingested zymosan. Arrows indicating zymosan and conditions in flow 
cytometry were compared with a Kruskal-Wallis-test. 
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Figure 4.19: Comparison of phagocytic ability of JSLE and healthy 
paediatric control patients PMN with control serum measured with 
pHrodo coated bioparticles.  PMN of JSLE and healthy paediatric control 
patients were incubated with control serum and S.aureus, E.coli and zymosan 
pHrodo coated bioparticles for 20 min at 37°C. Emitted fluorescence was 
measured using flow cytometry. # p=0.05, * p<0.05 using Mann Whitney test  
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4.6 Discussion 
In previous studies, an IFN gene signature was described for different 
inflammatory diseases including JSLE with 82% of these individuals showing a 
IFN high score [57]. In the JSLE cohort in this study, the IGS was found to be 
upregulated in the majority of patients. Of the ones tested for their IGS only five 
out of 19 were IFN low and 74% were classified as IFN high. Rice et al (2017) 
had selected IFI27, IFI44L, IFIT1, ISG15, RSAD2 and SIGLEC1 for their IFN-
induced gene signature. From their published panel of genes there was an 
overlap with this present study, as IFI44L was included in this thesis as well. 
Initial experiments conducted by our group showed high expression 
additionally for OAS2, IFI6 and LY6E in JSLE patients, and therefore these genes 
were included in the IGS panel. LY6E for example has also been used in other 
studies testing the prevalence of IFN type I in patients with Sjögren’s syndrome 
[247]. In this present study, IFI6 did not correlate with OAS2, IFI44L or LY6E 
when comparing IFN-induced genes over time. It was therefore excluded from 
subsequent evaluation as to whether patients remained IFN high or low. IFI6 
may be influenced by different or additional factors compared to the other 
genes. When using the panel of three genes (OAS2, IFI44L and LY6E) no changes 
in the IFN subtype were observed over time. This in consistent with data from 
Lindau et al. [111] proposing that there are IFN responders and non-
responders who are predefined if they react to stimuli.  
Besides the IGS itself, further differences between IFN high and low patients 
were identified within the transcriptomics data arising from our group. For this 
reason, investigation of genes coding for proteins related to repair or 
modification of DNA and phagocytosis related genes was conducted.  
BRCA2 and TREX1 were the only genes noted to be different between JSLE and 
healthy paediatric controls that were due to high expression in IFN high 
patients. Interestingly, loss of TREX1 was described to trigger systemic 
autoimmunity with IFN production as cells cannot cope with damaged DNA 
[248] and mutations in this gene have been described for SLE [42]. Increased 
expression found in IFN high patients may indicate increased need for nuclease 
activity processing ssDNA or compensation for a faulty protein.  
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BRCA2 is not studied as a gene for lupus, but usually considered important in 
cancer development. Higher expression has been associated rather with breast 
cancer tissue with 36.6% of breast cancer patients having developed 
autoantibodies against BRCA2 while only 0.7% of healthy controls had 
autoantibodies [249].  
BRCA2 together with TREX1 may indicate high DNA instability with increased 
DNA digestion potentially leading to increased apoptosis as it has been 
observed in JSLE [137].  
PRGs were also found to be significantly different between JSLE and healthy 
paediatric control patients, as well as between the JSLE IFN subgroups 
themselves. 
Phagocytosis has been shown to be dysregulated in both juvenile-onset and 
adult-onset SLE. Receptors of monocytes are differentially regulated in both 
groups and result in a decreased phagocytosis of apoptotic neutrophils [4], 
[169]. Furthermore the uptake of E.coli was impaired in SLE, as serum of 
patients can affect ingestion of E.coli particles by neutrophils of SLE [170] and 
by macrophages of JSLE patients [4]. Since neutrophils are the most abundant 
phagocyte in blood, it was important to establish if JSLE neutrophils express 
mRNA and protein of phagocytosis related proteins and if they are intrinsically 
capable of phagocytosis. 
For mRNA expression of AnxA3, CamK1D, CR3 and Dectin-1 there was no 
significant difference observed between JSLE and healthy paediatric control 
patients. TLR2 mRNA expression was significantly increased, which has also 
been shown to occur in PBMCs from SLE patients [250]. Even though they did 
not stratify patients for IFN high and IFN low, they did look at LY6E and IFN 
mRNA expression. Their results indicated no significant (p=0.089) positive 
correlation between IFN and TLR2. This supports our results with IFN low 
patients not being significantly lower than IFN highs. Similar to TLR2, in our 
study S100A9 was significantly increased in JSLE patients and higher with a 
stronger IFN signature. So far mRNA expression of S100A9 has not been 
investigated in neutrophils in JSLE, but it has been demonstrated that LDG in 
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SLE patients highly express S100A9 mRNA. This group also showed that protein 
expression of S100A9 in the PBMC fraction which contains LDGs correlates with 
measured plasma levels of S100A8/S100A9 which were significantly higher in 
SLE than in control patients [251]. As for this thesis, neutrophils were isolated 
with a density gradient and increased S100A9 expression was measured only in 
normal density neutrophils. S100A9 is bioactive when it forms a complex with 
S100A8. This tetrameric form of S100A8/S100A9, also called calprotectin, was 
shown to be increased in the serum of patients in the cohort studied in this 
thesis and was also found in serum from SLE patients with cardiovascular 
disease [252] and in patients with more active disease [253]. No study of the IGS 
of JSLE patients have investigated the role of S100A9 and TLR2. Interestingly, 
IFN low patients from our cohort were characterized by significantly higher 
TLR2 protein expression than the control group whereas only a non-significant 
increase was observed for the IFN high group. Serum levels for S100A8/S100A9 
for IFN low patients were higher than from control and IFN high patients, but 
did not reach significance.  
For both S100A9 and its bioactive form a wide spread has been observed in the 
IFN low group. Medication seems not to have any contribution to this 
observation as patients who donated blood for flow cytometry analysis were all 
on the same drugs. Similarly, serum samples used for ELISA were from patients 
who all received hydroxychloroquine and mycophenolate. Four of the five 
patients were additionally on prednisolone, therefore also not explaining the 
separation of two from the other three patients as seen in Figure 4.13C. If 
looking at S100A9 protein expression IFN low patients with a high disease 
activity are low and patients with a low disease activity display high protein 
expression. However, this is not found in JSLE IFN high patients and no 
correlation is found between disease activity and protein measured with ELISA. 
It remains therefore questionable if there is a link between disease activity and 
presence of S100A9 in neutrophils or S100A8/S100A9 in serum. The observed 
connection may be a coincidence due to the very low number of JSLE IFN low 
patients.  
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Upregulation of TLR2 might be due to the apoptotic environment which the 
neutrophils experience. HMGB-1, also called amphoterin, is for example 
released from necrotic cells and can trigger TLR2 signalling [254]. S100A9 is 
generally seen as a protein of inflammation and its expression was shown to be 
upregulated upon stimulation with LPS representing a bacterial infection [255].  
TLR2 and S100A9 mRNA and protein levels were both significantly increased 
for JSLE compared to control patients. For FcRIIIb on the other hand, only 
when splitting the JSLE group into IFN high and IFN low a significant increase 
was observed. High expression was linked to JSLE patients with an elevated IFN 
signature. Protein expression of FcRIIIb, CD16b, was not significantly increased 
for IFN high patients. To our knowledge, there has been no paper published 
with data of FcRIIIb mRNA expression. It has been shown that copy number 
variations and polymorphisms are related to SLE susceptibility and suggested 
that an impaired function due to a gene alteration could be the explanation for 
this relation [172]. Increased mRNA expression could be a result of trying to 
compensate for a dysfunctional receptor, but also a result of IFN as it was only 
seen in the IFN high patients. 
The influence of mRNA and protein expression was measured with functional 
assays comparing neutrophil phagocytosis in JSLE patients and controls. There 
was no difference in uptake of S.aureus, a trend for an increased ingestion of 
E.coli and a significant increase for zymosan uptake, which could be explained 
by the observed upregulation of TLR2. Phagocytosis of S.aureus might have 
already reached saturation and because of that no difference can be detected. 
We therefore looked at phagocytosis without serum and found a similar trend to 
E.coli. Denny et al. demonstrated in their study in 2010 that LDGs of SLE 
patients emit significantly less fluorescence when incubated with pHrodo 
coated S.aureus particles. Fluorescence released from normal density 
granulocytes was also decreased, but non-significantly [145]. The results are not 
comparable with our study as the incubation with particles and autologous 
serum was for two hours and effects can be biased by the serum present as JSLE 
serum has been shown to reduce phagocytosis [4]. Denny et al. also looked at 
the mean fluorescence which for pHrodo results from both the amount of 
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particles ingested and the acidity in the phagosome. Consequently, a decrease in 
fluorescence could also indicate a more alkaline pH in the JSLE neutrophils. 
Another study suggested that there is no difference in the uptake of E.coli and 
S.aureus-particles in JSLE patients, but did not indicate if, serum (and if so, what 
type) was used and they also did not state how long cells were incubated with 
particles [238]. Saturation might have occurred in the latter study, as observed 
with S.aureus in the data reported in this chapter. 
Functional phagocytosis assays reported in the literature are difficult to 
compare and it is crucial to know all exact timings and parameters. In our case, 
functional assays show JSLE neutrophils to be at least as efficient as control 
neutrophils, when the effect of serum is diminished with a short incubation 
without preopsonisation. This is also supported, as gene and protein expression 
in JSLE patients show a more activated profile for phagocytosis compared to 
control patients. Important receptors, like TLR2 and FcRIIIb, and stimulatory 
molecules, like S100A9, are upregulated and can explain the observed trend for 
even more efficient uptake of E.coli and zymosan in JSLE. 
 
4.7 Conclusion 
JSLE IFN high and IFN low patients differ as hypothesized not just in their IFN 
signature in neutrophils, but also regarding expression of phagocytosis-related 
genes and to a lesser extent expression of genes involved in DNA modification. 
Furthermore, the increased expression of PRG in JSLE patients compared to 
healthy paediatric controls was observed to be translated into protein. The 
difference between JSLE IFN high and JSLE IFN low patients was less clear than 
observed for mRNA expression. Upregulated expression of PRG was visible in 
phagocytosis assays as neutrophils of JSLE patients showed enhanced uptake of 
bioparticles compared to neutrophils of healthy paediatric controls. A difference 
between phagocytic ability between JSLE patients’ IFN subtypes has not been 
observed. 
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 The influence of the cell environment on IGS and 
PRGs in JSLE patients 
 
5.1 Introduction 
In Chapter 4, the IGS and PRGs were assessed in neutrophils of JSLE patients 
and their IFN subtypes compared to those of healthy paediatric control patient 
PMNs. Studies have been published about the presence of the IGS [56], [57]. 
However, the causes and influences of this signature are still unknown. 
Furthermore, the triggers for the PRGs in JSLE patients described in Chapter 4, 
require further investigation. 
Neutrophils in JSLE patients are influenced by many different stimuli. It may 
therefore be valuable to start the assessment of potential factors influencing 
these signatures with processes known to be dysregulated in JSLE.  
One of these processes is cell death and in particular apoptosis, which should be 
a non-inflammatory process leading to clearance of dead or dying cells – see 
Section 1.6.4. This however has been noted to occur at a higher rate and 
dysregulated manner in JSLE patients, as well as adult-onset SLE patients [137]. 
Apoptotic cell removal has additionally been found to be deficient in JSLE 
patients [168]. Uncleared apoptotic cells could release cytokines and increase 
the amount of cell debris that may stimulate both the IGS and PRGs. 
Another process identified as being dysregulated in JSLE is NETosis (also 
referred to as ‘netting’) and it is considered a cause of disease onset. This type of 
neutrophil-specific cell death is linked to LDGs in lupus, releases chromatin 
containing nucleosomes together with antimicrobial proteins and is causing 
damage to tissue in SLE [237].  
Both increased apoptosis and NETosis may lead to the presence of nucleosomes 
which was suggested to result in increased IFN production [111]. IFN itself 
should induce genes of the IGS and may also affect some PRGs. 
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Netting LDGs from SLE patients have also been shown to produce higher levels 
of TNF compared to healthy control PMN or even compared to SLE PMN [145]. 
Increased numbers of LDGs in JSLE and increased NETosis suggest TNF to play 
a role in diseases and may affect the IGS and PRGs [159], [237]. 
5.2 Chapter hypothesis 
The hypothesis to be investigated is that: Differences between JSLE patients and 
paediatric control patients in expressing an IGS and a PGS, may be explained by 
differences in components of the cellular environment of neutrophils, which 
causes changes in mRNA and protein expression. 
 
5.3 Objectives 
The objectives for this chapter are: 
Objective 1: To investigate the impact of the apoptotic environment, 
nucleosomes, IFN and TNF on gene and protein expression of PRGs in 
neutrophils or whole blood. 
Objective 2: To measure the influence of the apoptotic environment, 
nucleosomes, IFN and TNF on gene expression of IGS in neutrophils or whole 
blood.  
 
5.4 Chapter specific methods 
5.4.1 Selection of housekeeping genes 
As detailed in Section 4.4.2, the GeNorm™ reference gene selection kit from 
Primerdesign was used when possible with the following primers for testing 
appropriate housekeeping genes:  
18S, ACTB, ATP5B, B2M, CYC1, EIF4A2, GAPDH, RPL13A, SDHA, TOP1, UBC, 
YWHAZ. 
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For a comparison of two conditions for example cDNA of neutrophils stimulated 
with or without apoptotic supernatant, qPCRs with six cDNA samples were 
performed with three samples per condition  
Results were then analysed with qbasePLUS (Biogazelle), which gives the M- 
and V-value as results. The M-value expresses variability of each gene between 
the conditions with a cut-off of 0.5 considered as stable. Genes are presented 
from the weakest (high M-value) to the strongest gene (lowest M-value) from 
left to right. The V-value determines how many housekeeping genes are 
required for optimal normalization. Once the V-value reaches below 0.15 the 
number of housekeeping genes is considered sufficient. Results are shown in 
step-wise inclusion of the next most stable gene. 
For incubation with apoptotic supernatants healthy adult bead-purified 
neutrophils were stimulated with OVN medium (plus 10% FCS) or apoptotic 
supernatant (plus 10% FCS). To take into account the effect of other immune 
cells a further condition was included which involved 95% neutrophils together 
with 5% PBMCs stimulated in apoptotic supernatant (plus 10% FCS). All three 
sample types were tested with GeNorm™ reference gene selection kit (Figure 
5.1).  
Analysis showed that except for RPL13A, GAPDH and EIF4A2, all housekeeping 
genes had an M-value less than 0.5 which is considered the cut-off for stable 
gene expression (A). The three ideal genes for normalization with apoptotic 
supernatant were ACTB, UBC and B2M (B).  
For all other assays, either mRNA from 1 ml whole blood or paediatric control 
patient neutrophils were used.  
Due to the availability of the analysis software and chicken nucleosomes not 
coinciding, whole blood stimulations were tested with native HEK293-derived 
nucleosomes. UBC, TOP1 and EIF4A2 were the three most stable target genes, 
but all genes except for GAPDH were under the M-value of 0.5 and are therefore 
considered stable (Figure 5.2 A). With a V-value of 0.055 three housekeeping 
genes were suggested as appropriate: UBC, TOP1 and EIF4A2 (). Due to low 
mRNA values only the two most stable housekeeping genes were used. To 
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confirm that UBC and TOP1 alone were valid housekeeping genes also with 
chicken nucleosomes, anti-IFNAR-antibody and isotype control the CT-values of 
the different stimulations were compared (C). Statistical analysis showed that 
there was no difference (UBC p=0.64; TOP1 p=0.24) between the treatments for 
either of the housekeeping genes and UBC and TOP1 were therefore used for 
normalization.  
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Figure 5.1: Reference target stability and optimal number of housekeeping 
genes for neutrophil stimulation with apoptotic supernatants.  In total nine 
cDNA samples of bead-purified neutrophils, with or without apoptotic 
supernatant or neutrophils in the presence of apoptotic supernatant and 5% 
PBMCs, were tested for their expression of 12 housekeeping genes. Stability of 
each gene is shown in (A) with the least stable gene on the left and the most 
stable gene on the right. GeNorm V in (B) shows how many genes are required 
to reach V<0.150 by performing pairwise variation. A maximum of three genes 
(ACTB, UBC and B2M) is necessary for normalization. 
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Figure 5.2: Reference target stability and optimal number of housekeeping 
genes for whole blood stimulations.  Three cDNA samples of unstimulated 
and four cDNA samples of native nucleosome (HEK293-derived; AMS 
Biotechnology, UK) stimulated healthy adult control whole blood were tested 
for their expression of 12 housekeeping genes. Stability of each gene is shown in 
(A) with the least stable gene on the left and the most stable gene on the right. 
GeNorm V in (B) shows how many genes are required to reach V<0.150 by 
performing pairwise variation. Three genes (TOP1, UBC and EIF4A2) are 
sufficient for optimal normalization. UBC and TOP1 were chosen to be used as 
housekeeping genes and comparison of CT-values for their expression (n=8 for 
each condition; C) there is also no change of mRNA after stimulation with 
chicken nucleosomes with or without anti-IFNAR-antibody and with or without 
Isotype control. Friedman test with Dunn’s multiple comparison.  
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IFN stimulations of paediatric control patient neutrophils were conducted 
before the GeNorm™ kit and Biogazelle software were available and ACTB had 
been chosen as a housekeeping gene. Six cDNAs were run retrospectively 
comparing all 12 housekeeping genes to evaluate the strength of ACTB as a 
housekeeping gene.  
ACTB was the fourth most stable housekeeping gene with an M-value of 0.03 
showing very little variation between the conditions (Figure 5.3 A). 
Additionally, statistical analysis to identify differences between six 
unstimulated and stimulated samples showed that CT-values of ACTB does not 
vary between treated and untreated neutrophils (p=0.16; B). 
Paediatric control patient neutrophils were stimulated with TNF, but this was 
conducted after the Biogazelle software was available. CT-values of ACTB and 
TOP1 were therefore compared to establish that there is no variation between 
the treatments (Figure 5.4). Indeed, statistical analysis confirmed that both 
ACTB (p=0.31) and TOP1 (p=0.19) are not different for TNF treated or 
untreated neutrophils. 
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Figure 5.3: Reference target stability and optimal number of housekeeping 
genes for stimulation of paediatric control patient neutrophils with IFN.  
Three cDNA samples each of unstimulated and IFN stimulated paediatric 
control patient neutrophils were tested for their expression of 12 housekeeping 
genes. Stability of each gene is shown in (A) with the least stable gene on the left 
and the most stable gene on the right. ACTB has an M-value of 0.03 showing 
strong stability. Comparison of CT-values for ACTB expression (n=6; B) showed 
that there is also no change of mRNA after stimulation with IFN and confirm it 
to be a very good housekeeping gene. Wilcoxon matched-pairs signed rank test 
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Figure 5.4: mRNA expression of ACTB and TOP1 as housekeeping genes for 
TNF stimulation.  Paediatric control patient neutrophils were stimulated with 
1 ng/ml TNF and mRNA expression of ACTB and TOP1 were tested with real-
time PCR for their expression. No difference was observed either for the CT-
values for ACTB or for TOP1 between the stimulations. Wilcoxon matched-pairs 
signed rank test 
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5.4.2 Collecting supernatant from whole blood stimulations for ELISA 
For each stimulation, 1 ml of whole blood was used and incubated for 5 h at 
37°C as described in 2.2.10.2. Afterwards the blood was mixed with 200 l 
HetaSep and left to separate for 30-45 min. 550-600 l of plasma layer was 
removed and centrifuged with an additional 2.4 ml PBS. Supernatants were 
aliquoted and frozen at -80°C until used for ELISA and the pellet was used for 
further processing for RNA extraction as described in 2.10.3. 
 
5.4.3 Time course of paediatric control patient neutrophils stimulated 
with IFN  
A time course assay was performed over 8 h (n=3) to assess which time point 
would be best to investigate changes in protein levels reflecting the increase 
seen in the mRNA expression. While GM-CSF was already increased after 6 h, 
the highest difference with least variation between untreated and IFN 
stimulated cells was observed at 7 h (Figure 5.5). For all subsequent 
measurements of both intra- and extracellular protein, the 7-hour time point 
was chosen.  
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Figure 5.5: CD16b expression after incubation with IFN and GM-CSF over 
an 8 h time-course.  Neutrophils from three paediatric control patients were 
stimulated with or without 10 ng/ml IFN or 5 ng/ml GM-CSF and 10% FCS. 
After 4 h, CD16b surface expression was measured every hour with flow 
cytometry for a further 11 h. 
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5.5 Results 
5.5.1 Apoptotic environment and its influence on neutrophils 
Increased apoptosis occurs in JSLE patients and may therefore influence the 
PRG and IGS which were investigated in Chapter 4. To investigate the influence 
of cytokines released upon apoptosis on PRGs and IGS in neutrophils, we 
stimulated ultra-pure neutrophils or neutrophils with 5% PBMC in apoptotic 
supernatant (AS) (plus 10% FCS) or 10% FCS with media as described in 2.2.4.2. 
Ultra-pure neutrophils were used in this analysis to exclude the presence of 
IFN producing cells to allow analysis if apoptotic supernatant alone can change 
the IGS or PGS. For non ultra-pure cells a cut-off of 5% for PBMCs was chosen to 
allow production of IFN while permitting measurement of mostly neutrophil 
mRNA with downstream qPCR analysis. The two hour time span was primarily 
to investigate mRNA changes, while at six hours protein expression was 
expected to change. In order to observe changes in cell death both time points 
were evaluated. These stimulations were conducted with blood from healthy 
adult controls due to the high number of PMNs needed. Paediatric control blood 
would not have been sufficient to compare three conditions with one donor, 
especially because during the ultra-purification step neutrophils were lost. 
 
5.5.1.1 Influence of apoptotic environment on PRGs of neutrophils 
AS did not alter gene expression significantly for TLR2 (Figure 5.6 A) or 
S100A9 (B) at 2 or 6 h. TLR2 showed a trend to be increased at 6 h with an 
overall p-value of 0.08 and a Dunn’s multiple comparison p-value of 0.05 in the 
presence of supernatant and PBMCs compared to medium stimulated ultrapure 
neutrophils. Expression of FcRIIIb decreased significantly with the stimulation 
of AS when PBMCs were present after 6 h (C). This decrease may result partly 
from the sole presence of PBMCs as they have no FcRIIIb mRNA, but this result 
is supported by supernatant alone causing a non-significant decrease in FcRIIIb 
expression.  
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Figure 5.6: mRNA expression of PRGs at 2 h and 6 h for neutrophils in the 
presence or absence of PBMCs incubated with AS of 1.5x106 dying 
neutrophils.  Ultrapure neutrophils (purified with magnetic beads) (n=5) were 
used or as a mixture of 95% neutrophils and 5% PBMCs. They were stimulated 
with apoptotic supernatant (AS) for 2 h and 6 h. mRNA expression of TLR2 (A), 
S100A9 (B) and FcRIIIb (C) was measured with real-time PCR using SYBR 
green and results were normalized to the geometric mean of UBC, ACTB and 
B2M. TLR2 only increased non-significantly (p=0.08) at 6 h for ANOVA and 
p=0.05 for Dunn’s multiple comparison when medium treated PMN were 
compared with PMN with 5% PBMC and AS. There was no change in the 
expression of S100A9, but a significant difference for FcRIIIb comparing 
medium treated PMN with PMN with 5% PBMC and AS. ** p<0.01, Friedman test 
with Dunn’s multiple comparison 
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At the 6 h time point, protein expression was also measured, but as observed for 
the mRNA expression there were no changes in TLR2 or S100A9 (Figure 5.7 
A+B). For both intra- and extracellular CD16b protein there was no difference 
observed with incubation of AS in the absence or presence of PBMCs (C+D). This 
was in contrast to the findings on mRNA levels which had suggested a decrease 
of FcRIIIb with AS in the presence of PBMC. While there was also no difference 
in released S100A9, CD16b was significantly shed more (p=0.02) into the 
supernatant in the presence of apoptotic supernatant and PBMCs. Ultrapure 
neutrophils did not show a significant release. 
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Figure 5.7: Protein expression of PRGs after stimulation with apoptotic 
supernatant (AS).  Neutrophils (n=5) were stimulated either as ultrapure 
(purified with magnetic beads) or as a mixture of 95% neutrophils and 5% 
PBMCs with AS for 6 h. Protein of TLR2 (A), S100A9 (B) and CD16b (C+D n=3) 
was measured with flow cytometry. Release of S100A9 (F) and CD16b (E) was 
additionally measured in the supernatants. TLR2, S100A9, CD16b and released 
S100A9 did not show changes for their expression. Only shed CD16b increased 
significantly in the presence of PBMCs and AS (p=0.02). * p<0.05, Friedman test 
with Dunn’s multiple comparison 
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Neutrophils shed CD16b when they undergo apoptosis (Dransfield et al., 1994): 
an increase in CD16b may suggest apoptotic cells. Indeed, at 2 h there is a non-
significant increase of apoptotic cells for incubation with supernatant and a 
significantly higher percentage of apoptotic cells observed for incubation with 
apoptotic supernatant in the presence of PBMCs (Figure 5.8 A). There were no 
differences in apoptosis observed at 6 h (B). Cell death at 2 h may influence the 
presence of shed CD16b. PMN incubated with PBMC were not purified with 
magnetic beads before incubation, this process might have removed cells that 
were apoptotic in the other two conditions. Nevertheless, ultrapure PMNs 
incubated with supernatant indicate increased apoptosis at 2 h.  
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Figure 5.8: Apoptosis of PMN in the presence or absence of apoptotic 
supernatant and PBMCs at 2 h and 6 h.  Cell death was measured with flow 
cytometry using Annexin V and PI for ultrapure neutrophils (purified with 
magnetic beads) or as a mixture of 95% neutrophils and 5% PBMCs with AS at 2 
h (n=4) and 6 h (n = 5). A significant difference was observed at 2 h comparing 
medium treated-PMN with neutrophils treated with AS in the presence of 5% 
PBMCs. There was no difference at 6 h. * p<0.05, Friedman test with Dunn’s 
multiple comparison  
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5.5.1.2 Influence of apoptotic environment on IGS in neutrophils  
With regards to the PRGs, only CD16b was changed after exposure to apoptotic 
supernatant and only in the presence of PBMC (mRNA in Figure 5.6 and protein 
in Figure 5.7). For the IGS, OAS2 was significantly increased for incubation of 
neutrophils with apoptotic supernatant in the presence of PBMCs compared to 
the untreated PMNs (p=0.02, Figure 5.9 A). IFI44L expression was not 
significantly different between the groups (p=0.09, B), whereas LY6E showed a 
significant overall difference with Friedman’s test (p=0.02, C), but only showed 
a non-significant adjusted p=0.05 with Dunn’s multiple comparison for PMN 
with apoptotic supernatant in the presence of PBMCs compared to the 
unstimulated PMNs. 
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Figure 5.9: IGS induction of healthy adult control PMN with apoptotic 
supernatant in the presence of PBMC. mRNA expression of IGs was measured 
in ultrapure PMN with or without AS or PMN with 5% PBMCs and AS (n=5 each) 
after 6 h using real-time PCR with SYBR green. Results are shown as relative 
expression normalized to the geometric mean of three housekeeping genes 
(UBC, ACTB and B2M). A significant increase of OAS2 expression was observed 
for PMN which were incubated together with PBMCs and AS compared to 
untreated ultrapure PMN. PMNs with PBMCs stimulated with AS increased the 
expression for IFI44L only non-significantly (p=0.09). For LY6E a significant 
difference between the groups was observed (p=0.02) with a non-significant 
difference for AS stimulated PMN with PBMCs compared to unstimulated PMN. 
#=0.05; * p<0.05 Friedman test, Dunn’s multiple comparison 
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5.5.2 The impact of nucleosomes 
Nucleosomes, present in the JSLE environment in cell debris and NETs, contain 
both protein and DNA and are strong stimuli for antibody development. Whole 
blood was therefore stimulated with nucleosomes isolated from chicken blood 
as described in 2.2.10. After 5 h of incubation, mRNA and protein was measured 
to investigate the influence on PRGs and IGS. 
 
5.5.2.1 PRGs in the presence or absence of nucleosomes in whole blood 
Both TLR2 and S100A9 mRNA levels were not influenced significantly by the 
presence of nucleosomes, but a 31.3% and 15.8% decrease (p=0.07, p=0.19 
respectively, Figure 5.10 A+B) was observed. Nucleosomes significantly 
reduced FcRIIIb expression in whole blood after 5 h (C). 
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Figure 5.10: mRNA expression of TLR2, S100A9 and FcRIIIb in whole 
blood after 5 h stimulation with nucleosomes.  Whole blood (n=8) was 
stimulated with nucleosomes for 5 h or was left untreated and mRNA 
expression was measured with real-time PCR using SYBR Green. Target genes 
were normalized to the geometric mean of UBC and TOP1. Results are shown as 
fold change to donor 5. TLR2 (A) and S100A9 (B) did not show a significant 
difference although a decrease was observed in TLR2 (p=0.07). FcRIIIb (C) was 
significantly decreased in whole blood stimulated with nucleosomes. *p<0.05 
paired t-test after normality confirmation with D’Agostino & Pearson omnibus 
normality test  
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Protein expression was measured after whole blood stimulation of neutrophils 
from healthy adult controls with or without nucleosomes in the presence of 
Brefeldin A using flow cytometry (intracellular and cell surface staining). 
Supernatants for the S100A8/S100A9 ELISA were obtained from stimulations 
with or without nucleosomes without Brefeldin A as described in Section 5.4.3. 
Protein expression (Figure 5.11) of phagocytosis-related genes TLR2 and 
S100A9 in neutrophils showed no changes after nucleosome stimulation for 5 h 
(A+C). While TLR2 protein levels in neutrophils (B) also remained unaltered, 
PBMCs had significantly higher S100A9 protein expression (p= 0.048; D). The 
bioactive form of the S100A8/S100A9 protein was significantly increased after 
nucleosome stimulation (p=0.039; E). Nevertheless, S100A9 within this complex 
may result from both neutrophils as well as PBMCs, because Brefeldin A 
prevented the release of S100A9 in C and D. CD16b protein expression followed 
the observed changes in mRNA expression with a significant decreased level of 
extracellular protein expression (p=0.006), but unchanged intracellular CD16b. 
This would suggest shedding of protein into the supernatant. CD16b expression 
in the supernatant was measured using ELISA (data not shown), but assay 
technical issues stopped further exploration. There was a strong variation 
apparent between the replicates. Supernatants were frozen with HetaSep and 
PBS and some precipitate had built up when they were defrosted. Within the kit 
description it is mentioned, that precipitates may cause interference. 
These results suggest only PMN involvement for CD16b release, but comparison 
of granularity of neutrophils reveals a significant decrease with nucleosome 
stimulation (p=0.03; Figure 5.12 A). This was assessed by gating the neutrophil 
population with forward scatter (FSC) and sideward scatter (SSC). Compared to 
unstimulated PMN (B), nucleosome stimulation (C) causes the neutrophil 
population to drop for the SSC which represents a decrease in granularity. This 
may suggest that granules are released upon stimulation with nucleosomes. 
This process, called exocytosis, can release proteins such as antimicrobials, 
hydrolases and proteinases.  
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Figure 5.11: Changes in protein levels after 5 h stimulation of whole blood 
with nucleosomes.  Protein expression was measured with flow cytometry and 
ELISA for eight whole blood samples from healthy adult controls, which were 
incubated with or without nucleosomes for 5 h. Brefeldin A was added for flow 
cytometry samples after 1 h. TLR2 expression was unchanged for neutrophils 
(A) and PBMCs (B). S100A9 expression was also unchanged in neutrophils (C) 
but was significantly increased in PBMCs (D). Also, the bioactive form 
S100A8/S100A9 was released significantly after nucleosome stimulation (E). A 
significant reduction in CD16b was observed in neutrophils (F), but intracellular 
CD16b (n=7) remained unaltered (G). *p<0.05 **p<0.01 paired t-test or 
Wilcoxon matched-pairs signed rank test was used depending on results of 
D’Agostino & Pearson omnibus normality test 
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Figure 5.12: Granularity of neutrophils in whole blood stimulated with or 
without nucleosomes in the presence of Brefeldin A. Granularity was 
assessed with flow cytometry for eight whole blood samples from healthy adult 
controls stimulated with or without nucleosomes for 5 h with Brefeldin A being 
added after 1 h. Differences were observed by measuring the sideward scatter 
(SSC). A significant decrease in granularity was observed for nucleosome 
stimulated PMN compared to unstimulated (A). A representative dot plot of one 
donor’s neutrophil population for unstimulated cells can be seen in (B) and for 
nucleosome treated cells in (C). Drop in SSC is indicating reduced granularity. 
*p<0.05 with paired t-test after D’Agostino & Pearson omnibus normality test 
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5.5.2.2 IGS induction by nucleosomes in whole blood 
The IGS was also investigated after nucleosome stimulation and was 
significantly altered (Figure 5.13). NETs, in which nucleosomes are present, are 
considered a cause of IFN production [256]. To investigate which effects on 
the IGS are due to IFN additional incubations with nucleosomes and 5 g/ml 
anti-IFN-receptor antibody or Isotype control antibody were performed. 
Results show that nucleosome stimulation induces IFI44L (p=0.003; A), OAS2 
(p=0.02; B) and LY6E (p=0.006; C). Anti-IFN-receptor antibody significantly 
reduced the IGS (IFI44L p=0.04; OAS2 p=0.0499; LY6E p=0.006) showing that 
IFN causes the IGS resulting from the presence of nucleosomes. This effect was 
indeed due to a targeted block of the IFN-receptor, as the isotype control 
showed significant increase compared to the anti-IFN-receptor antibody 
treatments and restore IGS levels as seen for nucleosome only stimulation 
(IFI44L p=0.04; OAS2 p=0.016; LY6E p=0.022). 
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Figure 5.13: IGS after nucleosome stimulation of whole blood for 5 h with 
or without IFN-receptor antagonist or Isotype control.  Whole blood (n=8) 
was stimulated for 5 h with nucleosomes with or without 5 g/ml anti-IFN-
receptor antibody or Isotype control. mRNA expression was measured with 
SYBR green using real-time PCR. IFI44L (A), OAS2 (B) and LY6E (C) were 
measured and results were normalized to the geometric mean of UBC and TOP1. 
Results are shown as fold change compared to unstimulated whole blood of 
donor 5. This donor was picked as results from donor 5 represented the average 
of healthy controls. Nucleosomes induced significant increase of all three IGs. 
This was significantly reduced with anti-IFN-receptor antibody, but unaffected 
by Isotype control. One-way ANOVA with Tukey’s multiple comparison or 
Friedman test with Dunn’s multiple comparison after D’Agostino & Pearson 
omnibus normality test 
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5.5.3 The effect of cytokines from nucleosomes and apoptotic 
supernatant stimulation  
Both apoptotic supernatant and nucleosome stimulations caused responses in 
the IGS indicating IFN involvement. This has further been confirmed as 
addition of anti-IFN-receptor antibody reduced this signature (Figure 5.13).  
Another cytokine discussed in the involvement in JSLE is TNF, a protein 
considered pro-inflammatory. TNF release following nucleosome stimulation 
was therefore measured in the supernatants (Figure 5.14) which were 
collected as described in 5.4.2. Indeed, nucleosome-treated whole blood 
supernatants showed a significant increase (p=0.03) in TNF, reaching 
concentrations over 1 ng/ml. 
Results from this work suggest that both cytokines, IFN and TNF play an 
important role in JSLE disease activity. Consequently, their role on neutrophils 
specifically focusing on the PGS and IGS was studied further. 
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Figure 5.14: TNF release after 5 h nucleosome stimulation of whole 
blood.  Supernatants obtained from whole blood stimulations (n=6) with or 
without nucleosomes were measured for release of TNF with ELISA. Results 
show significant increase of TNF in the presence of nucleosomes with up to 
1.106 ng/ml. * p<0.05 Wilcoxon matched-pairs signed rank test 
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5.5.3.1 The influence of IFN and TNF on PRGs 
IFN was used at a concentration of 10 ng/ml and TNF at 1 ng/ml as this was 
the maximum concentration resulting from whole blood stimulation with 
nucleosomes. Neutrophils from paediatric control patients were stimulated for 
2 h with IFN and 30 min with TNF for mRNA expression and for 7 h 
(IFN) and 2 h (TNF) for protein expression. Neither IFN nor TNF 
stimulated mRNA expression of TLR2 (Figure 5.15 p=0.16 A; p=0.13 B) or 
S100A9 (p=0.56 C; p=0.13 D). Furthermore, TNF did not affect FcRIIIb mRNA 
expression (p=0.19), but it was significantly increased in the presence of IFN 
(p=0.03).  
The next step was therefore to investigate CD16b expression with IFN 
stimulation. As described in 5.4.3, PMN were incubated for 7 h with 10 ng/ml 
IFN and 10% FCS. GM-CSF was used as a positive control for CD16b induction. 
Protein expression was measured with flow cytometry and ELISA (Figure 
5.16). 
GM-CSF significantly induced extracellular expression of CD16b protein 
(p=0.02) compared to unstimulated PMN and, additionally, a higher 
intracellular expression was observed (p=0.05; A). IFN had no effect on 
extracellular levels (>0.99) but increased internal stores significantly (p=0.02; 
A). No shedding into the supernatants was observed for either IFN or GM-CSF 
(>0.99 and 0.41 respectively, B). 
mRNA expression was unaltered after TNF stimulation for all the PRGs and 
therefore all proteins were examined (Figure 5.17). TLR2 showed significant 
increase in protein expression for paediatric control patient neutrophils 
stimulated with TNF (p=0.03; A). While there was no difference for S100A9 
(B) and CD16b on the cell surface (C) (p=0.16, p=0.31, respectively). A trend for 
decrease in intracellular CD16b levels (D) was observed (p=0.09). Results of an 
ELISA showed no difference in S100A8/S100A9 (E) or CD16b (F) release 
(p=0.84 and p=0.88 respectively). This is similar to observations described in 
5.5.2.1, where CD16b was decreased in the presence of nucleosomes, although it 
had only decreased extracellular protein and mRNA.  
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Figure 5.15: mRNA expression of PRGs after stimulation of neutrophils 
with IFN and TNF.  Neutrophils of paediatric control patients were 
stimulated for 2 h with 10ng/ml IFN (n=6; A, C, E) or 30 min with 1 ng/ml 
TNF (n=5; B, D, F). mRNA expression of TLR2 (A, B), S100A9 (C, D) and 
FcRIIIb (E, F) was measured using real-time PCR with SYBR green. Results are 
shown as relative expression and PRGs are normalized to ACTB for IFN and to 
the geometric mean of ACTB and TOP1 for TNF. Only FcRIIIb showed a 
significant increase and only with IFN. * p<0.05 Wilcoxon matched-pairs 
signed rank test 
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Figure 5.16: Stimulation of paediatric control patients’ neutrophils with 
IFN or GM-CSF for 7 h.  Neutrophils were stimulated with 10 ng/ml IFN or 5 
ng/ml GM-CSF (n=5) for 7 h. Cell surface and intracellular CD16b protein 
expression was measured with flow cytometry (A). Release of CD16b into 
supernatants was assessed with ELISA (B). GM-CSF was significantly increased 
on the cell surface and a higher expression was observed intracellularly. IFN 
increased only intracellular stores significantly, but not cell surface expression. 
# p=0.05, * p<0.05 Friedman test with Dunn’s multiple comparison 
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Figure 5.17: Protein expression of PRGs after TNF stimulation.  Paediatric 
control patient neutrophils were stimulated with 1 ng/ml TNF for 2 h. Then 
protein expression was measured with flow cytometry (n=6; A-D) and ELISA 
(n=5 E, n=4 F). TLR2 protein was significantly elevated with TNF. S100A9 (B), 
CD16b on the cell surface (C) and intracellular CD16b (D) was unaltered. 
Furthermore, S100A8/S100A9 (E) and CD16b (F) were not released into the 
supernatants. * p<0.05 Wilcoxon matched-pairs signed rank test 
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5.5.3.2 The influence of IFN and TNF on the IGS 
Stimulations with nucleosome and apoptotic supernatant can change the IGS 
and it was therefore important to investigate the influence of IFN and TNF on 
these genes. Neutrophils of paediatric control patients were stimulated for 2 h 
with 10 ng/ml IFN or 30 min with 1 ng/ ml TNF before mRNA expression 
was measured (Figure 5.18). 
IFN stimulation led to a significant increase in OAS2 (p=0.03; A) and IFI44L 
(p=0.03; C). LY6E showed higher expression with IFN but this was not 
statistically significant (p=0.16; E). TNF stimulation did not cause changes in 
any of the IFN-induced genes after the 30 min incubation (OAS2 p=0.44 B; 
IFI44L p=0.63 D; LY6E p=0.63 F). 
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Figure 5.18: mRNA expression of IGS after stimulation with IFN or TNF. 
Neutrophils of paediatric control patients were stimulated for 2 h with 10 ng/ml 
IFN (n=6; A, C, E) or 30 min with 1 ng/ml TNF (n=5; B, D, F). mRNA 
expression of OAS2 (A, B), IFI44L (C, D) and LY6E (E, F) was measured using 
real-time PCR with SYBR green. Results are shown as relative expression and 
IGs are normalized to ACTB for IFN and to the geometric mean of ACTB and 
TOP1 for TNF. OAS2 and IFI44L were significantly increased and a non-
significantly higher LY6E expression was measured with IFN TNF did not 
alter any of the IFN-induced genes. *p<0.05 Wilcoxon matched-pairs signed 
rank test 
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5.6 Discussion 
In this study the influence of apoptotic supernatant, nucleosomes, IFN and 
TNF on the expression of TLR2, S100A9 and FcRIIIb was assessed. PMN 
incubated with apoptotic supernatant in the presence of PBMCs and whole 
blood in the presence of nucleosomes, showed a decrease in FcRIIIb. However, 
IFN alone upregulated FcRIIIb expression while TNF showed no effect. To 
date, there have been no published studies looking at the neutrophil mRNA 
expression of FcRIIIb in response to apoptotic supernatant, nucleosomes, 
TNF or IFN.  
In strong contrast, TLR2 expression was not altered following stimulation with 
either apoptotic supernatant, IFN or nucleosome treatment. TNF did not 
change TLR2 mRNA expression of neutrophils after 30 min, but protein 
expression had increased significantly on the cell surface after 2 h. Previously, in 
other studies the mRNA of this receptor was found to be upregulated with 
TNF in monocytes from healthy adult donors. The authors had incubated the 
cells for 1.5 h and with 100 ng/ml [257]. In this present study, only a maximum 
concentration of 1 ng/ml was released by cells from whole blood from healthy 
adult controls when stimulated with nucleosomes. Furthermore, phorbol 12-
myristate 13-acetate (PMA) differentiated THP-1 cells have also been shown to 
have increased TLR2 mRNA expression after 6 h with 20 ng/ml of TNF [258]. 
Therefore, a longer incubation time than 30 min for mRNA expression may have 
been more appropriate. Zarember and Godowski also identified IL-6, LPS, Gram-
positive and Gram-negative bacteria to be inducers of TLR2 gene expression 
which we have not investigated in this present study [258].  
Similar to the TLR2 increase with TNF, calprotectin, which contains S100A9, 
was observed to be increased by TNF in other studies, for example in human 
keratinocytes. This effect was only visible after an incubation of 24 h [259]. 
TNF incubation in conditions used in the studies presented in this chapter did 
not show any effect on S100A9 expression and nor did any other stimulation 
investigated. On the other hand, release of S100A8/S100A9 was significantly 
increased upon stimulation of healthy adult control whole blood with 
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nucleosomes. Calprotectin has not been linked to the presence of nucleosomes 
yet, except for both being present in NETs [260]. Even though an increased 
release with TNF was not seen after 2 h with 1 ng/ml, a stimulation with 100 
ng/ml of TNF for 30 min in monocytes has previously shown significant 
release compared to unstimulated cells. Another explanation for calprotectin 
secretion may also be due to IL-1 which has also been shown to cause its 
release [261], but has been neglected in this study.  
Observations in changes of the mRNA in response to factors tested in this study 
are relevant to neutrophil cell environment of JSLE patients. For example, the 
increase in FcRIIIb mRNA levels only observed in JSLE patients with an IFN 
high signature can be explained with observations that IFN stimulates both the 
IGS as well as FcRIIIb. 
The findings for FcRIIIb mRNA increase after IFN stimulation was supported 
with an intracellular increase in CD16b protein expression. There is a lack of 
studies investigating induction of CD16b in neutrophils, but it has been stated 
that Fc receptors are significantly increased after stimulation with IFN on 
human monocytes and HL-60 cells [262].  
In contrast, TNF incubations and stimulations with nucleosomes showed 
decrease in CD16b protein expression, but not in its shedding. It has been 
suggested that this cytokine can induce apoptosis in neutrophils which is 
expected to decrease extracellular CD16b by shedding [193], [263]. As a result 
of assay technical issues, we could not measure shedding following stimulations 
with nucleosomes to confirm that the protein is cleaved into the supernatant 
due to the presence of TNF 
While phagocytosis related genes have not been investigated much in the past, 
there was more work done on the IGS. Nevertheless, despite the importance and 
strong prevalence of the IFN signature in neutrophils [56], only very few studies 
have conducted research on the cause of this signature.  
IFN-induced genes which make up the IGS in our study were OAS2, IFI44L and 
LY6E. OAS2 and IFI44L were significantly and LY6E was non-significantly 
increased with IFN stimulation after two hours. All three genes have been 
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shown to be increased in monocytes after a 1.5 h stimulation in whole blood 
with either IFN2a or IFN, but high concentrations of 100 ng/ml were used 
[257]. Interestingly in their study, they also assessed the influence of TNF and 
measured decrease of OAS2 and IFI44L after cytokine treatment and no effect 
on LY6E. OAS2, IFI44L and LY6E was also induced by IFN in human PBMCs 
when incubated for 2 h with 100 U/ml [264].  
During the stimulation assays with nucleosomes in this present study, the 
initiation of an IGS was blocked completely in the presence of anti-Interferon-
α/β Receptor Chain 2 antibody. IFN may have been present but has not 
induced an IGS. Alternatively, there was no IFN release upon nucleosome 
stimulation as the antibody should not block its action and an IGS should be 
visible assuming this cytokine can increase the signature. IFN may have been 
present and would have been blocked by this antibody. 
The stimulation with apoptotic supernatant did not indicate presence of IFN-I in 
the supernatant itself. Bead-purified neutrophils in the presence of supernatant 
did not show a strong induction of IGS. In the presence of 5% PBMCs on the 
other hand, a strong induction of IGS was observed. This may be in response to 
free nucleosomes released from early necrotic cells or to apoptotic vesicles 
containing dsDNA. The latter idea is supported by a paper published in June 
2018 where the authors found apoptotic vesicles in SLE patients’ sera [265]. 
They contained dsDNA and these vesicles were therefore able to induce an IGS. 
Most papers had focused on the effect of IFN on apoptosis rather than the 
cytokine release due to an apoptotic environment [266], [267]. 
 
5.7 Conclusions 
In summary, components such as nucleosomes, apoptotic environment, TNF 
and IFN, all part of the neutrophil environment of JSLE can indeed cause 
changes in expression of PRG or IGS in healthy control neutrophils similar as 
observed in JSLE patients. IFN can increase mRNA expression of FcRIIIb in 
neutrophils. TNF increased protein expression of TLR2 and IFN increased 
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CD16b expression in neutrophils and nucleosomes stimulated protein 
expression of S100A9 in monocytes as well as release of S100A9. Apoptotic 
supernatant triggered increased shedding of CD16b which may be part of flares 
in JSLE, but samples of flaring patients were not available to confirm this 
hypothesis. All components except for TNF further caused neutrophils of 
healthy paediatric controls to show IGS induction as observed in JSLE IFN high 
patients. For nucleosomes it was further confirmed that they induce IGS via 
IFN. 
Higher expression of TLR2 and S100A9 as well as low IGS may indicate that IFN 
low patients have a signature more driven by TNF whereas IFN high patients 
with an IGS and high expression of FcRIIIb are driven by interferons. 
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6 Discussion and future directions 
 
6.1 Concept of this study 
Autoimmune diseases are characterised by autoantibody production by B-cells 
triggering a mechanistic pathway resulting in disease pathology [2]. Notably, for 
several autoimmune diseases, the enhanced expression of a genetic signature of 
neutrophil-related genes has been described, indicating the potential specific 
importance of neutrophils also in the disease aetiopathogenesis [19], [55]. In 
SLE, both tissue damage as well as the triggering of disease onset has been 
associated with neutrophils. Increased and dysregulated neutrophil apoptosis 
[137] and NETosis in JSLE [256] leads to nuclear auto-antigen presentation to 
the adaptive immune system and production of proteases that can harm the 
surrounding tissues [237], [268]. NETosis has been noted to be impaired, 
probably because of dysregulated phagocytosis. Furthermore, the presence of 
an increased IGS has been directly linked to increased expression of neutrophil-
related gene expression [55].  
The overarching hypothesis of this thesis was therefore to determine if it is 
possible to stratify patients with autoimmune diseases such as JSLE, based on 
their metabolite profiles in urine and serum and based on differential 
expression of phagocytic and IFN-induced genetic signatures. In view of their 
potential for providing a key, important contribution to disease pathogenesis, 
there was a specific emphasis on the role of neutrophils, and to explore 
potential inducers of these signatures.  
This hypothesis was therefore explored in a stepwise manner. Firstly, the 
metabolite signatures of JSLE patients and of JIA patients in both serum and 
urine were analysed and compared to signatures from healthy paediatric 
control patients. Secondly, the transcriptional signature of neutrophils was 
explored, including investigation of phagocytosis-related as well as IFN-induced 
genes. This included translation of phagocytosis-related genes into protein and 
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functional analysis. Finally, potential causes for these signatures from the JSLE 
environment were investigated. 
6.2 Metabolomics analysis 
Investigation of the metabolite signature with 1H NMR spectroscopy was 
conducted with the following three objectives for Chapter 3: 
• Objective 1: To determine if serum or urine is better for building a model to 
distinguish between metabolite profiles of JIA, JSLE and healthy paediatric 
control patients, and between the JSLE IFN high and low subtypes and 
healthy paediatric control patients. 
Comparison of PLS-DA results of urine and serum metabolites showed a more 
informative model created with urine metabolites. Models were characterized 
by higher robustness and better predictive power between disease and health 
and between the IFN subtypes of JSLE. These results may have important 
implications in the future, as urine can be obtained much more easily from 
patients (especially children and young people) with it being completely non-
invasive. Venepuncture can be potentially avoided or at least reduced to a 
minimum for paediatric patients. However, analysing each metabolite spectrum 
separately with Chenomx Profiler® is very time consuming and may therefore 
not be considered as a gold standard. A range of strategies may be adopted to 
address this limitation. For example, it may be possible to circumvent this 
problem if a script was developed that normalizes all spectra to the same pH, 
based on an extensive library which would have to be created with the ppm of 
metabolites at different pH.  
• Objective 2: To identify potential pathways differentially regulated between 
disease groups and healthy paediatric control patients, as well as between 
the IFN subtypes of JSLE patients.  
Combining data from both urine and serum together, four major metabolic 
pathways were identified to be important for both of the disease processes, JSLE 
and JIA, namely: Glycolysis, Pentose Phosphate Pathway, Krebs cycle and Urea 
cycle (summarized Chapter 3, Figure 3.9).  
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Glycolytic activity appeared to be increased for JSLE IFN low patients with 
products feeding into both the PPP and the Krebs cycle. An upregulated PPP was 
observed for JIA, JSLE IFN high and JSLE IFN low patients compared to healthy 
paediatric control patients and has also been described in the literature mainly 
for T-cells of these diseases (as discussed in 3.5). These data support strongly 
the importance of the adaptive immunity in disease pathogenesis. On the other 
hand, both an upregulated PPP and Urea cycle highlight and indicate the 
importance of neutrophils to this process. PPP shunts increase NADPH 
production important for phagocytes and ROS production [229]. JIA and JSLE 
IFN low patients both showed increase in side products from arginine to 
ornithine conversion, whereas JSLE IFN high patients had higher arginine levels. 
This seemed not to be converted into ornithine, but potentially directly into 
citrulline which is an essential protein in NETosis [234]. JIA and JSLE IFN low 
patients showed increased activity in the Krebs cycle with a higher abundance 
of inflammatory molecules like fumaric acid or -ketoglutarate. 
Therefore, from a metabolic pathway standpoint, JIA patients appeared to 
demonstrate greater similarity to that of JSLE IFN low patients in this cohort 
than paediatric healthy controls, with an emphasis on expression of products 
reflecting involvement of the adaptive immune system and inflammation. In 
contrast, JSLE IFN high patients from a metabolic pathway perspective seemed 
to be directed towards being more NET-producing. This in turn may lead to 
increased IFN production and later on to autoantibody production. It was 
surprising to see that JSLE IFN low patients had a metabolic pattern more 
similar to JIA patients, whereas JSLE IFN high patients were more similar (from 
a metabolic pathway perspective) to healthy paediatric controls. To date, and in 
gene expression studies, JSLE IFN high patients have rather been described as 
being markedly different compared to healthy paediatric controls, and more so 
than JSLE IFN low patients. In the original study describing the different 
transcriptomic signatures, JSLE IFN low patients did not demonstrate an 
increased IFN signature [55]. Sjögren’s syndrome patients displaying an 
increased IGS are considered to have more arthritic and cutaneous clinical 
manifestations and therefore be more distinct compared to healthy paediatric 
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controls and IFN low patients with the same disease [247]. It has to be 
considered however, that medication may play a significant role in this study in 
the measured metabolite signature. Patients (in this present study) were not all 
on the exact same medications and this may have influenced results of 
metabolite changes. JSLE IFN low patients were receiving on average 
7.5mg/6.7mg (serum evaluated / urine evaluated patients) of oral prednisolone, 
whereas JSLE IFN high patients were on an average dose of 5mg/3.6mg (serum 
evaluated / urine evaluated patients) at the time of sample collection. In 
metabolite profiles analysed with mass spectrometry, glucose concentration has 
been shown to positively correlate with prednisolone dose, whereas arginine 
concentration correlates negatively [269]. In this present study, JSLE IFN low 
patients were found to be higher in glucose levels and normal in arginine levels 
compared to JSLE IFN high patients which were normal for glucose, but high for 
arginine. Contradictory to these findings is that alanine has been previously 
positively correlated to oral prednisolone [269], but was increased in the JSLE 
IFN low patient cohort in this present study. These data support the 
consideration in this study that observations are disease-specific differences in 
metabolite profiles. 
Interestingly, in the same study of Surowiec et al., the main aim was to study 
fatigue in RA patients. Similar to the present study, they described 
hypoxanthine, alanine and phenylalanine to be low in RA patients with higher 
fatigue scores. This may suggest that JSLE IFN low patients and JIA patients are 
more likely to develop fatigue. They proposed in the paper that xanthine 
oxidase may be upregulated changing hypoxanthine into xanthine. As a 
superoxide-producing enzyme this would indicate ROS production. 
Consequently, ROS production as mentioned above may also cause fatigue. 
However, to date, no further studies have been identified supporting this 
hypothesis. 
Due to described similarities in their metabolite signatures, it may therefore be 
worth in the future considering if the disease mechanisms underpinning JSLE 
IFN low patients may be more driven by Th-17 cells as described in JIA patients 
[270], whereas JSLE IFN high patients may be driven primarily to produce IFN, 
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triggered by NETosis. This hypothesis is supported by the fact that SLE patients 
have been found to possess specific IL-17 producing T-cells [131]. The study by 
Crispín et al did not present any details about each single patient, but another 
study looking at JSLE patients did [133]. Plasma levels of IL-17 were 
significantly higher in the JSLE cohort compared to the healthy paediatric 
control cohort. In this paediatric study, they further stimulated JSLE and healthy 
control PBMCs with CD3/CD28 and found after two days incubation, a 
significant increase in IL-17A and IL-17F concentrations in supernatants. 
Interestingly, only a very small minority of patients reacted with high IL-17 
production [133]. Even though in that study they did not look specifically at IFN 
signature subtype stratification, these very small numbers of JSLE patients’ 
PBMCs reacting with IL-17 production may reflect the JSLE IFN low patient 
subset. This line of study would warrant further investigation. 
 
6.3 Phagocytosis related profile of patients with JSLE 
In Chapter 4, the focus was on the transcriptional signature in JSLE, to confirm 
and find further evidence for the importance of neutrophils in disease 
pathogenesis, and to identify if there were additional differences between JSLE 
IFN high and IFN low patients respectively. This was explored through a series 
of steps and specific objectives. 
• Objective 1: To determine an appropriate IGS to differentiate between JSLE 
IFN low and JSLE IFN high patients. 
Initially, four genes were chosen to investigate the IGS, namely IFI44L, OAS2, 
LY6E and IFI6. However, IFI6 was observed to not correlate with any of the 
other three genes and was in one patient higher in the PBMC fraction than in the 
neutrophil fraction. For this selected gene signature in neutrophils, in JSLE IFN 
low patients it remained low over time. In contrast, for JSLE IFN high patients it 
remained high, but showed variation in the amount of their gene expression. 
This may indicate an inherent signature in patients rather than dependence on 
disease development. Authors of other published data have suggested a 
potential relationship between IFN signature expression and production of both 
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BAFF and anti-dsDNA antibodies [220]. However, within the present study and 
available patient cohort, this could not be confirmed as BAFF was not tested and 
only one JSLE IFN low patient had developed anti-dsDNA antibodies over time. 
Consistency over time for a patient to be expressing an IFN low or IFN high 
signature would indicate potential subgroups of the SLE disease spectrum. 
Identification of the respective IFN subgroup of a patient (IFN high or IFN low 
signature expressions) may be a valuable tool to distinguish different treatment 
responses dependent on their respective IGS. It has been suggested that IFN 
high patients would respond better to type I IFN receptor antagonist treatment 
[271]. In the study described, both IFN high and IFN low patients had their own 
placebo group. The main differences observed was a higher response to 
treatment in the placebo group of the IFN low patients compared to the placebo 
group of IFN high patients. This meant that for the IFN low patients treated with 
the antagonist, there was not a significant difference in their response to 
treatment. The response rate to the type I IFN receptor antagonist itself was 
comparable between SLE IFN high and SLE IFN low patients [271]. It has also 
been reported that IFN low patients respond better to treatment with anti-IFN 
than IFN high patients [63]. This may indicate that IFN low patients express and 
produce interferon protein, but do not respond to it in the same way with an 
increased IGS, or that a different set of genes has to be used to distinguish 
between IFN high and IFN low patients for these differences to be shown. The 
selection of genes that together are used to define an IGS is further discussed in 
Section 6.5. Of note however, it does need to be considered that in the study of 
Kulunian et al. the genes HERC5, EPSTI and CMPK2 have been used to 
determine the IGS, but at the same time different genes have been used 
including OAS2 to determine the effect of the anti-IFN treatment [63]. As 
introduced in Section 1.4.2, it is essential to keep in mind that there are many 
genes related to and that can form part of an IGS. Different approaches using 
different sets of genes to define an IGS may result in altered outcomes. It may on 
the other hand just be a reflection that IFN patients are more likely to get better 
even with placebo treatment, as seen in the study of Furie et al. (2017) [271].  
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Objective 2: To measure the expression of genes that are involved in the 
modification of DNA and phagocytosis-related genes (PRGs) in neutrophils of  
JSLE patients with their respective IFN subtypes and healthy controls. 
Objective 3: To compare protein expression of PRGs in JSLE neutrophils, and 
their respective IFN subtypes, and healthy paediatric control patient 
neutrophils. 
Besides the described increased IGS expression, there was an increase 
expression observed for genes that are involved in the modification of DNA. 
However, there was an even stronger difference for the increased PGS noted in 
neutrophils of JSLE patients consisting of TLR2, S100A9 and FcRIIIb/CD16b. 
While the increased IGS was only present in JSLE IFN high patients, JSLE IFN low 
patients also showed in part an increased PGS, specifically for TLR2 and 
S100A9. Furthermore, the increased PGS was also present at the protein level. 
However, increased S100A8/S100A9 protein expression may be more related to 
increased disease activity than to IFN low or IFN high status. TLR2 protein was 
highest in JSLE IFN low patients which had higher disease activity, in which 
there may be a direct correlation. This correlation was not further investigated 
due to the small sample size. However, it has been described that TLR2 
activation can increase glycolysis which was also found (see Chapter 3) to be 
increased in JSLE IFN low patients [272]. Pyruvate, which is part of the 
glycolysis pathway, was detected in urine metabolite analyses to be increased in 
JSLE IFN low patients compared to JSLE IFN high patients. However, there was 
no difference in the SLEDAI-scores (average of 9.3 for IFN low / 9.8 for IFN high 
patients). CD16b expression was more dependent on IFN status and therefore, 
CD16b, more specifically serum and intracellular CD16b, could be identifiers for 
IFN high patients. It would require further investigation to validate this finding. 
Intracellular S100A9 protein was increased within neutrophils of JSLE patients, 
independent of IGS stratification. S100A9 protein expression inside neutrophils 
may therefore be a candidate protein helping identify JSLE patients, or may 
simply be a marker for autoimmune diseases in which there is an importance of 
neutrophil involvement. Nevertheless, importantly, for both JSLE and JIA 
patients, S100A9 levels within neutrophils have not previously been reported. It 
239 
 
has to be noted, that S100A9 is important in the disease both alone as S100A9 
and as calprotectin in the S100A8/S100A9. For example, in serum or plasma 
S100A8/S100A9 has been used as a biomarker for disease activity in sJIA [273]. 
In arthritic mice S100A8 and S100A9 have been detected in damaged joints and 
the calprotectin levels in sera of these mice reflected cartilage damage and bone 
erosion. It has also been demonstrated in an arthritis mouse model, that anti-
S100A9 reduces arthritis and inhibits release of pro-inflammatory cytokines. 
Calprotectin is strongly upregulated in sera of these arthritic mice if they were 
not treated with anti-S100A9 [274]. Nonetheless, the specific increased 
expression of intracellular S100A9 within neutrophils has not been previously 
investigated in JIA or JSLE. 
• Objective 3: To investigate the phagocytic ability of JSLE neutrophils 
compared to healthy control neutrophils. 
The PGS of JSLE patients indicated increased phagocytic activity which was 
confirmed with short incubations of 20 min with pHrodo coated bioparticles 
which included S.aureus, E.coli and zymosan. Neutrophils of healthy paediatric 
controls and JSLE patients were investigated together with serum of healthy 
paediatric control patients and showed increased phagocytosis by JSLE 
neutrophils compared to ones of healthy paediatric control patients. 
Unfortunately, it was not possible to undertake further differential investigation 
of phagocytosis in JSLE IFN high and IFN low patients respectively, for a number 
or reasons. Firstly, this was due to not enough JSLE IFN low patients being 
available during the period studied and secondly, because there was no clear 
separation between IFN low and IFN high patients in the number of 
phagocytosed particles identified. Thirdly, the main difference between JSLE 
IFN high and IFN low signatures was in CD16b expression, which is responsible 
for opsonized particles. It was therefore not expected to have a direct effect in 
this assay. 
An important finding from these data identified that JSLE neutrophils were 
observed to be in an activated state, enabling them to respond quicker to 
phagocytic stimuli. Other studies had suggested that after longer incubations 
with bacteria in the presence of JSLE serum, less phagocytosis was observed in 
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patients compared to controls (as discussed in 4.6). This may indicate that there 
are also factors in the serum rather than an intrinsic issue in neutrophils, which 
potentially inhibit phagocytosis and may trigger hyperactive neutrophils to 
undergo NETosis rather than phagocytosis. If this is the case, the data presented 
in this present study indicates that this would be independent of the IFN 
signature observed in patients, and furthermore, could be a contributing factor 
in the underlying disease mechanism for JSLE patients in general. 
Another factor potentially contributing to the serum effects are treatment that 
patients receive. Both cyclophosphamide and prednisolone are considered 
inhibitors of phagocytosis, therefore the incubation without serum and with 
healthy control serum gives specific insight into neutrophil rather than 
medication specific activity [275], [276]. Nonetheless, it is worth mentioning 
that none of the patients who donated blood for the phagocytosis assays was on 
cyclophosphamide and four out of five patients were on prednisolone. 
Therefore higher phagocytic activity is an even more striking finding. 
6.4 The influence of the environment of JSLE neutrophils 
The aim of Chapter 5 was to investigate potential causes of the increased IGS 
and PGS observed in JSLE patients. Potential influences from the neutrophil 
environment in JSLE patients were tested on their influence on the PGS and IGS. 
These included apoptotic supernatant of healthy control neutrophils, 
nucleosomes, IFN and TNF.  
The main objectives were:  
Objective 1: To investigate the impact of the apoptotic environment, 
nucleosomes, IFN and TNF on gene and protein expression of PRGs in 
neutrophils or whole blood. 
FcRIIIb mRNA expression decreased in the presence of apoptotic supernatant 
of neutrophils when PBMCs were present. At the same time, this stimulation 
triggered the shedding of CD16b protein into the supernatant. FcRIIIb/CD16b 
mRNA as well as protein expression was decreased with nucleosome 
stimulations of whole blood but increased with IFN. These results would 
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suggest that JSLE IFN high patients have IFN present and increased cytokines 
from apoptotic supernatant. Nucleosomes induced production of IFN in whole 
blood, but additionally release of up to 1 ng/ml TNF. The combination may 
have inhibited the upregulation of CD16b. Nucleosomes without the presence of 
other cytokines from the apoptotic environment could partly explain CD16b low 
neutrophil signatures in IFN low patients. 
TNF as seen in nucleosome stimulations of whole blood increased TLR2 
protein expression on neutrophils. TLR2 could be high in IFN low patients 
because of the presence of TNF. This cytokine also plays a role in JIA [277] and 
has been proposed to be important for lupus as discussed in Section 1.6.1.2. The 
results of this study showed that TNF is released upon nucleosome stimulation 
and that TLR2, a protein increased by TNF is increased on JSLE patients’ 
neutrophils. These data all support the findings of Chapter 3 that JSLE IFN low 
patients are more similar (from a metabolic perspective) to JIA patients. 
The final protein making up the PGS was S100A9 which was observed to have 
increased protein expression in PBMCs after stimulation with nucleosomes in 
whole blood. Expression was unaffected by any other treatment as well as in 
neutrophils. Nucleosome stimulation triggered release of the bioactive form 
S100A8/S100A9 the source of which may be neutrophils. Despite unchanged 
intracellular protein levels this stimulation may have caused increase of 
calprotectin. Measurement with flow cytometry detected decreased granularity 
after encounter of nucleosomes. Unchanged levels of S100A9 could therefore 
indicate release of preformed granules and replenishment of intracellular 
stores. S100A8/S100A9 has been described to be increased in disease active 
patients [253] and encounter of nucleosomes may therefore be a trigger of 
flares. This coincides with a study reporting nitrated nucleosomes in 63% of all 
patients and serum levels were associated significantly with vasculitis flares 
[278]. 
Objective 2: To measure the influence of the apoptotic environment, 
nucleosomes, IFN and TNF on gene expression of IGS in neutrophils or whole 
blood. 
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The IGS measured in neutrophils was increased by stimulation with IFN. 
Furthermore, apoptotic supernatant increased the IGS, but only when PBCMs 
were present which suggests PBMCs release IFN. Nucleosome stimulation of 
whole blood increased the IGS, too, which was due to IFN-type I. This was 
demonstrated by blocking of IFNAR which normalized the expression of IFN-
induced genes whereas isotype control stimulations with nucleosomes showed 
high IGS. Nucleosomes may be present in apoptotic supernatant causing the IGS 
to rise. Centrifugation of apoptotic supernatant was conducted only below 
113.000xg, the speed necessary to sediment nucleosomes. Summarising the 
results from Chapter 5, the strongest effect on the IGS was seen with stimulation 
of IFN alone. This cytokine can be stimulated by both supernatant of dying, 
uncleared cells or purified nucleosomes. 
While the IGS in this study only comprised JSLE IFN low and IFN high patients, 
there are also studies, for example in adult-onset SLE, describing several disease 
phenotype subtypes which includes differential expression of IFN as well as of 
TNF. These subgroups include: IFN low/TNF low, IFN high/TNF low, IFN 
high/TNF high and IFN low/TNF high [279]. These data support the hypothesis 
resulting from findings of Chapter 3-5, that JSLE patients have a signature 
potentially depending on both IFN and TNF This hypothesis is supported by 
the data in this present study indicating that JSLE IFN low patients may be more 
similar to JIA patients in disease aetiopathogenesis as they show similarities in 
their metabolite and cytokine profiles. As described in Section 1.6.1.2, where the 
role of TNF in SLE has been outlined, both the absence and presence of TNF 
has been assumed to play a role in SLE disease pathogenesis [126]–[128]. The 
occurrence of patients in different subgroups of expression of TNF as TNF 
high and TNF low patients may explain controversial findings that both the 
absence and presence of TNF can induce SLE. IFN expression and IFN-
inducible genes have been shown to increase upon blockade of TNF with 
etanercept in healthy PBMCs in vitro [280]. Addition of TNF to these cultures 
with etanercept reversed the effect and reduced expression of IFN and its 
inducible genes [280]. Presence of TNF in JSLE IFN low patients could 
therefore explain the absence of an increased IGS. Pre-incubation with IFN on 
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the other hand can inhibit TNF production of macrophages stimulated via 
TLR2, TLR4 or FcR [281]. A disproportion of either TNF or IFN may 
suppress the respective other cytokine leading to even stronger imbalance and 
resulting in IFN low or IFN high JSLE patients. 
 
6.5 Future directions 
Urine has been identified in this study as an accessible and useful biofluid to 
help establish a model of distinguishing metabolite profiles of patients with 
autoimmune diseases from healthy paediatric patients. However, it has also 
been shown to be quite a laborious process with the associated analysis, which 
may prevent its future development, validation and potential implementation 
into routine use. A study with an increased number of JIA and JSLE patients 
including investigating the expression of different IFN subtypes would first need 
to confirm the observed separations within the urine and serum models. These 
would then need to be validated in independent cohorts. From here, the 
metabolites most differentially expressed between the groups, and at the same 
time most influential on the PLS-DA model, would need to be determined. This 
would then allow samples to be compared solely for peaks relating to these 
specific metabolites, which would drastically reduce analysis time. 
Metabolomic pathway analysis revealed that JSLE IFN low patients were more 
similar to JIA patients than JSLE IFN high patients. One reason could be, that 
most of the JIA patients are IFN low, as described in Section 3.5. A comparison of 
metabolite profiles of more IFN low patients from JSLE and JIA patients could 
help distinguish if the similarity in metabolite signature found in this thesis is 
IFN low signature specific or may have been related to disease activity for 
example. 
Besides the metabolite signature in urine and serum, the IGS was also 
investigated in the JSLE cohort. It was found that of the four selected genes, only 
OAS2, IFI44L and LY6E could be correlated to each other, whereas it was not 
possible to correlate IFI6 to any of the three other IFN-induced genes. In this 
study, one example of an IGS has been investigated. However, there may be 
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different IGS with different implications. Initially, IFI44L, OAS2, LY6E and IFI6 
were used in this study as part of the IGS (IFI6 excluded after further analysis). 
Each of the four genes had been part of an IGS in other studies, but not in 
combination [57], [63], [64], [68]. While Rice et al. included IFI27, IFIT1, ISG15, 
RSAD2 and SIGLEC1 besides IFI44L, Kalunian et al. measured changes in IGS 
with IFI27, IFI44, IFIT1, MX1, OAS1 and OAS3 alongside OAS2. Other than LY6E 
Feng et al. initially tested expression of OAS1, OAS2, OASL, IFIT1, IFIT4, IFI44, 
STAT1, ISG15, MX1, MX2, PLSCR1, XIAPaf1, and IRF7 as part of an IGS, but 
found, that several of those were dependent on each other. They subsequently 
reduced their IGS to only LY6E, OAS1, OASL, MX1 and ISG15. In their paper they 
also showed that there are strong differences between the diseases, but they did 
not test if the genes correlated within one disease [68]. El-Sherbiny et al.’s IGS 
contained IFI6 and IFI44L, together with ISG15, IFI44, IFI27, CXCL10, RSAD2, 
IFIT, CCL8, XAF1, GBP1, IRF7, CEACAM1, HERC5, EIF2AK2 and MX1. This study 
focused on the analysis of samples of different diseases, namely RA, SLE and 
undifferentiated connective tissue disease (UCTD) [64]. Each of these diseases 
may have a different IGS and be dependent on various factors including several 
different cytokines. The IGS cluster chosen may therefore be reflective of the 
disease with most samples, which was UCTD. Correlations studies of IFN-
induced genes for a big group of patients may help elucidate influence of genes 
on each other and can help find disease specific IGS. This approach should also 
include other signatures, like the PGS and TNF, to really define patient 
subgroups with potentially different underlying disease mechanisms. 
Besides the importance of the IGS noted in this present study, a PGS has also 
been observed to be important, with increased phagocytic activity in JSLE 
patients compared to healthy paediatric control patients. A future study should 
look at healthy paediatric and JSLE neutrophils incubated with bacteria and 
JSLE serum. JSLE serum may inhibit phagocytosis leading to NETosis instead. 
This may be further increased in neutrophils of JSLE patients due to their 
increased activity to phagocytose seen in the presence of serum of healthy 
paediatric control patients. This could explain disease development and should 
therefore be investigated further. 
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6.6 Limitations 
JSLE being a rare disease and IFN low patients being uncommon in JSLE led to 
low sample numbers for all assays and no possibility to age and sex-match 
patients. Therefore, all results have to be treated with caution and statistical 
significance may not have been reached despite a biological difference. 
Furthermore, while it was possible to retrieve information about disease 
activity scores for most patients, any missing information may result in missed 
links between measured markers and disease activity.  
Additionally, analysis of metabolite profiles of serum may not show the full 
picture of disease and health. Metabolites can have several peaks and observed 
separation can be biased by one metabolite causing a high percentage of the 
separation as all peaks would change simultaneously. Furthermore, statistical 
analysis is very strict due to the high number of peaks resulting from good 
assignment and annotation of metabolites. In this thesis, results of non-adjusted 
p-values were considered sufficient for further analysis. Nevertheless, this may 
also cause false-positive results. Similarly, no annotation of peaks leads to loss 
of data and informative differences may therefore not have been observed in 
this study. Peaks annotated by Chenomx Profiler® as Ethanol for example were 
excluded as discussed in Section 3.3.2, but it still remains an option that there is 
additional information in this data. Ethanol could be produced by the gut 
microbiota [282] and thereby affect serum levels and health of patients. 
Furthermore, in the metabolomics studies, JIA patients were included in the 
analysis, but no data on their IFN subtypes was available. It was assumed that 
they were mostly IFN low patients as described [57]. It can therefore not be 
distinguished if similarity between JSLE IFN low and JIA patients was due to the 
IFN signatures or to causes in disease. Nevertheless, findings that upregulation 
of TLR2 as seen in IFN low patients could be caused by TNF (Chapter 5) 
supports the hypothesis that factors are in the cell environment of JIA and JSLE 
IFN low patients are comparable. 
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Nucleosome stimulations of whole blood showed that TNF was released and 
can play a role in JSLE. Subsequently, only stimulations of TNF and IFN alone 
have been studied, but a combination of both may show a profile more similar 
to JSLE IFN low patients. As described in [283], cytokines can act synergistically 
and can cause changes that are only observed when both cytokines are present. 
Moreover, only effects of IFN were studied, but yet other type-I IFNs or type-II 
or –III IFNs may also play a role and influence the IGS and PGS. TLR2 for 
example was measured to be increased in keratinocytes after a stimulation with 
IFN, the type-II IFN [284]. Furthermore, even though altered pathways have 
not been investigated, stimulation of murine bone marrow derived 
macrophages with IFN resulted in increased phagocytosis of latex particles 
[285].  
Nucleosomes were used for stimulations resulting in differences for the IGS and 
PGS, but in diseases nucleosomes are often modified upon release. For NETosis 
neutrophils alter their histones with peptidylarginine deiminase 4 (PAD4) 
which converts arginine into citrulline and thereby decondensates the 
chromatin [286]. Anti-citrulline antibodies have been found in RA sera which 
suggested that these modified proteins are stimuli for the immune system [287]. 
Results may differ strongly with different types of nucleosomes, although IGS 
induction should remain high as this is a natural response to dsDNA. Especially 
evaluation of PGS upon stimulation with modified nucleosomes would be 
valuable. 
The functional effects of the PGS have been studied with pHrodo coated 
particles and increased phagocytosis was found. However, uptake of life 
bacteria may give different results and bacterial killing also remains to be 
evaluated.  
The main studied cell type were neutrophils and several dysregulations and 
differences to healthy paediatric patients were found. Nevertheless, also LDGs 
were mentioned to play a role in JSLE. Metabolite profiles described in Chapter 
3 were created from serum and urine and metabolites of LDGs can contribute to 
these profiles. However, very few metabolomic studies look at specific cell 
247 
 
subsets [226] and no study has been found that looks at LDGs. This entire 
subset of neutrophils was not addressed in the investigations outlined in 
Chapters 4 and 5. Gene expression, protein expression and functional assays 
investigated in Chapter 4 were limited to normal density granulocytes as cells 
were obtained by Histopaque separation. LDGs are more likely to undergo 
NETosis and are considered to be in a more activated state than normal density 
granulocytes [237]. While in this thesis neutrophils were found to be strongly 
activated to phagocytose, LDGs have been described to be impaired in 
phagocytosis which may influence the likeliness of NETosis [145]. A cause for 
the development of LDGs is not known and they are less frequent in healthy 
controls compared to JSLE patients [159]. In Chapter 5, blood from healthy 
controls was used and LDGs were therefore not further investigated. 
 
6.7 Implications of findings 
Despite low numbers of samples from patients, comparison of metabolite 
profiles from urine was superior to comparison of metabolite profiles from 
serum in distinguishing between diseases and their subgroups. As mentioned in 
Section 1.5.3, urine is commonly used for distinguishing between active and 
inactive and the different stages of nephritis. The results from this thesis 
support the position that to determine metabolite profiles of urine (instead of 
serum) may also be a tool for investigation of disease pathogenesis, 
stratification of patients and potentially biomarker discovery for JIA and JSLE.  
In this study another novel finding was the increased protein expression of 
S100A9 within neutrophils of JSLE patients compared to healthy paediatric 
controls. Even though this may help to distinguish JSLE patients from healthy 
children and potentially (but not investigated here) from other diseases, 
intracellular protein expression of neutrophils is not a test which could be 
performed routinely as a diagnostic test. Nevertheless, decreasing S100A9 
production in JSLE could be a therapeutic target and prevent flares as increased 
release has been associated with higher disease activity as discussed in Section 
6.4. 
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Lastly, JSLE IFN high patients showed to be distinctly different compared to 
JSLE IFN low patients and healthy paediatric controls in their metabolite profile, 
in their IGS and their PGS. Consequently, for studies investigating JSLE and its 
treatment options, and not solely for anti-IFN treatment, patients should be 
stratified into subgroups when a study is being set up and when results are 
being analysed. 
 
6.8 Final conclusions 
This thesis presents evidence that specific neutrophil signatures are present in 
patients with autoimmune diseases like JIA and JSLE. Metabolite profiles of 
serum and urine show pathways like the PPP to be upregulated which support 
neutrophil activity especially phagocytosis, and the urea cycle indicating 
increased NETosis. The IFN-induced gene signature measured in the cohort of 
JSLE patients in this study has been found not to change over time, if a strict 
selection of genes is used which includes only the correlating ones, namely 
IFI44L, OAS2 and LY6E. For the first time JSLE patients were shown to have a 
phagocytosis-related gene signature which comprised of TLR2, S100A9 and 
FcRIIIb/CD16b. Differences of FcRIIIb/CD16b were only found in JSLE IFN 
high patients compared to IFN low and healthy paediatric control patients. 
Importantly, the PGS was translated into protein and functional assays revealed 
JSLE neutrophils to be enhanced in phagocytosis. This was a novel finding, as 
functional assays with JSLE serum and/or long incubation times have given the 
impression that neutrophils were impaired in phagocytosis. In this study 
apoptotic supernatant and nucleosome stimulation, both present in the JSLE 
environment, displayed effects on neutrophils causing both the IGS and PGS to 
become more similar to the JSLE signatures than to the one in healthy paediatric 
children. The two main cytokines found to play a role were IFN and TNF.  
Interestingly, findings within this thesis suggest that JSLE IFN low patients have 
more in common with JIA patients than JSLE IFN high patients do, for example 
their metabolite profiles. High TLR2 in JSLE IFN low patients may further 
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suggest that JIA and JSLE IFN low patients have a similar involvement of cells 
and cytokine. This hypothesis remains to be tested further. 
 
To conclude, this study has demonstrated that it is possible to stratify JSLE 
patients by their metabolite profiles in serum, urine and by both phagocytic and 
IFN-induced gene signatures present in neutrophils. Furthermore, it has shown 
that the PGS is visible in the phagocytic activity of PMN of JSLE patients and 
variation of signature expression are caused in part at least by variations in the 
environment in which PMNs find themselves. 
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Appendix B: Reagents 
Appendix 1.1: Assay materials 
Material – plastic ware Supplier 
1.5 ml tubes Fisher scientific, UK 
5 ml tubes Fisher scientific, UK 
10 ml tubes Fisher scientific, UK 
25 ml universals Fisher scientific, UK 
50 ml falcon Starlab, UK 
5, 10, 25 ml stripette Fisher scientific, UK 
Transfer pipette PE Fisher scientific, UK 
Tips (10, 20, 200, 1000) Starlab/ Fisher scientific, 
UK 
24-well plates Fisher scientific, UK 
96-well round bottom plates Fisher scientific, UK 
Corning™ Clear Polystyrene 96-Well Microplates Fisher scientific, UK 
Cover Slips 13mm diameter Appleton Woods 
Microscope slide Fisher scientific, UK 
Test tube 12x75mm Elkay, UK 
Syringe-drive filter unit, 0.22 m Millex-GP, UK 
  
Appendix - Table 1: Plasticware used for experiments. 
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Material – sample collection Supplier 
Micro tube 1.3ml Z Sarstedt, Germany 
Lithium heparin vacutainer  Sarstedt, Germany 
Scalp vein set  Nipro, UK 
10 ml, 20 ml Syringe BD Plastipak, UK 
Appendix - Table 2: Materials used for collection of blood. 
 
Material – Cell isolation and incubations Supplier 
HetaSep Stemcell, UK 
PBS Fisher, UK 
Roswell Park Memorial Institute 1640 (RPMI-
1640) with L-Glutamine 
Lonza, Belgium 
Histopaque-1077 Sigma-Aldrich, UK 
Ammonium chloride Sigma-Aldrich, UK 
EDTA Fisher, UK 
Potassium Bicarbonate Sigma-Aldrich, UK 
EasySepTM Buffer  Stemcell, UK 
EasySep™ Human Neutrophil Enrichment Kit  
- EasySep™ Human Neutrophil Enrichment 
Cocktail 
- EasySep™ Magnetic Particles 
Stemcell, UK 
Foetal bovine serum (FBS) Life Technologies, UK 
Recombinant GM-CSF R&D Systems, UK 
Recombinant IFN PeproTech, UK 
Recombinant TNF PeproTech, UK 
Appendix - Table 3: Materials used for cell isolation and stimulation. 
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Material – real-time PCR Supplier 
TRIzol Life technologies 
(Molecular probes), UK 
RNeasy Mini Kit 
- RNeasy Mini Spin Columns 
- Collection Tubes (1.5 ml) 
- Collection Tubes (2 ml) 
- Buffer RLT 
- Buffer RW1 
- Buffer RPE 
- RNase-Free Water 
Qiagen, Germany 
Chloroform Sigma-Aldrich, UK 
Isopropanol Sigma-Aldrich, UK 
Ethanol University of Liverpool 
RNase-free DNase set 
- Lyophilized DNase 
- Nuclease-free water 
- RDD-Buffer 
Qiagen, Germany 
AffinityScript QPCR cDNA Synthesis Kit  
-      10X AffinityScript RT buffer 
-      dNTP mix 
-      RNAse block RNAse inhibitor 
-      AffinityScript RTase 
Agilent Technologies, USA 
Brilliant II SYBR® Green QPCR Master Mix 
- 2× Brilliant II SYBR® Green QPCR Master Mix 
- ROX dye, 1 mM 
Agilent Technologies, USA 
PrecisionTM Reverse Transcription Premix 2 Primerdesign, UK 
RT negative control premix Primerdesign, UK 
Precision®PLUS qPCR Master Mix for the 
Stratagene with SYBR-Green 
Primerdesign, UK 
Optical Tube and Cap 8xstrip Agilent Technologies, USA 
BrightWhite qPCR Plates Primerdesign, UK 
Appendix - Table4: Materials used for real-time PCR. 
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Material – Flow cytometry Supplier 
Annexin V-FITC Apoptosis Detection  
- Annexin V-FITC Conjugate 
- Propidium Iodide Solution 
- 10x Binding buffer 
Sigma, USA 
Paraformaldehyde 37% Sigma-Aldrich, UK 
Triton-X 100 BDH Limited Poole 
England, UK 
Appendix - Table 5: Materials used in flow cytometric assays. 
 
Materials – phagocytosis assay Supplier 
pHrodo™ Red S. aureus BioParticles® Conjugate Life technologies 
(Molecular probes), UK 
pHrodo™ Red E.coli BioParticles® Conjugate Life technologies 
(Molecular probes), UK 
pHrodo™ Red Zymosan A BioParticles® Conjugate Life technologies 
(Molecular probes), UK 
HBSS Sigma-Aldrich, UK 
HEPES BDH Limited Poole 
England, UK 
Tris-Base Fisher scientific, UK 
NaCl Fisher scientific, UK 
ProLong™ Gold Antifade Mountant with DAPI Invitrogen, Fisher 
Scientific, USA 
Appendix - Table 6: Materials used to investigate phagocytosis. 
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Materials – whole blood assay Supplier 
2.0ml Graduated, Skirted Tube, Natural EasyGrip 
Cap (Sterile) 
Starlab, UK 
Native nucleosome (HEK293-derived) AMS Biotechnology, 
UK 
SigmaUltra Sucrose Sigma-Aldrich, UK 
Chicken Blood Cells (Adult) in Alsever's TCS Biosciences Ltd, 
UK 
BD FACS™ Lysing Solution BD Biosciences, UK 
Brefeldin A Solution 1000x Invitrogen, Fisher 
Scientific, USA 
Appendix - Table 7: Materials used for whole blood assays. 
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Materials ELISA Supplier 
ELISA kit FCGR3b 
- FCGR3B Microplate 96 Wells 
- FCGR3B Lyophilized Standard 
- 100X Biotinylated FCGR3B Detector Antibody 
- 100X Avidin-HRP Conjugate 
- Sample Diluent 
- Detector Antibody Diluent 
- Conjugate Diluent 
- 25X Wash Buffer 
- Stop Solution 
- TMB Substrate 
 
Aviva Systems 
Biology, USA 
DuoSet® ELISA human S100A9, 
S100A8/S100A9  
- Capture Antibody 
- Human S100A9, S100A8/S100A9 
Standard 
- Detection Antibody 
- Streptavidin-HRP 
 
R&D systems, UK 
BSA Sigma-Aldrich, UK 
TMB Substrate Reagent Set 
- Hydrogen peroxide (H2O2) 
- 3,3', 5,5' tetramethylbenzidine (Substrate B) 
BD Biosciences, UK 
H2SO4 BDH Limited Poole 
England, UK 
Appendix - Table 8: Materials used for ELISAs. 
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Appendix 1.2: List of antibodies 
All antibodies were mouse anti-human antibodies, supplied by BD Biosciences, 
UK if not stated otherwise. 
Antigen Dye Fc-part Dilution 
TLR2 PE IgG1, κ 1:40 
CD16b FITC IgG2a, κ 1:10 
Isotype  FITC IgG2a, κ 1:10 
Isotype 
(extracellular) 
PE IgG1, κ 1:80 
S100A9 PE IgG1, κ 1:20 
Isotype 
(intracellular) 
PE IgG1, κ 1:80  
Appendix - Table 9: Antibodies used for flow cytometry and 
immunohistochemistry. 
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Appendix C: Metabolite profiles 
Appendix 1.1: Pattern file for serum referenced to glucose 
PATTERN       = 1 human 
serum   
GROUP         =    
DESCRIPTION   = serum pattern file glucose referenced 
AUTHOR        =   Anna   
DIM           = 2   
ORIGIN        = 1   
ITEMS         = 279   
0 0 8.4644 8.4569    0 Formate.1 
0 0 8.2378 8.2327    0 UNID.2 
0 0 8.2077 8.183    0 Hypoxanthine.3 
0 0 7.9092 7.8767    0 UNID.4 
0 0 7.8767 7.843    0 UNID.5 
0 0 7.843 7.8276    0 UNID.6 
0 0 7.8276 7.7812    0 Histidine|UNID.7 
0 0 7.7812 7.7607    0 UNID.8 
0 0 7.7607 7.7467    0 UNID.9 
0 0 7.7033 7.6808    0 UNID.10 
0 0 7.6808 7.6678    0 Tau-Methylhistidine.11 
0 0 7.446 7.4066    0 Phenylalanine.12 
0 0 7.3897 7.3809    0 UNID.13 
0 0 7.3809 7.3693    0 N-Acetylserotonin|Phenylalanine.14 
0 0 7.3693 7.3552    0 Phenylalanine|N-Acetylserotonin.15 
0 0 7.3552 7.3439    0 UNID.16 
0 0 7.3439 7.3141    0 Phenylalanine|UNID.17 
0 0 7.296 7.2821    0 UNID.18 
0 0 7.2699 7.2558    0 UNID.19 
0 0 7.2558 7.2405    0 UNID.20 
0 0 7.2405 7.226    0 UNID.21 
0 0 7.226 7.213    0 UNID.22 
0 0 7.2106 7.1808    0 Tyrosine.23 
0 0 7.1802 7.1713    0 UNID.24 
0 0 7.1622 7.1509    0 UNID.25 
0 0 7.1509 7.1391    0 UNID.26 
0 0 7.1391 7.1302    0 UNID.27 
0 0 7.0788 7.0629    0 UNID|Histidine.28 
0 0 7.0553 7.0222    0 UNID.29 
0 0 7.0222 7.0047    0 UNID.30 
0 0 7.0047 6.9961    0 UNID.31 
0 0 6.9961 6.9862    0 UNID.32 
0 0 6.9765 6.9601    0 UNID.33 
0 0 6.9601 6.9431    0 UNID.34 
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0 0 6.9291 6.9183    0 UNID.35 
0 0 6.9273 6.8928    0 Tyrosine.36 
0 0 6.8928 6.886    0 UNID.37 
0 0 6.7512 6.7399    0 UNID.38 
0 0 6.7399 6.7326    0 UNID.39 
0 0 5.387 5.3792    0 UNID.40 
0 0 5.3792 5.373    0 UNID.41 
0 0 5.3636 5.2486    0 mobile_unsaturated_lipids.42 
0 0 5.2486 5.2295    0 Glucose.43 
0 0 5.2203 5.2136    0 UNID.44 
0 0 5.2136 5.2037    0 UNID.45 
0 0 5.2037 5.1948    0 UNID.46 
0 0 5.1948 5.1845    0 UNID|Mannose.47 
0 0 4.9089 4.8994    0 Mannose.48 
0 0 4.4795 4.4299    0 UNID.49 
0 0 4.3849 4.3699    0 UNID.50 
0 0 4.3699 4.3614    0 UNID.51 
0 0 4.2937 4.286    0 UNID.52 
0 0 4.286 4.2798    0 UNID.53 
0 0 4.2798 4.2719    0 UNID.54 
0 0 4.2719 4.2662    0 UNID.55 
0 0 4.2662 4.2594    0 UNID.56 
0 0 4.2571 4.2526    0 Threonine.57 
0 0 4.2526 4.2486    0 Threonine.58 
0 0 4.2455 4.2413    0 Threonine.59 
0 0 4.1708 4.1657    0 UNID.60 
0 0 4.1614 4.1529    0 UNID.61 
0 0 4.1529 4.143    0 UNID.62 
0 0 4.1376 4.1339    0 UNID.63 
0 0 4.1344 4.094    0 Lactate.64 
0 0 4.094 4.0855    0 UNID.65 
0 0 4.0855 4.0776    0 UNID.66 
0 0 4.0776 4.0739    0 UNID.67 
0 0 4.0739 4.0671    0 UNID.68 
0 0 4.066 4.0603    0 UNID|myo-Inositol.69 
0 0 4.0586 4.0504    0 Creatinine.70 
0 0 4.0139 4.0075    0 UNID.71 
0 0 4.0075 4.0007    0 UNID|Arabinose.72 
0 0 4.0007 3.9952    0 UNID|Histidine.73 
0 0 3.9925 3.9866    0 UNID.74 
0 0 3.9866 3.9811    0 UNID|Histidine.75 
0 0 3.9811 3.9761    0 UNID|Histidine.76 
0 0 3.9738 3.9665    0 UNID.77 
0 0 3.9665 3.9601    0 UNID.78 
0 0 3.9574 3.951    0 Creatine_phosphate.79 
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0 0 3.9401 3.9359    0 UNID.80 
0 0 3.9359 3.9318    0 UNID|Mannose.81 
0 0 3.9318 3.9255    0 Creatine|Mannose.82 
0 0 3.9203 3.887    0 Glucose.83 
0 0 3.8816 3.8715    0 UNID.84 
0 0 3.8718 3.8663    0 UNID.85 
0 0 3.8636 3.853    0 Glucose.86 
0 0 3.8517 3.8466    0 UNID.87 
0 0 3.847 3.8143    0 Glucose.88 
0 0 3.8124 3.8096    0 UNID.89 
0 0 3.8096 3.8067    0 UNID.90 
0 0 3.8058 3.8016    0 N-Nitrosodimethylamine.91 
0 0 3.8018 3.798    0 UNID.92 
0 0 3.7985 3.7944    0 Alanine.93 
0 0 3.7943 3.7904    0 Guanidoacetate|Arginine.94 
0 0 3.7903 3.7804    0 Glucose|Glycerol.95 
0 0 3.7804 3.7731    0 Glucose|Glycerol.96 
0 0 3.7731 3.7711    0 UNID.97 
0 0 3.7711 3.7343    0 Glucose.98 
0 0 3.7332 3.731    0 UNID.99 
0 0 3.7302 3.715    0 Glucose.100 
0 0 3.7165 3.7113    0 UNID.101 
0 0 3.7108 3.7034    0 Glucose.102 
0 0 3.6925 3.687    0 UNID.103 
0 0 3.6793 3.6757    0 UNID.104 
0 0 3.6757 3.6707    0 Glycerol.105 
0 0 3.6685 3.6623    0 UNID.106 
0 0 3.6563 3.6511    0 UNID.107 
0 0 3.6501 3.6448    0 Glycerol.108 
0 0 3.6448 3.6403    0 UNID.109 
0 0 3.6352 3.6295    0 UNID.110 
0 0 3.6224 3.6185    0 myo-Inositol.111 
0 0 3.6185 3.6137    0 Valine.112 
0 0 3.6137 3.606    0 Valine.113 
0 0 3.6063 3.6037    0 UNID.114 
0 0 3.6037 3.5998    0 UNID.115 
0 0 3.5975 3.5941    0 UNID.116 
0 0 3.5941 3.5884    0 Threonine.117 
0 0 3.5884 3.5833    0 Glycerol.118 
0 0 3.5833 3.5797    0 UNID.119 
0 0 3.5797 3.576    0 UNID.120 
0 0 3.576 3.5712    0 Glycerol.121 
0 0 3.5689 3.5659    0 Glycine|Glycerol.122 
0 0 3.5569 3.5513    0 Glucose|Glycerol.123 
0 0 3.5513 3.4506    0 Glucose.124 
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0 0 3.4501 3.4447    0 Acetoacetate|UNID.125 
0 0 3.4447 3.4414    0 UNID.126 
0 0 3.4407 3.4255    0 Glucose.127 
0 0 3.4255 3.4171    0 Glucose|UNID.128 
0 0 3.4154 3.3941    0 Glucose.129 
0 0 3.3884 3.384    0 UNID.130 
0 0 3.384 3.3783    0 UNID.131 
0 0 3.3783 3.374    0 UNID.132 
0 0 3.368 3.3616    0 Methanol.133 
0 0 3.3616 3.3576    0 UNID.134 
0 0 3.3576 3.3528    0 UNID.135 
0 0 3.3456 3.3398    0 UNID.136 
0 0 3.3369 3.3318    0 UNID.137 
0 0 3.3256 3.3188    0 UNID.138 
0 0 3.3086 3.3041    0 myo-Inositol.139 
0 0 3.2985 3.2936    0 UNID|Histamine.140 
0 0 3.2936 3.2877    0 myo-Inositol.141 
0 0 3.2809 3.2746    0 UNID.142 
0 0 3.2746 3.2695    0 UNID.143 
0 0 3.2695 3.2653    0 Glucose.144 
0 0 3.2653 3.2608    0 Betaine|Glucose.145 
0 0 3.2598 3.2494    0 Trimethylamine_N-oxide|Glucose.146 
0 0 3.2483 3.2443    0 UNID|Arginine.147 
0 0 3.2415 3.2355    0 Glucose.148 
0 0 3.2282 3.2214    0 UNID.149 
0 0 3.2214 3.1953    0 Mobile-N(CH3)3.150 
0 0 3.1953 3.1865 
   0 Mobile-N(CH3)3|glycerol-
phosphocholine.151 
0 0 3.1732 3.1676    0 UNID.152 
0 0 3.1571 3.1528    0 N-Nitrosodimethylamine.153 
0 0 3.1528 3.1373    0 UNID|Histidine.154 
0 0 3.133 3.1265    0 UNID|Histidine.155 
0 0 3.1183 3.1112    0 UNID|Histidine.156 
0 0 3.1112 3.1038    0 UNID.157 
0 0 3.0769 3.0713    0 Ornithine.158 
0 0 3.0713 3.0662    0 UNID.159 
0 0 3.0636 3.0571    0 Ornithine.160 
0 0 3.0506 3.0427 
   0 
Creatinine|Lysine|Creatine_phosphate.161 
0 0 3.0427 3.0373    0 Creatine.162 
0 0 3.0373 3.0291    0 Lysine.163 
0 0 3.0291 3.0152    0 UNID|Lysine.164 
0 0 3.0152 3.0024    0 UNID.165 
0 0 3.0024 2.9917    0 UNID.166 
0 0 2.9707 2.9625    0 UNID.167 
0 0 2.9625 2.9552    0 UNID.168 
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0 0 2.9416 2.935    0 Asparagine.169 
0 0 2.9336 2.9305    0 Asparagine.170 
0 0 2.9305 2.9248    0 UNID.171 
0 0 2.9186 2.9064    0 UNID.172 
0 0 2.8923 2.8869    0 UNID.173 
0 0 2.8713 2.8645    0 Asparagine.174 
0 0 2.8645 2.8597    0 UNID.175 
0 0 2.858 2.8538    0 Asparagine.176 
0 0 2.845 2.8385    0 UNID.177 
0 0 2.8051 2.712    0 Polyunsaturated_fatty_acids.178 
0 0 2.6898 2.6813    0 Citrate.179 
0 0 2.6629 2.6564    0 Citrate.180 
0 0 2.6517 2.6453    0 Methionine.181   
0 0 2.6385 2.6325    0 Methionine.182 
0 0 2.553 2.545    0 Citrate.183 
0 0 2.5377 2.5295    0 Isocitrate.184 
0 0 2.5258 2.5197    0 Citrate.185 
0 0 2.5111 2.5054    0 UNID.186 
0 0 2.5054 2.4997    0 UNID|Glutamine.187 
0 0 2.4955 2.4847    0 UNID|Glutamine.188 
0 0 2.4815 2.4327    0 Glutamine.189 
0 0 2.4327 2.4263    0 UNID.190 
0 0 2.4263 2.4219    0 UNID.191 
0 0 2.4219 2.4163    0 UNID.192 
0 0 2.4163 2.4111    0 Succinylacetone.193 
0 0 2.4082 2.4017    0 Succinylacetone|UNID.194 
0 0 2.4017 2.3969    0 UNID.195 
0 0 2.3969 2.391    0 UNID.196 
0 0 2.3839 2.3762    0 UNID.197 
0 0 2.3762 2.3694    0 Pyruvate|Glutamate.198 
0 0 2.3694 2.3655    0 UNID.199 
0 0 2.3626 2.339    0 UNID|Glutamate.200 
0 0 2.3339 2.3299    0 UNID.201 
0 0 2.3303 2.3268    0 UNID.202 
0 0 2.3193 2.3139    0 UNID.203 
0 0 2.3136 2.3091    0 UNID.204 
0 0 2.3091 2.3084    0 UNID.205 
0 0 2.3084 2.2979    0 UNID.206 
0 0 2.2979 2.2934    0 UNID.207 
0 0 2.2934 2.2893    0 UNID.208  
0 0 2.2851 2.2774    0 Acetoacetate.209 
0 0 2.2774 2.2725    0 UNID|Succinylacetone.210 
0 0 2.2725 2.2707    0 UNID|Valine.211 
0 0 2.2703 2.2647    0 UNID|Valine.212 
0 0 2.266 2.2615    0 UNID|Valine.213 
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0 0 2.2615 2.225    0 LIPID_hOOC-CH2|Acetone.214 
0 0 2.1862 2.1811    0 UNID.215 
0 0 2.176 2.172    0 UNID.216 
0 0 2.172 2.1689    0 UNID.217 
0 0 2.1678 2.163    0 UNID.218 
0 0 2.163 2.1567    0 Glutamine|UNID.219 
0 0 2.1533 2.1463    0 Glutamine|O-Acetylcholine.220 
0 0 2.1463 2.14    0 UNID|Glutamine.221 
0 0 2.14 2.1352    0 Glutamine.222 
0 0 2.1352 2.1083    0 UNID|Glutamine|Methionine.223 
0 0 2.1083 2.1041    0 UNID.224 
0 0 2.1041 2.099    0 UNID.225 
0 0 2.099 2.0953    0 UNID.226 
0 0 2.0933 2.0621    0 UNID.227 
0 0 2.0607 2.0296    0 Glycoprotein.228 
0 0 2.0296 1.9997    0 LIPID_FA_=Ch-CH2-CH2-.229 
0 0 1.9341 1.9285    0 Arginine|Lysine.230 
0 0 1.9219 1.9166    0 Acetate.231 
0 0 1.9166 1.912    0 Arginine.232 
0 0 1.9081 1.9001    0 Arginine|Lysine|N-Acetylserotonin.233 
0 0 1.8976 1.8914    0 Lysine.234 
0 0 1.8894 1.8831    0 Lysine.235 
0 0 1.7616 1.7557    0 UNID.236 
0 0 1.7557 1.7518    0 UNID.237 
0 0 1.7518 1.6666    0 Leucine|Arginine|Lysine.238 
0 0 1.6666 1.661    0 UNID.239 
0 0 1.661 1.6559    0 UNID.240 
0 0 1.6502 1.643    0 UNID.241 
0 0 1.6381 1.6328    0 UNID.242 
0 0 1.6171 1.5335    0 Lipid_dolichol.243 
0 0 1.4932 1.4708    0 Alanine.244 
0 0 1.4429 1.4377    0 UNID.245 
0 0 1.4377 1.4339    0 UNID.246 
0 0 1.4303 1.4254    0 UNID.247 
0 0 1.4254 1.417    0 UNID.248 
0 0 1.4118 1.408    0 UNID.249 
0 0 1.408 1.4023    0 UNID.250 
0 0 1.3977 1.3913    0 UNID.251 
0 0 1.3389 1.3169    0 Lactate.252 
0 0 1.3166 1.2504    0 mobile_lipid.253 
0 0 1.2504 1.2453    0 UNID.254 
0 0 1.2412 1.2373    0 UNID.255 
0 0 1.2063 1.2024    0 UNID.256 
0 0 1.1997 1.1799    0 Ethanol.257 
0 0 1.1799 1.1752    0 UNID.258 
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0 0 1.1752 1.1696    0 Ethanol.259 
0 0 1.1696 1.1647    0 UNID.260 
0 0 1.1516 1.1367    0 Propylene_glycol.261 
0 0 1.0908 1.0872    0 UNID.262 
0 0 1.0806 1.0749    0 Methylsuccinate|UNID.263 
0 0 1.0677 1.0636    0 Methylsuccinate.264 
0 0 1.0508 1.0321    0 Valine.265 
0 0 1.0174 1.0007    0 Isoleucine.266 
0 0 1.0007 0.9836    0 Valine.267 
0 0 0.9836 0.9794    0 UNID.268 
0 0 0.9743 0.9666    0 Leucine.269 
0 0 0.9666 0.9571    0 Leucine|UNID.270 
0 0 0.9571 0.9528    0 UNID.271 
0 0 0.9528 0.9474    0 Leucine|Isoleucine.272 
0 0 0.941 0.9345    0 UNID|Isoleucine.273 
0 0 0.9281 0.9235    0 UNID|Isoleucine.274 
0 0 0.9203 0.9074    0 UNID.275 
0 0 0.8995 0.786    0 LDL-mobile_lipid-CH3.276 
0 0 0.7112 0.6898    0 UNID.277 
0 0 0.6768 0.646    0 UNID.278 
0 0 0.1641 0.1591    0 UNID.279 
Appendix - Table 10: Pattern file for serum referenced to glucose. 
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Appendix 1.2: Confidence table of serum metabolites 
 
METABOLITE TOTAL 
ASSIGNED 
FEATURES 
OVERLAPPED NON-
OVERLAPPED 
NOTED PEAKS PER FEATURE ASSIGNMENT 
CONFIDENCE 
ACETATE 1 0 1 1 low 
ACETOACETATE 2 1 1 1 low 
ALANINE 2 1 1 4 (quadruplet), 2 (doublet) medium 
ARGININE 6 6 0 3 (triplet), 3 (triplet), multiplets low 
ASPARAGINE 4 2 1 4 (quadruplet) medium 
BETAINE 2 2 
 
1 low 
CITRATE 4 2 2 1 (parts of two doublets) high 
CREATINE PHOSPHATE 2 2 
 
1 low 
CREATINE 2 2 
 
1 low 
CREATININE 2 1 1 1 low 
FORMATE 1 0 1 1 low 
GLUCOSE 17 8 9 2 (doublet), 2 (quadruplet),1 (triplet), 2 
(triplet), 4 (quadruplet), 2 (multiplet), 
multiplet 
high 
GLUTAMATE 2 2 
 
multiplet low 
GLUTAMINE 8 6 2 Triplet,1 (multiplet), multiplets high 
O-ACETYLCHOLINE 3 3 
 
1, multiplet low 
GLYCEROL 7 5 2 1 (quadruplet), multiplet high 
GLYCINE 1 1 
 
singlet low 
GLYCOPROTEIN 1 1 
 
singlet low 
GUANIDOACETATE 1 1 
 
singlet low 
HISTIDINE 9 9 
 
singlet, 1 (quadruplet), doublet, 2 
(quadruplet), multiplet 
medium 
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ARABINOSE 2 2 
 
1 (multiplet) low 
HYPOXANTHINE 1 0 1 2 (two singlets) high 
ISOCITRATE 3 2 1 doublet, quadruplet, multiplet low 
ISOLEUCINE 4 3 1 doublet, 1 (triplet) medium 
LACTATE 2 
 
2 doublet, quadruplet high 
LDL-MOBILE_LIPID-CH3 1 
 
1 multiplet (distinct feature) medium 
LEUCINE 4 4 
 
1 (doublet), multiplet medium 
LIPID_DOLICHOL 1 
 
1 multiplet (distinct feature) medium 
LIPID_FA_=CH-CH2-CH2- 1 
 
1 multiplet (distinct feature) medium 
LIPID_HOOC-CH2 1 1 
 
multiplet (distinct feature) medium 
LYSINE 7 7 
 
1 (triplet), multiplet medium 
MANNOSE 4 3 1 2 (doublet), multiplet medium 
METHANOL 1 1 
 
singlet low 
METHIONINE 3 2 1 1 (triplet), singlet medium 
METHYLSUCCINATE 2 1 1 1 (doublet), multiplet medium 
MOBILE_LIPID 1 1 
 
multiplet (distinct feature) medium 
MOBILE_UNSATURATED_LIPIDS 1 1 
 
multiplet (distinct feature) medium 
MOBILE-N(CH3)3 2 2 
 
multiplet (distinct feature), singlet 
(distinct feature) 
medium 
GLYCEROL-PHOSPHOCHOLINE 1 1 
 
singlet (distinct feature) medium 
MYO-INOSITOL 4 4 
 
3 (triplet), 1 (triplet) medium 
N-ACETYLSEROTONIN 3 3 
 
Singlet, 1 (doublet) low 
N-NITROSODIMETHYLAMINE 2 2 
 
singlet low 
ORNITHINE 2 2 
 
1 (triplet) low 
PHENYLALANINE 4 3 1 multiplet high 
POLYUNSATURATED_FATTY_ACIDS 1 1 
 
multiplet (distinct feature) medium 
PROPYLENE_GLYCOL 1 
 
1 doublet 
 
PYRUVATE 1 1 
 
singlet low 
SUCCINYLACETONE 3 3 
 
Singlet, 1 (triplet) low 
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TAU-METHYLHISTIDINE 1 
 
1 singlet low 
THREONINE 4 2 2 1 (doublet), 1 (multiplet) medium 
TRIMETHYLAMINE N-OXIDE 1 1 
 
singlet low 
TYROSINE 2 
 
2 multiplet high 
VALINE 7 3 4 Doublet, 1 (doublet), multiplet high 
Appendix - Table 11: Confidence table of assigned serum metabolites detected with 1H NMR spectroscopy.  Metabolites 
were considered part of a peak if the Chenomx Profiler® software detected more than 10% contribution to a peak. For each 
metabolite the number of features is listed which can be a singlet, doublet, triplet, quadruplet or a multiplet. Column three and 
four indicate the number of overlapped and non-overlapped peaks. Confidence was determined using the number of features 
and overlaps. Low= one singlet, or several features, but all overlapping; medium= very high number of features or at least one 
feature not overlapped; high= several features not-overlapped or one feature not-overlapped if in a very distinct region of the 
ppm scale/very distinct feature.  
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Appendix 1.3: Confidence table of urine metabolites 
 
METABOLITE TOTAL 
ASSIGNED 
FEATURES 
OVERLAPPED NON-
OVERLAPPED 
TYPE OF FEATURES ASSIGNMENT 
CONFIDENCE 
1-METHYLNICOTINAMIDE 5 2 3 2xsinglet, 2x doublets, 1 multiplet high 
1,3-DIMETHYLURATE 2 1 1 2xsinglet medium 
1,7-DIMETHYLXANTHINE 3 3 0 3xsinglet low 
2-AMINOADIPATE 6 6 0 1xquadruplet, 5x multiplet low 
2-FUROYLGLYCINE 5 5 0 2xdoublet, 1x quadruplet, 2xmultiplet low 
2-HYDROXYBUTYRATE 4 4 0 1xtriplet, 1x quadruplet, 2xmultiplet low 
2-HYDROXYISOBUTYRATE 1 0 1 singlet low 
2-METHYLGLUTARATE 5 4 1 1xdoublet, 1xtriplet, 3xmultiplet medium 
2-OXOGLUTARATE 2 2 0 2xtriplet low 
2'-DEOXYADENOSINE 9 9 0 
2xsinglet, 1xtriplet, 3xquadruplet, 
3xmultiplet low 
2'-DEOXYGUANOSINE 8 8 0 
1xsinglet, 1xtriplet, 2xquadruplet, 
4xmultiplet low 
2'-DEOXYINOSINE 9 9 0 
2xsinglet, 1xtriplet, 2xquadruplet, 
4xmultiplet low 
3-CHLOROTYROSINE 6 6 0 2xdoublet, 4x quadruplet low 
3-HYDROXY-3-METHYLGLUTARATE 3 3 0 1xsinglet, 2xdoublet low 
3-HYDROXYISOVALERATE 2 0 2 2xsinglet low 
3-HYDROXYMANDELATE 5 5 0 1xsinglet, 2xtriplet, 2xmultiplet low 
3-INDOXYLSULFATE 6 6 0 1xsinglet, 2xdoublet, 3xmultiplet low 
3-METHYLXANTHINE 2 2 0 2xsinglet low 
3-PHENYLLACTATE 6 6 0 3xquadruplet, 3xmultiplet low 
3-PHENYLPROPIONATE 7 7 0 4xquadruplet, 3xmultiplet low 
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3,4-DIHYDROXYBENZENEACETATE 5 5 0 2xsinglet, 2xdoublets, 1xquadruplet low 
3,5-DIBROMOTYROSINE 4 4 0 singlet, 3xquadruplet low 
4-GUANIDINOBUTANOATE 6 6 0 4xtriplet, 2xquadruplet low 
4-HYDROXY-3-
METHOXYMANDELATE 5 4 1 2xsinglet2xdoublet, 1x quadruplet medium 
4-HYDROXYBENZOATE 2 0 2 2xmultiplet high 
4-HYDROXYPHENYLACETATE 3 2 1 1xsinglet, 2xmultiplets medium 
4-PYRIDOXATE 3 3 0 3xsinglet low 
5-AMINOLEVULINATE 5 5 0 1xsinglet, 4xtriplet low 
5-HYDROXYINDOLE-3-ACETATE 5 5 0 
1xsinglet, 2xdoublet, 1xquadruplet, 
1xmultiplet low 
5-HYDROXYTRYPTOPHAN 8 8 0 
1xsinglet, 2xdoublet, 4xquadruplet, 
1xmultiplet low 
5-METHOXYSALICYLATE 4 4 0 1xsinglet, 1xdoublet, 1xquadruplet,  low 
ACETATE 1 1 0 singlet low 
ACETOACETATE 2 2 0 singlet low 
ADENOSINE 8 6 2 
singlet, 1xdoublet, 1xtriplet, 
3xquadruplet high 
ADIPATE 2 2 0 2xmultiplets low 
ADP 8 8 0 
2xsinglet, 1xdoublet, 2xtriplet, 
3xmultiplet low 
ALANINE 2 1 1 1xdoublet, 1xquadruplet medium 
ALLANTOIN 4 4 0 4xsinglet low 
ANSERINE 11 11 0 
3xsinglet, 1xdoublet, 2xquadruplet, 
5xmultiplet low 
ARABINOSE 24 24 0 
4xdoublet, 2xtriplet, 14xquadruplet, 
4xmultiplet low 
ATP 8 8 0 
2xsinglet, 1xdoublet, 2xtriplet, 
3xmultiplet low 
BETAINE 2 1 1 2xsinglet medium 
CARNITINE 6 6 0 1xsinglet, 2xquadruplet, 3xmultiplet low 
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CARNOSINE 10 10 0 3xsinglet, 2xquadruplet, 5xmultiplet low 
CELLOBIOSE 28 28 0 
4xdoublet, 8xtriplet, 11xquadruplet, 
5xmultiplet low 
CHOLINE 3 3 0 1xsinglet, 2xmultiplet low 
CIS-ACONITATE 2 1 1 1xdoublet, 1xmultiplet medium 
CITRATE 2 0 2 2xdoublet high 
CREATINE 2 1 1 2xsinglet medium 
CREATINE PHOSPHATE 2 2 0 2xsinglet low 
CREATININE 2 0 2 2xsinglet high 
DIMETHYLAMINE 1 0 1 1xsinglet low 
DTTP 9 9 0 1xtriplet, 8xmultiplet low 
ERYTHRITOL 6 6 0 2xquadruplet, 4xmultiplet low 
ETHANOLAMINE 2 2 0 2xmultiplet low 
FORMATE 1 1 0 singlet low 
FRUCTOSE 14 14 0 5xdoublet, 7xquadruplet, 2xmultiplet  low 
FUCOSE 24 23 1 
8xdoublet, 2xtriplet, 
7xquadruplet,7xmultiplet medium 
FUMARATE 1 1 0 singlet low 
GALACTARATE 2 2 0 2xsinglet low 
GALACTITOL 3 3 0 1xsinglet, 1xtriplet, 1xmultiplet low 
GALACTONATE 6 6 0 1xdoublet, 3xquadruplet, 2xmultiplet low 
GALACTOSE 14 14 0 2xdoublet, 9xquadruplet, 3xmultiplet low 
GALLATE 2 2 0 2xsinglet low 
GLUCARATE 4 4 0 2xdoublet, 1xtriplet, 1xquadruplet low 
GLUCONATE 6 6 0 1xdoublet, 1xtriplet, 4xmultiplet low 
GLUCOSE 14 14 0 
2xdoublet, 3xtriplet, 7xquadruplet, 
2xmultiplet low 
GLUCOSE-6-PHOSPHATE 14 14 0 
2xdoublet, 4xtriplet, 5xquadruplet, 
3xmultiplet low 
GLUCURONATE 10 9 1 4xdoublet, 4xtriplet, 1xquadruplet, medium 
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1xmultiplet 
GLUTAMINE 7 7 0 1xsinglet, 1xtriplet, 5xmultiplet low 
GLUTARIC ACID MONOMETHYL 
ESTER 4 4 0 1xsinglet, 2xtriplet, 1xmultiplet low 
GLYCINE 1 0 1 1xsinglet low 
GLYCOLATE 1 1 0 1xsinglet low 
GLYCYLPROLINE 17 17 0 
1xsinglet, 2xdoublet, 2xquadruplet, 
12xmultiplet low 
GUANIDOACETATE 1 1 0 singlet low 
HIPPURATE 5 2 3 1xsinglet, 1xdoublet, 3xmultiplet high 
HISTAMINE 4 4 0 1xsinglet, 1xdoublet, 2xtriplet low 
HISTIDINE 5 4 1 1xsinglet, 1xmultiplet, 3xquadruplet medium 
HOMOVANILLATE 5 4 1 2xsinglets, 2xdoublets, 1xquadruplet medium 
HYPOXANTHINE 2 1 1 2xsinglet medium 
IMIDAZOLE 2 2 0 2xsinglet low 
IMP 7 5 2 
2xsinglet, 1xdoublet, 1xquadruplet, 
3multiplet high 
INDOLE-3-ACETATE 7 7 0 2xsinglet, 2xdoublet, 3xmultiplet low 
INOSINE 8 8 0 
2xsinglet, 1xdoublet, 1xtriplet, 
4xquadruplet low 
ISOBUTYRATE 2 1 1 1xdoublet, 1xmultiplet medium 
KYNURENATE 5 5 0 
1xsinglet, 1xdouplet, 1xtriplet, 
2xmultiplet low 
KYNURENINE 6 6 0 
1xdoublet, 1xtriplet, 2xquadruplet, 
2xmultiplet low 
LACTATE 2 1 1 1xdoublet, 1xquadruplet medium 
LACTOSE 28 17 1 
5xdoublet, 4xtriplet 16xquadruplet, 
3xmultiplet medium 
LACTULOSE 42 41 1 
2xsinglet, 12xdoublet, 1xtriplet, 
21xquadruplet, 6xmultiplet medium 
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LEUCINE 6 5 1 2xdoublet, 1xquadruplet, 3xmultiplet medium 
LYSINE 7 7 0 2xtriplet, 5xmultiplet  low 
MALATE 3 3 0 3xquadruplet low 
MALONATE 1 0 1 1xsinglet low 
MALTOSE 28 28 0 
4xdoublet, 3xtriplet, 17xquadruplet, 
4xmultiplet low 
MANNITOL 4 4 0 1xdoublet, 2xquadruplet, 1xmultiplet low 
MELATONIN 10 9 1 
4xsinglet, 1xtriplet, 3xdoublet, 
2xquadruplet,  medium 
METHANOL 1 1 0 singlet low 
METHIONINE 5 5 0 
1xsinglet, 1xtriplet, 1xquadruplet, 2x 
multiplet low 
METHYLAMINE 1 0 1 singlet low 
METHYLGUANIDINE 4 3 1 singlet, 3xmultiplet low 
METHYLMALONATE 2 2 0 1xdoublet, 1xquadruplet low 
METHYLSUCCINATE 4 3 1 1xdoublet, 2xquadruplet, 1xmultiplet medium 
N-ACETYLSEROTONIN 9 9 1 
3xsinglet, 3xdoublet, 1xtriplet, 
2xquadruplet medium 
N-METHYLHYDANTOIN 2 1 1 2xsinglet medium 
N-NITROSODIMETHYLAMINE 2 1 1 2xsinglet medium 
N-PHENYLACETYLGLYCINE 6 3 3 2xsinglet, 1xdoublet, 3xmultiplet high 
N,N-DIMETHYLFORMAMIDE 3 2 1 2xsinglet, 1xdoublet  medium 
N,N-DIMETHYLGLYCINE 2 1 1 2xsinglet medium 
N6-ACETYLLYSINE 11 10 1 
2xsinglet, 1xtriplet, 2xquadruplet, 
6xmultiplet medium 
NÎ±-ACETYLLYSINE 12 12 0 1xsinglet, 1xdoublet, 10xmultiplet low 
O-ACETYLCARNITINE 7 7 0 
2xsinglet, 1xdoublet, 3xquadruplet, 
1xmultiplet low 
O-ACETYLCHOLINE 4 4 0 2xsinglet, 2xmultiplet,  low 
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O-PHOSPHOCHOLINE 3 2 1 1xsinglet, 2xmultiplet low 
P-CRESOL 3 2 1 1xsinglet, 2xmultiplet medium 
PANTOTHENATE 9 8 1 
3xsinglet, 2xdoublet, 1xsinglet, 
2xquadruplet, 1xmultiplet medium 
PHENYLACETATE 4 4 0 1xsinglet, 3xmultiplet low 
PHENYLALANINE 6 6 0 3xmultiplet, 3xquadruplet low 
PYRIDOXINE 4 3 1 4xsinglet medium 
PYRUVATE 1 0 1 singlet low 
QUINOLINATE 3 3 0 3xquadruplet low 
RIBOFLAVIN 11 10 1 
4xsinglet, 1xtriplet, 3xquadruplet, 
3xmultiplet medium 
SARCOSINE 2 1 1 2xsinglet low 
SERINE 3 3 0 3xquadruplet low 
SN-GLYCERO-3-PHOSPHOCHOLINE 8 7 1 1xsinglet, 2xquadruplet, 5xmultiplet medium 
SUCCINATE 1 1 0 singlet low 
SUCCINYLACETONE 4 3 1 2xsinglet, 2xtriplert medium 
SUCROSE 14 12 2 
4xdoublet, 4xtriplet, 4xquadruplet, 
2xmultiplet high 
TARTRATE 1 0 1 singlet low 
TAURINE 2 2 0 2xtriplet low 
THEOPHYLLINE 3 1 2 3xsinglet medium 
THREONATE 4 3 1 1xdoublet, 2xquadruplet, 1xmultiplet medium 
THREONINE 3 2 1 2xdoublet, 1xmultiplet medium 
TRANS-ACONITATE 2 1 1 2xsinglet low 
TRIGONELLINE 5 2 3 2xsinglet, 2xdoublet, 1xtriplet high 
TRIMETHYLAMINE 1 0 1 singlet low 
TRIMETHYLAMINE N-OXIDE 1 0 1 singlet low 
TRYPTOPHAN 9 6 3 
2xsinglet, 2xdoublet, 2xtriplet, 
3xquadruplet high 
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TYROSINE 5 3 2 3xquadruplet, 2xmultiplet high 
UDP-GLUCOSE 15 14 1 
3xdoublet, 4xtriplet, 3xquadruplet, 
5xmultiplet medium 
URACIL 2 2 0 2xdoublet low 
UREA 1 0 1 singlet low 
VALINE 4 2 2 3xdoublet, 1xmultiplet high 
VANILLATE 4 3 1 1xsinglet, 2xdoublet, 1xquadruplet medium 
XANTHINE 1 0 1 singlet low 
XANTHOSINE 7 6 1 
1xsinglet, 1xdoublet, 1xtriplet, 
4xquadruplet medium 
-METHYLHISTIDINE 6 5 1 3xsinglet, 3xdoublet medium 
-METHYLHISTIDINE 6 5 1 3xsinglet, 3xdoublet medium 
Appendix - Table 12: Confidence table of assigned urine metabolites detected with 1H NMR spectroscopy. Metabolites 
were considered part of a peak if the Chenomx Profiler® software detected more than 10% contribution to a peak. For each 
metabolite the number of features is listed which can be a singlet, doublet, triplet, quadruplet or a multiplet. Column three and 
four indicate the number of overlapped and non-overlapped peaks. Confidence was determined using the number of features 
and overlaps. Low= one singlet, or several features, but all overlapping; medium= high number of distinct features or one 
feature not overlapped; high= several features not-overlapped or one feature not-overlapped if in a very distinct region of the 
ppm scale/very distinct feature.  
 
 
